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From microscope to microarray
The genetic information is carried by DNA, which is packaged in chromosomes, tread-like 
structures located in the nucleus of the cell. Each chromosome is made up of DNA tightly 
coiled many times around histones that support its structure. The number and appearance 
of chromosomes in the nucleus of a eukaryotic cell is referred to as the karyotype. In 1956, 
the total number of chromosomes per cell in humans was visualized by microscope and 
determined to be 46, consisting of 22 pairs of autosomes and a single pair of sex chromosomes. 1
A few years later the underlying genetic cause of Down syndrome was revealed to be an extra 
chromosome 21. 2 It appeared to be that chromosomal rearrangements are an important 
cause of distinctive and recognizable clinical phenotypes. Subsequently, other numerical 
chromosomal aberrations have been detected in patients presenting with an overlapping 
phenotype, including Patau syndrome (trisomy 13) 3, Edwards syndrome (trisomy 18) 4, 
Turner syndrome (45,X) 5 and Klinefelter syndrome (47,XXY). 6 
With the implementation of chromosome banding techniques, not only numerical but also 
structural rearrangements and partial chromosome aberrations could be identified. 7-9 This has 
led to the identification and categorization of numerous unbalanced chromosome aberrations 
in individuals with intellectual disability and/or congenital anomalies such as deletions 
and duplications, as well as inversions and translocations. 10 However, small chromosome 
aberrations of less than 5 Mb cannot be detected by standard karyotyping.
The introduction of fluorescence in situ hybridization (FISH) techniques and multiplex 
ligation-dependent probe amplification (MLPA) allowed for the detection of small, 
submicroscopic cytogenetic rearrangements. 11,12 Yet, both FISH and MLPA approaches 
are targeted and, as such, only allow analysis of specific chromosome regions correlated to 
a suspected clinical syndrome, which can be recognized by characteristic clinical features. 
The cytogenetic origin of a number of well-known syndromes has been revealed by extensive 
cytogenetic examination of large cohorts of individuals with similar clinical characteristics, 
for example velo-cardio-facial syndrome, caused by a interstitial deletion of 22q11.2, 
Williams-Beuren (7q11.23) and Miller-Dieker syndrome (17p13.3). 13-19 Most often the 
submicroscopic aberration was revealed after association of balanced translocations with 
the clinical phenotype. 20,21 
However, in the majority of patients with developmental delay a normal karyotype is seen and 
no specific submicroscopic syndrome diagnosis can be made. The gap between the demand 
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for whole genome analysis on one side and the possibility to detect small aberrations on the 
other side has been closed by the introduction of microarray techniques, also referred to as 
molecular karyotyping. 22-24 This whole genome technology is able to detect chromosomal 
aberrations at a resolution beyond the detection level of conventional karyotyping and has 
therefore been one of the most significant changes in the diagnostic process of individuals with 
intellectual disability and/or congenital anomalies. 25-27 An overview of current cytogenetic 
and molecular techniques used in clinical cytogenetics is given in Table 1.1.
Using new molecular karyotyping techniques, many new microdeletion and microduplication 
syndromes have been identified and the list is still growing. 28-31 Whereas in the pre-
microarray era a clinical syndrome diagnosis was made first, followed by a confirmation on 
chromosome level, the expansion of high resolution whole genome techniques led to a shift 
from the original ‘phenotype first’ approach, to a ‘genotype-first’ approach, a development 
also labeled as ‘reverse phenotypics’. 32 High resolution genotyping rapidly found its way as 
a first screening test in the daily diagnostic process of individuals with intellectual disability 
and/or congenital abnormalities.
In addition, these techniques are of great value in improving genotype-phenotype studies 
of patients with microscopically visible chromosomal imbalances by precisely determining 
the genomic region affected. The exact determination of breakpoints needed for genotype-
phenotype studies used to be very time-consuming and only feasible for rather common 
cytogenetic syndromes. Examples are the determination of the Wolf-Hirschhorn syndrome 
critical region on chromosome 4p and the cat-cry region on chromosome 5p in Cri du Chat 
syndrome. 33,34 Nowadays, size and localization of the chromosomal aneuploidies can be 
determined with very high accuracy by whole genome oligonucleotide- and/or SNP-based 
arrays 35-40, reaching a resolution as low as 1 kb for detecting copy number variations (CNV).
Deconstructing chromosomal syndromes
With the use of new molecular techniques, various chromosomal syndromes have been 
analyzed in detail. Whereas in some a single gene appeared to be responsible for most of the 
phenotypic features, for other syndromes an increasing number of critical regions for specific 
clinical features can be determined. In this section the detection of critical regions and some 
candidate genes in a number of microscopically visible chromosome disorders are described. 
Subsequently, some examples are given of submicroscopic aberrations in which single genes 
appear to play a major role in the phenotypes of patients.
Chapter 1
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Cri du Chat syndrome (5p-)
Cri du Chat syndrome (CDC, OMIM 123450) was first described by Lejeune and co-workers 
in 1963. 41 The syndrome is caused by a partial deletion of the short arm of chromosome 
5 and is characterized by a high-pitched cat-like cry, microcephaly, facial dysmorphology 
and intellectual disability. 42 Chromosome analysis showed different deletion sizes, but no 
clear association between deletion size and the clinical features could be demonstrated. 43 
In 1978, Niebuhr made an attempt to locate the genetic segment responsible for the clinical 
features of Cri du Chat syndrome by investigating 35 individuals with a 5p- karyotype. 33 
He concluded that the typical features of this syndrome were probably caused by a deletion 
of the midportion of the 5p15 segment, more specifically 5p15.2. This region is shown in 
the schematic overview in Figure 1.1. These findings have subsequently been confirmed by 
other groups. 44-47
In 2005, Zhang and co-authors applied the new array CGH technique to analyze genomic 
DNA of 94 patients with known deletions of 5p. 48 As a detailed clinical description of all 
patients was available, the authors were able to define three critical regions for the cry, speech 
delay, and facial dysmorphology on 5p15.31, 5p15.32-15.33 and 5p15.2-15.31, respectively. 
Figure 1.1 Schematic overview of the clinical features of Cri du Chat syndrome and the associated 
critical regions on chromosome 5p. Array CGH was used in the study shown on the right, resulting 
in a signifi cant refi nement of the critical regions. ID =Intellectual Disability.
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Moreover, they concluded that there were three adjacent regions on chromosome 5p that 
have differential effects on the level of intellectual disability (ID) if deleted. A distal 1.2 Mb 
deletion in 5p15.31 produces moderate ID, whereas isolated deletions of more proximal 
located regions result in mild or no discernible ID.
In Figure 1.1 an overview of critical regions associated with the different clinical features is 
provided.
Wolf-Hirschhorn syndrome (4p-)
In 1965, groups led by Wolf and Hirschhorn each described a patient with a deletion of 
the short arm of chromosome 4p presenting with growth delay, intellectual disability, and 
congenital anomalies suggestive of a midline fusion defect. 49,50 Numerous case-reports on 
similar patients followed. One of the first studies in which the investigators tried to localize 
the segment of chromosome 4p associated with the clinical features of Wolf-Hirschhorn 
syndrome (WHS, OMIM 194190) was published in 1981. 51 Giemsa-banding (GTG) was 
performed in 13 patients. The authors concluded that the critical region involved in WHS is 
within 4p16, the most distal band of the p-arm (see Figure 1.2). However, not in all patients 
displaying the clinical features of WHS a terminal deletion could be detected by conventional 
karyotyping. The contribution of new molecular cytogenetic techniques, such as FISH, enabled 
the diagnosis of WHS in patients with submicroscopic interstitial or terminal deletions or 
subtle unbalanced translocations. 52,53
A preliminary phenotypic map of chromosome 4p16 was put forward in 1995. A systematic 
genotype-phenotype analysis was performed in 11 patients with chromosome 4p deletions 
and/or rearrangements. 54 It was suggested that specific regions within 4p16 correlated with 
different clinical features.
In 1997 the WHS critical region (WHSCR) was refined to 165 kb by using FISH with a series 
of landmark cosmids in a collection of WHS patient-derived cell lines, see Figure 1.2. 34 The 
WHSCR is a gene-rich region and contains, among others, the FGFR3 gene which is mutated 
in achondroplasia and other skeletal dysplasias.
A gene designated as Wolf Hirschhorn Syndrome Candidate 1 (WHSC1) was described in 
1998. 55 This 25 exon gene was found to be expressed ubiquitously in early development and 
to undergo complex alternative splicing and differential polyadenylation. It encodes a 136 kD 
protein containing 4 domains also present in other developmental proteins. It is expressed 
Chapter 1
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preferentially in rapidly growing embryonic tissues, in a pattern corresponding to the affected 
organs in WHS patients. The nature of the protein motifs, the expression pattern, and its 
mapping to the critical region led the authors to propose WHSC1 as a good candidate gene 
for WHS. A second candidate gene (WHSC2) was identified one year later, as well as LETM1, 
which may contribute to the neuromuscular features of WHS patients. 56,57 The location of 
all candidate genes is depicted in Figure 1.2.
In 2000 an Italian group reported the cytogenetic, molecular, and clinical findings in 16 
WHS patients. 58 Submicroscopic deletions ranging from 2.8 to 4.4 Mb were detected in four 
patients. In one patient, no molecular deletion could be detected within the WHSCR. The 
precise definition of the cytogenetic defect permitted an analysis of genotype/phenotype 
correlations in WHS, leading to the proposal of a set of minimal diagnostic criteria. Deletions 
of less than 3.5 Mb resulted in a mild phenotype in which major malformations were absent. 
Figure 1.2 Schematic overview of the deconstruction of the Wolf-Hirschhorn syndrome in 
critical regions and candidate genes. WHS = Wolf-Hirschhorn syndrome; WHSCR-1 = WHS critical 
region 1; WHSCR-2 = WHS critical region 2; FGFR3 = Fibroblast growth factor receptor 3 ; LETM1 
= Leucinezipper/ef-hand-containing transmembrane protein 1; WHSC1 = WHS candidate gene 1; 
WHSC2 = WHS candidate gene 2. Mb = Megabase.
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1
The authors proposed a ‘minimal’ WHS phenotype in which the clinical manifestations are 
restricted to the typical facial appearance, mild intellectual disability, growth retardation, 
and congenital hypotonia.
In 2003, the same group reported their findings in eight patients carrying a 4p16.3 
microdeletion. 59 The WHSCR was fully preserved in one patient with a 1.9 Mb deletion, 
in spite of a typical WHS phenotype. Therefore, the authors proposed a second critical 
region, WHSCR2, a 300 kb interval located distally from the known WHSCR1 (Figure 
1.2). Furthermore, for the purpose of genetic counseling, they recommended to divide the 
WHS phenotype into two distinct clinical entities, i.e., a ‘classical’ and a ‘mild’ form, which 
are usually caused by cytogenetically visible and submicroscopic deletions, respectively. 
Another patient with a 1.9 Mb subtelomeric deletion was described in 2005, which supports 
the proposed WHSCR2. 60
A Belgian group reported six additional patients with an atypical 4p16.3 deletion, of whom 
five patients showed a (very) mild form of WHS and one patient had no clinical signs of 
WHS. 61 By means of a contiguous 4pter BAC array, the sizes and breakpoints were physically 
mapped and 4 terminal deletions (range 0.4-3.81 Mb) and 2 interstitial deletions (1.55 and 
1.7 Mb) were revealed. This study enabled further refinement of the phenotypic map of this 
region, suggesting hemizygosity of WHSC1 to cause the typical WHS facial appearance.
Recently a 432 kb deletion located 600 kb proximal to both WHSCR1 and WHSCR2 has been 
identified in a patient and his mother with a WHS facial phenotype (Figure 1.2). 62 Sanger 
sequencing of WHSC1 and WHSC2 did not reveal any mutations. The authors hypothesize 
that either this locus harbors regulatory sequences which affect the expression of genes in 
WHSCR1 and WHSCR2 or, alternatively that this locus is another genetic locus co-segregating 
with the WHS phenotype. They concluded that the microdeletion leads to a borderline WHS 
phenotype and propose that this locus predisposes to WHS.
In summary, although molecular analysis allows a more detailed view of the WHS critical 
regions, the exact contribution of each of the proposed critical regions to the WHS phenotype 
still remains to be determined.
18q deletion syndrome
The 18q deletion syndrome (OMIM 601808) was described first in 1964 by De Grouchy et al. 63
Most 18q cases are associated with terminal deletions and the phenotype of this syndrome is 
Chapter 1
20
mainly characterized by neonatal hypotonia, intellectual disability, facial dysmorhpisms, ear 
canal anomalies and foot deformities. A first preliminary phenotypic map based on seven 
patients with deletions of 18q21.3 or 18q22.2 to 18qter was published in 1993. 64 In Figure 
1.3 an overview of clinical features and associated chromosome regions is provided.
Figure 1.3 Overview of the long arm of chromosome 18 and the critical regions defi ned for 
distinctive clinical features. ID = Intellectual Disability; CAA = congenital aural atresia.
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A substantial percentage of 18q- patients has congenital aural atresia (CAA), leading to hearing 
loss. 65 By applying a 670 kb resolution chromosome 18-specific BAC array to analyse genomic 
DNA of 20 patients with CAA, a critical region for CAA was mapped on 18q22.3-18q23. 66 Of 
these, 18 patients had a microscopically visible 18q deletion. In 2 patients, a submicroscopic 
18q deletion was detected which allowed the mapping of CAA to a region of 5 Mb located 
in 18q22.3-18q23 (Figure 1.3).
1p36 deletions
One of the relatively new microdeletion syndromes, as this aberration has only been 
known since 1997, is the 1p36 deletion syndrome. 67 With an estimated prevalence of 1 
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in 5,000 live births, monosomy of 1p36 (OMIM 607872) is the most common terminal 
deletion syndrome. 68 Because of the variability in deletion size, parental origin and clinical 
presentation, it has been proposed that monosomy 1p36 is a contiguous gene syndrome in 
which haploinsufficiency of functionally unrelated genes leads to the phenotypic features. 69
The first physical map of 1p36 deletions was published in 2003. 70 First, DNA samples of 61 
patients were screened with 25 microsatellite markers for the most distal part of 1p36. Then, a 
contig of 99 overlapping large-insert clones of this 10.5 Mb region was used to further refine 
the deletion size. Furthermore, clinical phenotypes of 30 patients were carefully defined. The 
authors proposed critical regions for hypotonia (2.2 Mb region from the telomere), a large 
fontanel (2.2 Mb), hearing loss (2.5 Mb), cardiomyopathy (3.1 Mb), hypothyroidism (4.1 
Mb) and clefting (4.1 Mb). Because the terminal region of 1p36 is gene rich, no candidate 
genes could be determined.
In the same year, this group published their data using a dedicated 1p36 array CGH. 71 This 
array was designed by using the previously assembled contig, consisting of 97 clones from 
1p36, supplemented by clones for the subtelomeric regions of all chromosomes and clones 
for both sex-chromosomes. Genomic DNA of twenty-five patients with well-defined 1p36 
deletions was studied and the array results agreed with the previously determined deletion 
sizes and breakpoint locations as detected by FISH and microsatellite analyses.
Recently, a tiling resolution BAC array covering 99.5% of the euchromatic parts of chromo-
some 1 has been applied to study six patients with a 1p36 deletion phenotype. In all 
patients a 1p36 deletion was confirmed, with sizes ranging from 2 to 10 Mb. Remarkably, 
in two clinically similar patients two non-overlapping deletions were detected. Therefore, 
the authors concluded that the 1p36 phenotype is a consequence of distinct and non-
overlapping deletions having a positional effect rather than being a true contiguous gene 
deletion syndrome. 72 Battaglia and collagues evaluated the clinical features in a large series 
of 60 patients with the 1p36 deletion syndrome in order to thoroughly delineate the natural 
history with the purpose of developing complete and accurate information that can be used 
for answering families’ questions in the clinical setting. 73 The 1p36 deletions were detected 
by regular karyotyping, FISH of the subtelomeric region or array comparative hybridization, 
yet the authors did not mention specific critical regions for the various clinical features 
described. 
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Cytogenetic microdeletion syndromes and the impact of single genes
In a number of (micro)deletion syndromes, the molecular determination of breakpoints 
together with a comparison of clinical features has resulted in such small critical regions that 
single genes appear to be responsible for the (majority of) phenotypic features.
An example is Smith-Magenis Syndrome (SMS, OMIM 182290), characterized by behavioural 
problems, speech delay, psychomotor and growth retardation and distinct craniofacial features. 74
About 75% of the SMS patients have a common deletion spanning 3.5 Mb in the 17p11.2 
region, although deletion sizes vary from 1.5 Mb to 9 Mb. 75,76 Successively a number of 
patients who fulfill the criteria for SMS but without the 17p11.2 deletion were analyzed for 
mutations of RAI1, located within the central portion of the critical region for SMS, using 
PCR and sequencing strategies. 77-79 This resulted in the identification of nine patients having 
RAI1 mutations and to the conclusion that haploinsuffiency of this gene is associated with 
the craniofacial, behavioral and neurological symptoms of SMS.
The 22q13.3 deletion or Phelan-McDermid syndrome (OMIM 606232) is characterized by 
neonatal hypotonia, severe expressive language delay in combination with mild intellectual 
disability. 80,81 Included in the critical region of this syndrome is SHANK3, which is 
preferentially expressed in the cerebral cortex and the cerebellum. DNA analysis of SHANK3 
in a patient carrying a de novo balanced translocation between chromosomes 12 and 22, 
t(12;22)(q24.1;q13.3), revealed a disruption within exon 21. 82 Since the patient displayed 
all 22q13.3 deletion features, the authors proposed that SHANK3 haploinsufficiency is the 
cause of the 22q13 deletion syndrome. This finding was supported by another group who 
tested 45 patients with variable sizes of 22q13 deletions, thereby confirming a deletion for 
the SHANK3 gene in all patients. 83 An array CGH study for molecular characterization of 
nine patients with 22q13 aberrations identified deletion sizes ranging from 3.3 to 8.4 Mb. 84 
The authors did not observe a relation between clinical features and deletion size, thereby 
supporting the idea that a gene in the 3.3 Mb minimal deleted region, notably SHANK3, may 
be the major candidate gene in the 22q13 deletion syndrome. Another group using array CGH 
reported their findings in two unrelated 22q13.3 deletion patients 85, which were consistent 
with the concept of SHANK3 being the best candidate gene for the neurological deficits in 
the 22q13.3 syndrome 86, although patients with the same kind of SHANK3 disruption can 
exhibit different degrees of severity in their phenotype. 
Another terminal deletion syndrome is the 9q34 subtelomeric deletion syndrome. This 
syndrome is characterized by severe intellectual disability, hypotonia, microcephaly 
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and a typical face with midface depression, hypertelorism, everted lower lip, cupid bow 
configuration of the upper lip, and a prominent chin. The minimum critical region involved 
is ~1.2 Mb in size and encompasses at least 14 genes. 87 In a mentally retarded patient with a 
typical 9qter deletion phenotype, a balanced translocation t(X;9)(p11.23;q34.3) was detected. 88
Extensive analysis of the breakpoints revealed a disruption of EHMT1, indicating that 
haploinsuffiency of this gene may be responsible for the 9q subtelomeric deletion syndrome. 
Subsequently, sequence analysis of EHMT1 in a series of patients with clinical phenotypes 
suggestive of a 9qter deletion but with intact telomere region according to FISH and MLPA, 
was performed. This resulted in a de novo nonsense mutation in one such patient and a 
frameshift in another, establishing that EHMT1 haploinsufficiency is indeed the cause of 
the 9qter deletion phenotype. 89 Numerous patients with an EHMT1 mutation have been 
identified since then.
Recently, Koolen and colleagues showed that haploinsufficiency of KANSL1 is sufficient to 
cause the 17q21.31 microdeletion syndrome, a multisystem disorder which is characterized 
by intellectual disability, severe neonatal hypotonia an amiable personality and distinctive 
facial features. 90 They were able to delineate the critical region from five to two known 
genes by using the Affymetrix Cytogenetics Whole Genome 2.7M array, which detected a 
very small and atypical deletion in each of two patients with a classical 17q21.31 phenotype. 
The overlapping region encompassed only parts of MAPT and KANSL1, in which Sanger 
sequence analysis revealed loss of function mutations in KANSL1 in two other individuals 
with a comparable phenotype yet without a 17q21.31 deletion.   
Other examples of cytogenetic syndromes of which the (majority of) clinical features appear 
to be caused by mutations in single genes are Rubinstein-Taybi Syndrome (RSTS, OMIM 
180849), Sotos syndrome (OMIM 117550) and DiGeorge/VCFS Syndrome (DGS, OMIM 
188400). 91-95 Furthermore, it has been described that atypical deletions may be associated 
with variant phenotypes. 96,97
These examples illustrate how the boundary between cytogenetic deletion syndromes 
and single gene conditions is becoming more and more indistinct. Ultimately, we should 
be able to assess the phenotype contribution of each gene within known microdeletion / 
microduplication syndromes.
An overview of the above-mentioned syndromes and the possible genes responsible for most 
phenotypic features is given in Table 1.2.
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In summary, the examples above show three different forms of associations between 
chromosomal disorders and a phenotype. In a number of syndromes the phenotype is 
primarily caused by disruption of a single gene, like Rubinstein-Taybi syndrome. In contrast, 
Cri du Chat syndrome is a contiguous gene deletion syndrome as the different clinical features 
seem to be caused by deletions of non-overlapping critical regions. A third mechanism is 
seen in Wolf-Hirschhorn syndrome, where the identification of two critical regions for the 
complete phenotype, shows that disturbance of the integrity of a chromosomal region can 
lead to a recognizable phenotype.
Mapping of malformations by chromosomes; Mendelian cytogenetics
The first successful mapping of a Mendelian disorder by chromosome rearrangements was that 
of the Duchenne muscular dystrophy, located at Xp21. 98 Since then, chro mosome aberrations 
which delete, truncate, or otherwise rearrange and alter specific genes have not only helped 
in the mapping of other disease loci, but have turned out to be key elements for the rapid 
isolation of disease genes by positional cloning strategies. 99,100 Tommerup documented that 
the frequency of associated chromosome rearrangements in Mendelian disorders may be 
rare, however not exceptional. 101 
Using a mathematical model, chromosome maps for specific malformation patterns based on 
the catalogue of unbalanced chromosome disorders and associated congenital malformations 
collected in the Zurich Cytogenetic Database were created. 102,103 The chromosomal deletion 
Table 1.2 Examples of cytogenetic microdeletion syndromes in which single genes appear to be 
responsible for the (majority of ) clinical features
Syndrome Chromosome location Gene responsible
Sotos Syndrome 5q35 NSD1
Kleefstra syndrome 9q34 EHMT1
Rubinstein-Taybi Syndrome 16p13.3 CREBBP, EP300
Smith Magenis Syndrome 17p11.2 RAI1
Koolen-De Vries syndrome 17q21.31 KANSL1
DiGeorge/VCFS Syndrome 22q11.2 TBX1
Phelan-McDermid syndrome 22q13.3 SHANK3
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map was assembled through the analysis of 1,753 patients with a single, non-mosaic 
contiguous autosomal deletion and the presence of common major malformations. This 
resulted in 284 positive associations between specific malformations and deleted bands, 
distributed among 137 malformation-associated chromosome regions (MACRs). In a second 
article, a chromosomal duplication map was described. 103 Here, a total number of 143 MACRs 
were identified, of which 21 were highly significant.
Obviously, such maps should always be interpreted with care. Although the number of 
cases available for analysis was high, the accuracy of breakpoints is not known since the 
cytogenetic analyses were mostly performed with standard karyotyping. Nonetheless, this 
type of analyses can point to those chromosome regions where the search for loci involved 
in congenital malformations is most likely to be successful. This has been abundantly proven 
for holoprosencephaly, where at least four genes have been found based on chromosomal 
mapping of critical regions. 104-109
As more and more submicroscopic deletions and duplications are mapped, further candidate 
genes for specific malformations are being revealed. For instance, a study in 100 patients with 
intellectual disability and malformations detected a small duplication in 5q35.1 in a patient 
with lobar holoprosencephaly. 25 This region contains seven known genes of which FBXW11 
is a likely candidate gene for holoprosencephaly. 110
Storage of genomic and clinical data
Cytogenetic and clinical information concerning specific chromosome disorders are 
continuously published in the (inter)national medical literature. Thus, systematic collection 
and archiving are essential.
Many of these reports have been collected in the ‘Catalogue of Unbalanced Chromosome 
Aberrations in Man’, containing around 2,000 descriptions of patients with a rare chromosome 
aberration. 10 This catalogue provides an unprecedented resource for genotype-phenotype 
studies in cytogenetically visible chromosome anomalies. In order to perform searches 
directed towards specific chromosome aberrations and/or clinical features, a computerized 
version is commercially available as the Zurich Cytogenetic Database, which contains 
cytogenetic and clinical information on more than 7,200 cases from the medical literature 
and references to the original papers. 111
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What about the phenotype?
Abnormal phenotypes have played significant roles in the discovery of critical chromosome 
regions and gene function, but organized collection of phenotype data has been overshadowed 
by developments in genetic technology. As high resolution genotyping is currently part of 
the standard genomic testing in individuals with intellectual disability and/or congenital 
abnormalities in developed countries, there is a need for equally high accuracy of phenotyping 
to fully benefit from the advantages of these new techniques.
The phenotype, defined as the appearance (physical, biochemical and physiological) of 
an individual which results from the interaction of the environment and the genotype, is 
usually presented in scientific articles by a clinical description, sometimes accompanied by 
clinical photographs. Any description of clinical features of a patient is inherently subjective. 
It varies between independent physicians and any emphasis on specific features may reflect 
the background specialty of the observer.
Description of phenotypes
To overcome the bias of subjectivity, proposals have been made to standardize the phenotypic 
description by a systematic collection of clinical information. 112-114
A detailed proposal for the organization and standardization of clinical descriptions of 
human malformations has been made by Biesecker. 115 The author felt that, in contrast to the 
enormous improvements in molecular biology, the processes and approaches of the clinical 
component of molecular dysmorphology have not changed substantially. He argued that the 
current way of collecting phenotypic information holds several weaknesses. The quality and 
completeness of clinical descriptions published in the medical literature depend on the authors 
and editors involved. Another threat is confusion in understanding the terms used by the 
authors, due to the existence of synonyms, various definitions for one word, and sometimes 
overlapping of two different terms. The author pointed out a number of criteria for an ideal 
standardized clinical genetics nomenclature.
An international working group was subsequently formed to develop standardized definitions 
and terms to describe the physical variations used in human phenotypic analyses. This project, 
which came to be known as the Elements of Morphology, resulted in six articles proposing 
consensus definitions for almost 400 phenotypic variations of the head and face; periorbital 
region; ear, nose, and philtrum; mouth and lips; and hands and feet. 116-121 Every variation was 
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accompanied by a representative figure depicting the feature. As a result, several human and 
medical genetic journals implemented the inclusion of the use of the Elements terminology 
into manuscripts submitted to their journals.  
Currently the group is working on four more articles on proposed terminology for the trunk, 
genital region, skin, and remainder of the limb. 122  
Standardization of phenotype descriptions will be crucial for a ‘Human Phenome Project’, 
in which comprehensive databases are created for such systematically collected phenotypic 
information. 112 The authors argued that phenotypic information should be collected on 
different levels: molecules, cells, tissues and whole organisms.
Visualization of phenotype
In a number of cytogenetic syndromes, such as WHS or 1p36 deletion syndrome, the clinical 
diagnosis is primarily based on characteristic facial features. Clinical geneticists are trained in 
recognizing specific patterns in different syndromes and can do this relatively well. 123 Multiple 
efforts have been made to implement objective, quantitative criteria and analytical techniques 
for craniofacial assessments. 124,125 In previous decades, anthropometry, photogrammetry and 
cephalometry have been applied as diagnostic methods. 126-129
More recently, computer programs have been designed to analyze and identify faces of patients 
with certain syndromes on the basis of specific craniofacial features. In one study, standardized 
photographs of 55 patients with different syndromes were analyzed in a mathematical way 
by comparing feature vectors at 32 facial nodes. 130 Over 75% of the patients were correctly 
classified by the computer, whereas clinicians who were shown the same pictures achieved 
a recognition rate of 62%.
In 2005, a large study on computer-based three-dimensional (3D) imaging of the face of 
696 individuals was published. 131 This study demonstrated the potential contributions of 
dense surface models (DSM) in clinical training, making clinical diagnoses and objective 
comparisons. Such mathematical pattern recognition might improve phenotype-genotype 
analyses, particularly in patients with rare or atypical chromosome aberrations.
A first application of 3D face surface models in genotype-phenotype studies was demonstrated 
in Williams-Beuren syndrome (WBS, OMIM 194050), involving a 7q11.23 deletion. 132 As 
the typical deletion size in WBS is 1.5 Mb and contains 28 genes, a clear genotype-phenotype 
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correlation for craniofacial features could not be made so far. In this study, a patient with 
a small, atypical deletion was identified and 3D surface images of this patient’s face were 
compared with those of WBS-individuals and controls. The patient was classified as borderline 
WBS with mildly dysmorphic features. Chromosome analysis revealed a heterozygous deletion 
at 7q11.23 of ~1 Mb, resulting in reduced expression of GTF2IRD1. In mice, homozygous 
loss of Gtf2ird1 results in craniofacial abnormalities reminiscent of those seen in WBS, 
together with growth retardation. These observations suggest that GTF2IRD1 plays a role in 
mammalian craniofacial and cognitive development. The authors suggested that cumulative 
dosage of TFII-I family genes explains the main phenotypes of WBS. Gtf2ird1-null mice and 
classic WBS patients have two functional copies (in trans and cis, respectively), whereas the 
atypical patient had three functional genes of the GTF2IRD1/GTF2I cluster and showed a 
milder WBS phenotype.
Recently, DSM and pattern recognition techniques were used to compare the facial phenotype 
of WHS in individuals with a small terminal deletion (breakpoint within 4p16.3) compared 
to those with a large deletion (breakpoint more proximal than 4p16.3). 133 By using these 
sensitive and accurate visualization and quantitative tools it was demonstrated that small 
terminal deletions are associated with milder facial dysmorphology than large deletions. 
Further, fine-grained facial analysis of several individuals with an atypical genotype and/
or phenotype suggested that multiple genes contiguously contribute to the characteristic 
Wolf–Hirschhorn syndrome facial phenotype, as suggested previously. 61
Aims and outline of the thesis
The main aim of this thesis was to provide genotype-phenotype relationships for rare 
chromosomal abnormalities. Such genotype-phenotype relationships provide valuable 
information for clinicians and molecular cytogeneticists working in the fields of clinical 
genetics and prenatal diagnosis. They may further add to disease gene discovery.
As there is a need for sophisticated phenotyping and data collection, we started by setting 
up a web-based genotype-phenotype database for rare chromosomal aberrations which is 
accessible for everyone working in this field, in order to increase the level of knowledge 
among physicians and their patients (Chapter 2). 
The detection of submicroscopic chromosomal abnormalities (CNVs) by arrays is well 
established in the evaluation of children with significant learning disability or major 
General introduction and outline of this thesis
29
1
malformations. Whether arrays would provide relevant information in patients with 
karyotypically balanced rearrangements, or in patients with prenatally detected structural 
abnormalities on ultrasound is largely unknown. These situations are especially challenging. 
In Chapter 3, we therefore evaluated the use of high resolution whole genome arrays in the 
diagnostic setting of these two groups of patients, where either the genotype or the phenotype 
is incomplete. We studied submicroscopic imbalances in individuals with congenital 
abnormalities or developmental delay and a de novo apparently balanced translocation or 
inversion and applied a predictive clinical scoring system in Chapter 3.1. In Chapter 3.2, a 
study on the evaluation of the clinical and laboratory aspects of non-targeted whole genome 
array analysis for prenatal diagnosis of foetuses with structural anomalies is described.  
Detailed genotype-phenotype analysis of small chromosomal imbalances may point to specific 
genes for the phenotype or a component of a complex phenotype. By comparing multiple 
small CNVs a chromosomal phenotype map can be generated that allows the mapping of 
such genes. We decided to study a large cohort of patients with overlapping 18q deletions in 
order to generate an upgrade to the existing phenotypic map, and to study neuropsychiatric 
aspects and the occurrence of congenital heart defects. Results are reported in Chapters 4.1, 
4.2 and 4.3, respectively.
After generating this 18q deletion map, we studied specific subphenotypes linked to single 
genes on 18q. A chromosome translocation leading to disruption of TCF4 in a female patient 
with mild to moderate intellectual disability and minor facial anomalies was studied and 
compared to previously reported patients with Pitt Hopkins syndrome in Chapter 5.1. 
In addition, we wanted to determine whether the features of the distal 18q deletion syndrome 
are caused by disruption of one single gene, or should be considered as a true contiguous 
gene deletion syndrome (Chapter 5.2).
Finally, the implications of this work and future directions are discussed in Chapter 6. 
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ABSTRACT
During recent years a considerable improvement in diagnostic techniques has enabled 
cytogeneticists to find more and smaller chromosomal aberrations. However, accurate 
clinical knowledge about rare chromosome disorders is frequently lacking, mostly due to a 
significant decline in publishable cases. On the other hand, there is an increasing demand 
from parents and physicians for reliable information. In order to improve the quality and the 
quantity of data available, we designed a new database named the European Cytogeneticists 
Association Register of Unbalanced Chromosome Aberrations (ECARUCA) at http://www.
ecaruca.net. This Internet-database contains cytogenetic and clinical data of patients with 
rare chromosome abnormalities, including microscopically visible aberrations, as well as 
microdeletions and -duplications. Cases with certain breakpoints collected in the Zurich 
Cytogenetic Database were transferred to ECARUCA. The advantages of ECARUCA 
compared to existing sources are that ECARUCA is interactive, dynamic and has long-
term possibilities to store cytogenetic, molecular and clinical data. Professionals can login 
to submit new cases and perform searches in the database through the Internet. Currently 
the database contains 1500 unique chromosomal aberrations from almost 4000 patients. A 
frequent submission of new data ensures the up-to-date quality of the collection. Individual 
parent accounts allow parents to inform the ECARUCA team about the follow-up of their 
child. The ECARUCA database provides health care workers with accurate information on 
clinical aspects of rare chromosome disorders. Additionally, detailed correlations between 
chromosome aberrations and their phenotypes are of invaluable help in localising genes for 
mental retardation and congenital anomalies.
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INTRODUCTION 
Up to 0.6% of the general population have an unbalanced chromosome aberration. 1 
Depending on the diagnostic methods used and the population studied, microscopically visible 
chromosomal aberrations occur in 4–28% of mentally retarded patients, making chromosomal 
abnormalities a major cause of mental retardation. 2,3 Relatively common conditions like 
Turner syndrome and Down syndrome are clinically well known and recognisable, in contrast 
to the very limited knowledge on many rare chromosome abnormalities. 
These rare chromosome disorders have a total incidence of at least 0.07% 4 and with an annual 
birth rate of slightly more than 7 million in Europe 5, it can be estimated that currently 3000–
5000 children with a rare chromosome aberration are born each year on this continent only.
Moreover, the number of more or less unique chromosomal aberrations that are identified is 
rapidly increasing due to the development of new molecular and cytogenetic techniques such 
as multiplex ligation-dependent probe amplification (MPLA), multiplex amplifiable probe 
hybridisation (MAPH) and array-based comparative genomic hybridisation (array CGH). 6-9
Subtelomere screening by fluorescence in situ hybridisation (FISH) and genetic markers 
resulted in the identification of submicroscopic subtelomeric rearrangements in approximately 
5% of mentally retarded patients. 10,11 More advanced techniques such as genome wide high 
resolution array CGH, will allow the detection of submicroscopic interstitial deletions 
and duplications, which consequently will considerably increase the number of detectable 
chromosomal aberrations. 
However, while the number of chromosomally defined syndromes is rising, the clinical 
knowledge about individual syndromes remains limited due to the low number of patients 
that will actually be published in detail.
The source for clinical information concerning specific chromosomal disorders that is 
available for clinicians, counsellors, researchers and parents is the (inter)national medical 
literature. The main sources of information in scientific journals are case reports and 
occasionally a review discussing a chromosomal syndrome like Wolf–Hirschhorn or Cri du 
Chat. 12,13 Many reports have been collected in the “Catalogue of Unbalanced Chromosome 
Aberrations in Man” written by Schinzel. 4 This standard work is based on the literature of 
the last 30 years and contains around 2000 descriptions of patients with a rare chromosome 
aberration. In addition, the commercially available Zurich Cytogenetic Database, which 
contains over 7200 cases, can be used as a digital resource for information. 14
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Although all references mentioned are extremely valuable, the number of reports per 
individual chromosome aberration remains rather limited. This is mostly due to the declining 
number of published or publishable papers describing the clinical features of a single patient 
with a rare chromosome abnormality. 
Furthermore, articles illustrating the diagnostic improvements of new cytogenetic techniques 
usually provide only a limited clinical description of a large number of patients. Moreover, 
patients with a rare chromosome aberration are mostly diagnosed and described in scientific 
journals at a (very) young age. Follow-up information in these cases is hard to obtain, resulting 
in a lack of valuable information.
In conclusion, there is a need for an accessible dynamic database to fulfil the demand for 
information from clinicians, scientists and parents about rare (sub) microscopic chromosome 
aberrations. The Internet has been chosen as the medium for establishing the interactive online 
European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations 
(ECARUCA). In this article the development of the ECARUCA project and the structure of 
the database are described.
MATERIALS AND METHODS 
Objectives 
The objectives of ECARUCA are to improve two supplementary areas: the medical and 
scientific working fields of rare chromosome aberrations (see Figure 2.1).
The ECARUCA project aims to increase knowledge on clinical features in patients with rare 
chromosome aberrations. Within the medical field, physicians, genetic counsellors and other 
health care providers are explicitly calling for an improvement of availability of medical and 
psychosocial information. Due to the absence of detailed knowledge on the clinical features 
and follow-up in rare chromosome aberrations, parents may currently not receive the 
optimal clinical information related to the chromosomal aberration of their child, especially 
concerning complications that occur later in life and information about the achievement of 
developmental milestones.
Furthermore, contact between parents of children with a similar chromosome aberration 
has shown to be very valuable and should be facilitated.
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For the reliability of the database the accuracy of the cytogenetic studies performed in each 
case is very important. Therefore ECARUCA has set up a program for less facilitated centres 
to get free support in further cytogenetic characterisation of patient samples. Through this 
program, the number of cases in the database will increase. Moreover, exact determination of 
the breakpoints enables the medical professional to search for clinical information described 
in similar patients, thereby informing parents more accurately.
For scientists, ECARUCA aims to be a resource of information that is useful in localizing 
candidate genes as well as the identification of new syndromes. As (cytogenetic) techniques 
improve and smaller, unique genomic aberrations are detected, the collective registration of the 
clinical features occurring in these patients is of utmost importance. Therefore, cooperation 
between different centres and the exchange of knowledge will be initiated by ECARUCA.
Integrating the medical and scientific objectives should eventually lead to the improvement 
of quantity and quality of knowledge on rare chromosome aberrations available to both 
professionals and patients.
European network
In order to facilitate communication and cooperation between countries, physicians and 
scientists, a European network has been set up (Figure 2.2).
Figure 2.1 The main objectives of the ECARUCA project.
Medical issues
• Increase of information on clinical features and  complications in patients with (sub)-
microscopic chromosome aberrations
• Encourage and facilitate contact between patients & parents
• Support less facilitated centres specifying chromosome aberrations
Scientific issues
• Compile a resource of biological material useful for  mapping candidate genes for specific 
clinical abnormalities and identification new syndromes
• Enhance co-operation between centres
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First, a National Coordinator has been assigned in each participating country. The National 
Coordinator acts as an intermediary between the professionals of his or her country and 
ECARUCA. The National Coordinator represents ECARUCA during national meetings 
and informs colleagues on new developments within the project. Furthermore, the National 
Coordinator can assist and stimulate colleagues to submit new cases to the ECARUCA 
database.
Sometimes, language difficulties can discourage a person to take part in an international 
project. To lower this threshold, the National Coordinator acts as the first contact person 
to whom people can turn to for information. Conversely, the Coordinator can inform 
ECARUCA on important developments on clinical genetics within his or her country. An 
up-to-date list of all National Coordinators including contact information is available on the 
ECARUCA website.
Figure 2.2 Overview of the European network of the ECARUCA project.
 
European CytogeneƟcist AssociaƟon:  PMB members 
NaƟonal Coordinators 
 
MicrodeleƟon Research Network   PaƟent organisaƟons
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Another important role in the European network is fulfilled by the patient organisations. 
Several support groups in different European countries support the ECARUCA project. 
Patient organisations play an important role in supplying information to family members 
of patients with a rare chromosomal aberration. They also offer a contact service between 
patients and they can provide patient data.
Furthermore, a Microdeletion Research Network composed of several research centres 
around Europe has been set up. Now and in the future, collaboration between centres 
working on rare chromosome aberrations will be of great importance. A better understanding 
of the underlying genetic mechanisms and clinical outcome can only be reached through 
collective, standardised registration of these unique patients in one database, accessible to 
all participants.
Database model and confidentiality
The cytogenetic, molecular and clinical data collected by ECARUCA is stored in a relational 
database management system. All cases receive a unique case ID number and all data like 
cytogenetic, clinical and pedigree information are linked to that ID number. The database 
can be queried about aberrations of chromosome regions according to the ISCN 1995 
nomenclature.
The design of the ECARUCA data model also allows storage of aberrations at base pair level 
in order to collect molecular data of patients with a submicroscopic aberration.
The database is situated on a secure server at the Department of Human Genetics in Nijmegen. 
A web interface, using state of the art Java technology, enables users to view and submit data 
to ECARUCA safely and promptly on the website.
The security and integrity of the data is not only ensured by the correct implementation of 
hardware and software solutions, but also at the level of the user, by only allowing account 
holders to have access to the data. Accounts are granted exclusively to professionals in 
the field of human genetics and health care, in order to ensure confidentiality and correct 
interpretation of (clinical) data.
Before submission of data of a new patient, parents or the legal guardian need to sign an 
informed consent form. This form is stored in the patient file of the submitting centre.
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RESULTS
Database contents
Currently, the database contains around 4000 cases with almost 1500 unique aberrations. 
A large number of cases have been derived from the Zurich Cytogenetic Database, established 
by A. Schinzel and collaborators. This database contains cytogenetic and clinical data of 
published cases. Excluded are the three most frequent autosomal trisomies (for chromosomes 
13, 18 and 21), and X and Y chromosome aberrations unless combined with an autosomal 
aberration.
Before transferring cases to the ECARUCA database, all cases with uncertain breakpoints 
were excluded. Breakpoints were considered to be uncertain if the original publication did 
not provide a complete confirmation of breakpoints in the patient described. Moreover, 
because of the different data models of the Zurich and ECARUCA databases, all individual 
aberrations needed to be redefined. In the original database they are stored as text fields, 
while in ECARUCA they are stored as alphanumerical values, allowing conversion to base 
pair level. An aberration is defined by the start and end position in base pair running from 
pter to qter. In this way all molecular and cytogenetic data can be optimally integrated.
Currently we are working on the implementation of query possibilities and display of data 
on the base pair level.
Figure 2.3 shows an overview of the number of deletions and duplications per chromosome. 
The aberrations are distributed over the entire genome and include the following types: 
deletions, duplications, rings, uniparental disomies, trisomies, triploidies and tetraploidies. 
The majority are deletions (N = 2296), followed by duplications (N = 1773). As expected, 
some chromosomes contain more abnormalities (e.g. 4, 11, 13, 15, 18, 22) than others (e.g. 
12, 14, 16, 19), partly due to differences in size and gene density. Moreover, a number of 
chromosomes are involved in more common aberrations such as the 138 cases of DiGeorge 
syndrome, with a deletion of 22q11.2.
Website
The collection and distribution of information on rare chromosome aberrations takes place 
through the ECARUCA website (www.ecaruca.net). The website consists of two sections: 
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public pages that are freely available to each Internet user and restricted pages containing 
patient information that are only accessible to account holders.
Via the homepage (Figure 2.4), an Internet user can access four main areas: Submit Cases, 
Query Database, Cytogenetic Verification and Frequently Asked Questions. The menu on 
the left side of the homepage gives entry to remaining topics such as an overview of the data 
and a frequently changing introduction of a European patient organisation.
On a monthly basis, an interesting patient that has been submitted to the database will be 
published on the website. A general description of this patient is given at the public pages, 
whereas the restricted pages contain detailed cytogenetic and clinical information and 
illustrative clinical pictures. Cases considered for this topic are selected by the Clinical 
Database Managers (I.F. and D.A.K.) in accordance with the Project Management Board, 
consisting of the delegates from the centres in London, Zurich and Nijmegen. Furthermore, 
professionals are encouraged to bring interesting patients to the attention of ECARUCA.
Figure 2.3 Overview of the number of deletions and duplications per chromosome.
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In addition to the public pages, the following restricted options on the ECARUCA website 
are available to professional account holders:
•  Submit cytogenetic and molecular information.
•  Submit clinical information.
•  Search by chromosomal aberration.
•  Search by clinical feature(s).
•  List of all cases submitted by the centre of the account holder.
•  List of all participating centres.
•  Detailed Case of the Month information.
Furthermore, account holders receive an overview by email of all cases submitted to the 
ECARUCA database in the past month, thereby providing up-to-date clinical information 
and the possibility for publications together with colleagues.
A unique feature of the website is the restricted page for parents of children whose data has 
been submitted to the ECARUCA database. A case-specific parent account is created for all 
Figure 2.4 Homepage of the ECARUCA website.
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newly submitted cases and sent to the referring clinician. With this account parents have 
access to the information of their own child in the database and can directly send follow-up 
information to the Clinical Database Managers.
Submission of cases
Submission of new cases takes place through a clear online process. This process is composed 
of the submission of cytogenetic and/or molecular data and, subsequently, the submission 
of accompanying clinical data.
All new cases are presented to ECARUCA by entering the required cytogenetic and/or 
molecular information (Figure 2.5a). Data that are required include the karyotype, the exact 
breakpoints, ISCN quality and, if performed, the outcome of molecular techniques used. 
Furthermore, the name and email address of the clinician involved should be reported in 
case the cytogenetic submitter and the clinician are not the same person. The data submitted 
are checked by the Clinical Database Manager and, upon approval, the clinical data can be 
submitted by means of a separate data registration interface (Figure 2.5b). After entering 
all the data in the interface the user submits the information to the database with a single 
mouse click.
Figure 2.5a Submission of a new case starts with entering the required cytogenetic and/or 
molecular information.
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Any additional cytogenetic, molecular data and clinical follow-up information is submitted 
by email. The Clinical Database Manager carefully reviews all incoming data. Only when no 
further essential information is expected for a particular case and all data are confirmed to 
be certain, the case is made available for viewing by other account holders.
Search functionalities
Account holders have access to query the database either by chromosome aberration or 
by clinical features according to a select list derived from the Winter–Baraitser London 
Dysmorphology DataBase. 15
The option “Search by chromosomal aberration” allows the user to retrieve information 
about cases that concern a particular region on a chromosome of choice (Figure 2.6a). In 
the example, the search is specified to include all deletions in the region between the bands 
q21.3 and qter of chromosome 18. The search result provides not only cases for which the 
aberration is located within the boundaries of the chosen chromosome bands, but also 
those, which overlap the specified region. The user will see a list of all aberrations present in 
the database that are present within the region of interest (Figure 2.6b). By clicking on the 
aberration of interest, all features that accompany that aberration are listed. The final result 
(Figure 2.6c) is an overview of major and other clinical features of the total number of cases 
of that specific aberration. Also, information on average age at last examination and IQ are 
given together with a list of relevant publications.
Figure 2.5b Secondly, the clinical data can be submitted by means of the clinical interface. The 
feature tree is used for selecting clinical features.
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Figure 2.6 An example of how to use the option “Search by chromosomal aberration”, in which 
the physician/account holder is interested in all deletions in the region between the bands q21.3 
and qter of chromosome 18 (A). The search results in a list of aberrations (B). The user selects the 
most suitable aberration to view the associated clinical features (C). These clinical features can be 
used to provide advice to the patient concerned (Step 3).
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The option “Search by clinical feature(s)” allows the user to find all chromosomal aberrations 
in the database that are associated with specified features. An example for the features platelet 
abnormalities, ptosis and ventricular septal defect is shown in Figure 2.7. The clinical features 
can be selected from a user-friendly expandable selection “tree”, which is based on the feature 
list present in the widely known Winter–Baraitser London Dysmorphology DataBase. 
The User needs to indicate how many of the chosen features are minimally required to be 
associated with an aberration for it to be included in the search results. As a result, all types of 
aberrations for which patients display these clinical features are shown. This search strategy 
can provide a possible diagnosis and can in addition help to identify chromosomal regions 
and candidate genes for specific feature(s).
In case a professional has specific interest in a particular aberration, he or she can contact the 
Clinical Database Manager in order to receive more detailed information on an individual case.
Figure 2.7 An example of how to use the option “Search by clinical features”, in which the account 
holder is interested in all cases which display the following three features as present in a patient: 
ptosis, platelet abnormalities and ventricular septal defect (A). The search yields a number of 
aberrations in which patients display the selected features (B). This result can be used as input for 
further genetic analysis (Step 3). The obtained laboratory result is submitted to ECARUCA (Step 4a) 
and sent to the physician in attendance (Step 4b).
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Cytogenetic verification
Another important component of the ECARUCA project is a collaboration between centres 
in Europe and the Mediterranean that provide cytogenetic, molecular and, if needed, 
clinical diagnostics on cases with a rare chromosomal aberration or cases with incomplete 
investigations. 
In a number of genetic centres, especially in Eastern Europe, the financial or technical 
possibilities to perform high quality cytogenetic analyses are limited. As a consequence, 
breakpoints cannot be determined accurately. Because ECARUCA aims to be a reliable, high-
standard database, these cases cannot be entered into the database without additional studies, 
resulting in a loss of a potentially high volume of interesting data. This may subsequently 
contribute to the growing gap between laboratories in Western Europe and those in the less 
developed countries.
In order to prevent the issue outlined above, less facilitated centres can receive assistance with 
the verification of cytogenetic data. Material can be sent to the Institute of Medical Genetics 
in Zurich, where the exact breakpoints will be determined. Subsequently, the case will be 
entered in the ECARUCA database.
In the year 2004, the samples of 57 patients originating from 10 different countries have been 
investigated. Techniques used include routine karyotyping, reverse painting, micro satellite 
analysis, chromosome micro dissection, FISH and array CGH. For most of these cases, the 
advanced cytogenetic analysis with high-resolution techniques resulted in a more precise 
delineation of the breakpoints. Subsequently, in a number of cases the initial designation 
of the breakpoints had to be revised, thereby having implications for karyotype–phenotype 
correlation. 16,17
The correct determination of the chromosome aberration is not only important for the 
reliability of the ECARUCA database, but also has implications for clinical, counselling and 
scientific research activities.
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DISCUSSION
Future aims
The main feature of the ECARUCA database is its interactivity: users can query the database, 
and at the same time they can submit cases in order to increase the number of cases in the 
database, making it more powerful and informative. Submitting an unpublished case to the 
database will create a platform for such rare cases to be viewed by colleagues who might 
themselves have observed a similar case, leading to joint publications. 
At present, almost 4000 patients are collected in the database. In Europe alone, an annual 
number of 3000–5000 children carrying a rare chromosome aberration are born. Therefore 
it is expected that a considerable number of new cases coming from all over the world will 
be submitted to the database each year. Furthermore, by reviewing the medical literature 
on case reports and other publications, a supplemental number can be included every year.
The functionality of the ECARUCA database and the website are constantly being improved 
to meet the needs of its users. We try to make the submission procedure as complete as 
possible and simultaneously less time consuming. Furthermore, the adaptation of the database 
regarding the implementation of a search and entering facility at base pair level will ensure 
that the ECARUCA database can accommodate future techniques that have much higher 
resolution than that of the routine cytogenetic techniques presently used. New high-tech 
methods like array CGH are currently used in a limited number of laboratories, but the 
general expectation is that this technique will become a standard diagnostic method in the 
near future.
The possibility of collecting aberrations at the level of base pairs will have positive implications 
for the scientific use of the ECARUCA database. First of all, it will become easier for non-
clinical professionals to interpret and use the available data. Secondly, scientists, notably in the 
field of molecular genetics, require a standardised way of storing data at the submicroscopic 
level, which will be provided by ECARUCA. Storing of molecular data generated by high 
quality experiments in a standardised format greatly enhances the international search for 
new genes.
The easy and free access to the database for doctors and scientists is a good basis for 
collaboration in genotype–phenotype studies. The fast progress in the development of new 
techniques provides an increasing knowledge on genetic abnormalities. However, only by 
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understanding the clinical consequences of these genetic changes can progress be made 
towards gene identification and ultimately perhaps diagnostic interventions.
A limited other Internet sources are available to look for information on rare chromosome 
aberrations, e.g. DECIPHER and the Mendelian Cytogenetics Network. However, the first 
database only collects submicroscopic aberrations while the second one collects and provides 
information on balanced chromosomal rearrangements. Therefore, the ECARUCA database 
complies with the need to fill this gap.
In the future, ECARUCA will also focus on the follow-up of patients present in the database. 
This will give physicians more insight into how their patient will most likely develop and 
whether there are any specific new motor skills or physical abnormalities that need special 
attention.
In addition to the expected increase in knowledge among professionals, we wish to develop 
correct, understandable and clear information for parents and other interested parties. This 
should comprise a textual summary of the main clinical and developmental aspects of the 
aberrations included in the database. Since it would be impossible to include a description 
of all aberrations, we will restrict the information to a certain extension of chromosome 
regions or to more frequently arising small aberrations. The physician in attendance can 
retrieve more specific information that matches the exact deleted or duplicated region in 
the patient from the database.
Concluding remarks
The Internet era has given rise to all kinds of new possibilities in information processing. 
The Internet is especially helpful in finding information about unusual matters like rare 
chromosome aberrations. Until the existence of ECARUCA, however, an Internet search on a 
particular rare chromosome disorder usually yielded only a couple of websites with a limited 
amount of information, sometimes out-of-date and never including follow-up data of patients.
Although professionals have the opportunity to look up information in medical journals, 
books and other sources, these have the limitation, except for review articles, that only one or 
two patients are described independently and not the frequency of clinical features occurring 
in a group of patients with the same aberration. Furthermore, follow-up data of published 
patients is hard to retrieve.
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Altogether, ECARUCA can be considered to be a new system that meets the needs of 
scientists, physicians and patients and their family members involved with rare chromosomal 
aberrations, in an interactive way.
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ABSTRACT
High-resolution genome-wide array analysis enables detailed screening for cryptic and 
submicroscopic imbalances of microscopically balanced de novo rearrangements in patients 
with developmental delay and/or congenital abnormalities.
In this report, we added the results of genome-wide array analysis in 54 patients to data on 
117 patients from seven other studies. A chromosome imbalance was detected in 37% of all 
patients with two-breakpoint rearrangements. In 49% of these patients, the imbalances were 
located in one or both breakpoint regions. Imbalances were more frequently (90%) found in 
complex rearrangements, with the majority (81%) having deletions in the breakpoint regions. 
The size of our own cohort enabled us to relate the presence of an imbalance to the clinical 
features of the patients by using a scoring system, the De Vries criteria, that indicates the 
complexity of the phenotype. The median De Vries score was significantly higher (P=0.002) 
in those patients with an imbalance (5, range 1-9) than in patients with a normal array result 
(3, range 0-7). This study provides accurate percentages of cryptic imbalances that can be 
detected by genome-wide array analysis in simple and complex de novo microscopically 
balanced chromosome rearrangements and confirms that these imbalances are more likely 
to occur in patients with a complex phenotype.
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INTRODUCTION 
The estimated frequency of balanced chromosome rearrangements in a population of 
unselected newborns is 0.52%. 1 The majority of these translocations, insertions and inversions 
is transmitted from one of the parents and not associated with abnormal phenotypes. 2 In 1991, 
Warburton 3 reported data on the frequency and outcome of cases with apparently balanced, 
de novo, rearrangements detected at amniocentesis in over 350 000 pregnancies. She found 
that a microscopically balanced, de novo, reciprocal translocation was detected in 1 out of 
every 2000 pregnancies. The frequency of congenital abnormalities in fetuses and newborns 
with de novo, reciprocal translocations or inversions has been estimated at 6.1 and 9.4%, 
respectively. 3 This is more than twice as high as the risk of 2-3% in the general population.
The increased number of abnormal phenotypes can be caused by:
(1) a microdeletion or microduplication at the translocation or inversion breakpoint(s) 
which is only detectable by high-resolution techniques, (2) disruption or modulation of 
the expression of gene(s) located at the breakpoint(s) and (3) otherwise inactivation (po-
sition effect) of gene(s) at the breakpoint region(s). Thus, an apparently balanced, de novo, 
chromosome rearrangement can underlie an abnormal phenotype, but it may also be coi-
ncidental. The actual confirmation or rejection of causality by detecting a cryptic deletion 
or duplication at the assumed breakpoints or elsewhere in the genome is often lacking. The 
unbalanced nature of small rearrangements will most often escape detection, as the resolu-
tion of standard cytogenetic banding techniques is only 5-10 Mb. It has already been shown 
that the yield of chromosome abnormalities in patients with developmental delay (DD) 
and/or multiple congenital anomalies (MCA) increases considerably with the resolution 
of the technique used. A microscopically visible chromosome abnormality can be detected 
by routine karyotyping in 3-5% of all DD/MCA patients, excluding Down’s syndrome, 4-6 
whereas genome-wide array-based techniques are able to detect a chromosome imbalance 
in up to 15-20% of such cases. 5,7,8
Recent studies have reported on genome-wide array analysis used to identify cryptic 
imbalances in cohorts of DD/MCA patients with an apparently balanced, de novo, 
chromosome rearrangement (Table 3.1.1). 9-15 A cryptic imbalance was detected by 
genome-wide array analysis in 33-100% of DD/MCA patients with a de novo chromosome 
rearrangement. In the majority of patients, the imbalance was detected at one or more 
breakpoints, although a large percentage of imbalances (15-40%) was found elsewhere in 
the genome. The frequency of detected imbalances is significantly higher in patients with a 
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more complex chromosome rearrangement (CCR), involving more than two chromosomes 
and/or more than two breakpoints. 9,10,14 In all studies, the reported imbalances were assumed 
to cause the abnormal phenotype.
In contrast to the studies performed in DD/MCA patients, Baptista et al. 12,16 compared a cohort 
of 31 phenotypically normal individuals carrying a balanced chromosome rearrangement with 
a cohort of 14 DD/MCA patients. No genomic imbalances at the breakpoints, or elsewhere 
in the genome, were detected in the 31 normal carriers, whereas a disease-causing imbalance 
was detected in 4 out of 14 DD/MCA patients. The authors concluded that translocations 
in patients with a clinically abnormal phenotype are molecularly distinct from those in 
normal individuals. An unexpected finding was that the frequency of gene disruption due 
to a chromosome rearrangement did not differ between phenotypically abnormal patients 
and the normal study population. 12 However, the percentage of disrupted genes that have a 
role in the nervous system was higher in the phenotypically abnormal patients.
Since there is limited data on patients with apparently balanced chromosome rearrangements, 
we decided to evaluate the results obtained from genome-wide array analysis in a cohort of 54 
DD/MCA patients and a cytogenetically balanced, de novo, chromosome rearrangement. Since 
this is the largest postnatal cohort of DD/MCA patients with de novo balanced rearrangements 
reported thus far, we were able to improve the estimated percentage of submicroscopic 
imbalances detected by genome-wide array analysis in de novo chromosome rearrangements. 
The size of the cohort also enabled us to relate the probability of finding an imbalance to the 
clinical phenotype of the patient by using the De Vries scoring system. 17
PATIENTS AND METHODS 
Patient selection 
Clinical data and samples were collected from 54 patients with an apparently balanced, de 
novo, structural chromosome rearrangement. All patients had been referred for karyotyping 
because of DD and/or MCA and were enrolled in the study for diagnostic purposes. All 
chromosome rearrangements were detected by routine cytogenetic analysis at a minimum 
band level of 500: 46 patients carried a two-breakpoint rearrangement; 40 patients had a 
reciprocal translocation, while 6 patients carried an inversion. Eight patients had a CCR 
with at least three breakpoints.
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All patients, parents or legal representatives gave informed consent for this study, according 
to local guidelines.
Collection of clinical data
Clinical data were derived from medical records using a standardized form. Additional 
information was requested from the referring clinicians whenever necessary. All patients were 
scored according to adapted De Vries criteria, which provided a checklist for patients with 
submicroscopic subtelomeric rearrangements (Table 3.1.2). 17 Family history was replaced 
by DD in this scoring system, because a positive family history, either compatible or non-
compatible with Mendelian inheritance, does not enhance the chance of finding imbalances 
in the breakpoint regions in patients with a de novo chromosome rearrangement.
In contrast, the De Vries criteria were developed for patients with an intellectual disability, 
while not all the patients in our study had a DD. Therefore, one and two points were given for 
mild-to-moderate and severe DD, respectively. Severe DD was defined as a Developmental 
Quotient <30, while mild-to-moderate DD was a Developmental Quotient between 30 and 70. 
In this way, the maximum number of points that could be scored remained 10 (Table 3.1.2).
Table 3.1.2 De Vries score and adjusted De Vries score for assessing clinical phenotypes
Original De Vries score 17 De Vries score, adjusted for this study
Trait (points) Score Trait (points) Score
Family history of MR
Compatible with Mendelian inheritance (1)
Incompatible with Mendelian 
inheritance (2) a
Prenatal onset of growth retardation
1-2 
2
Developmental delay
Mild-moderate developmental delay (1)
Severe developmental delay (2)
Prenatal onset of growth retardation
1-2
2
Postnatal growth abnormalities
Microcephaly (1)
Short stature (1)
Macrocephaly (1)
Tall stature (1)
Max 2
Postnatal growth abnormalities
Microcephaly (1)
Short stature (1)
Macrocephaly (1)
Tall stature (1)
Max 2
≥ 2 Facial dysmorphic features b 2 ≥ 2 Facial dysmorphic features b 2
Non-facial  dysmorphism and congenital 
abnormalities c
1-2 Non-facial  dysmorphism and congenital 
abnormalities c
1-2
Total maximum 10 Total maximum 10
a Including discordant phenotypes.
b Notably, hypertelorism, nasal anomalies and ear anomalies.
c Notably, hand anomaly, heart anomaly, hypospadias with/without undescended testis; assign 1 point for each, 
with a maximum score of 2 points.
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Genome-wide array analysis
Array analysis with an average genome-wide resolution of ~200 kb was performed using 
either an Agilent 105k or 244k oligo array, a 32k BAC array as previously described, 18 or the 
Affymetrix 250k SNP array platform, 19 following the protocols provided by the manufacturers 
(Agilent Technologies and Affymetrix Inc., Santa Clara, CA, USA).
For the Agilent array reference DNA, a mixture of 40 male or female DNA samples of the 
same gender was used as control. The data were processed using Feature Extraction V.9.1 
and CGH analytics V.3.4.27 provided by the manufacturer (Agilent Technologies). For the 
SNP array experiments, copy number estimates were determined using the updated version 
2.0 of the CNAG (Copy Number Analyzer for Affymetrix GeneChip mapping) software 
package. 20 The normalized ratios were then analyzed for genomic imbalances by a standard 
Hidden Markov Model, essentially as described before. 18 The SNP array data obtained from 
patient DNA were compared with SNP array data from 10 healthy, sex-matched individuals.
Regardless of the array platform employed, genome-wide data analysis was performed using 
previously determined criteria which provide 95% confidence of representing a true copy 
number variation (CNV). 21 A CNV was considered significant if five or more consecutive 
probes showed a single copy number loss (n=1), or at least seven consecutive SNPs showed a 
single copy number gain (n=3) for the Affymetrix array, or four or more consecutive probes 
showed gains or losses for the Agilent array. For interpretation purposes, various public 
web sources were consulted, including the Online Mendelian Inheritance of Man (http://
www.ncbi.nlm.nih.gov/Omim), the DECIPHER database (http://decipher.sanger.ac.uk) and 
ECARUCA (http://www.ecaruca.net). A CNV was considered a normal genomic variant if it 
had been detected in at least three control individuals as reported in the Database of Genomic 
Variants (http://projects.tcag.ca/variants), and/or been encountered in at least three in-house 
control samples. Data analyses were based on the NCBI36/hg18 build of the human genome.
Fluorescent in situ hybridization analysis
To validate the gains or losses identified by genome-wide array analysis, region-specific 
fluorescent in situ hybridization (FISH) was performed following routine protocols. Bacterial 
Artificial Chromosome (BAC) clones were selected from the human library RPCI-11 
according to the UCSC Human Genome Assembly (freeze March 2006) and kindly provided 
by the Wellcome Trust Sanger Institute (http://www.sanger.ac.uk) or obtained from the 32k 
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set of BAC DNAs in the Nijmegen laboratory. BAC DNA was indirectly labeled with biotin- 
or digoxigenin-11-dUTP using Nick translation. Slides were hybridized overnight at 37 °C 
and fluorescently labeled with FITC or Texas Red.
Multiplex ligation-dependent probe amplification. 
To validate the gains identified by array analysis, region-specific multiplex ligation-dependent 
probe amplification (MLPA) was performed. For each region, two uniquely sized probes 
were developed in accordance with a protocol provided by MRC Holland (Amsterdam, the 
Netherlands). Ten probes were combined in one MLPA assay together with a DNA quantity 
and a DNA denaturation control mix (EK-1 kit, MRC Holland). The procedure was further 
carried out as described by De Vries et al. 18
RESULTS
In this study, 54 patients with an apparently balanced, de novo chromosome rearrangement and 
an abnormal clinical phenotype were analyzed for submicroscopic chromosome imbalances 
by genome-wide array analysis. Forty-six patients had a two-breakpoint rearrangement upon 
routine karyotyping. In eight patients, a more complex aberration was found. All patients 
had facial dysmorphisms and/or congenital malformations and 46 out of 52 patients (88%) 
showed DD, varying from mild psychomotor retardation and speech delay to severe DD. 
Development could not be assessed in two patients because they died at the age of 1 day and 
2 months, respectively (patients 12 and 43). A detailed description of all the phenotypes is 
presented in Table 3.1.3.
The total number of CNVs, including well-known benign CNVs, detected by the platforms 
used ranged from 2 to 12 with an average of 5.6 per patient (Table 3.1.3). All the potentially 
causative, copy number alterations detected by array could be confirmed by FISH (losses), 
MLPA (gains) or an independent array platform.
CNVs at or near the breakpoint regions
In 11 out of 54 patients (20%), the apparently balanced rearrangement was found to be un-
balanced at the breakpoint region(s). We found no gains but 16 losses in these 11 patients in 
total (Table 3.1.4A). The size of the losses varied from 0.1 to 15.3 Mb. Seven patients had a 
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single loss, two patients (6 and 53) had losses at multiple breakpoints and two patients (49 
and 51) had multiple, non-overlapping losses in one breakpoint region. Patient 51 also had 
a loss elsewhere in the genome (Table 3.1.4B). In patient 6, with a loss at both breakpoints 
(1p22.1 and 6q15), the 1.1-Mb loss of chromosome 1 appeared to contain no known genes. 
The 4.25-Mb deletion in patient 42 contained the FBN1 gene, explaining the observed Marfan 
phenotype. 22
Five out of forty-six (11%) patients with a two-breakpoint chromosome rearrangement had a 
cryptic imbalance related to their reciprocal translocation. No imbalances were found related 
to inversions (n=6). Six out of eight (75%) patients with a CCR (more than two breakpoints) 
appeared to have an abnormal genome profile upon array analysis. All of these six patients 
had losses at the breakpoint regions.
Imbalances elsewhere in the genome
Copy number changes elsewhere in the genome were present in seven patients: six patients 
had a reciprocal translocation and one patient had a CCR (Table 3.1.4B). Six losses and three 
gains not related to the breakpoints were detected in total in these seven patients. Only the 
patient with a CCR (51) had additional copy number alterations at one of the breakpoint 
regions (Table 3.1.4A). In this and two other patients (30 and 32), the respective CNV was 
inherited from a healthy parent. Patient 29 had three imbalances: two losses were de novo 
(on the paternal allele) and one loss was also observed in his healthy father.
In an adult patient (10) with a translocation (1;17)(p36.1;q11), a 650-kb gain in 1p34.1 was 
found. Unfortunately, this patient’s parents were not available for further investigation. A 
partially overlapping, de novo 650 kb gain was found in a clinically more severely affected 
boy (18). Both gains overlap a 450-kb region in 1p34.1.
The last imbalance detected elsewhere was a 270-kb deletion at 5p13.1 in a patient with a 
translocation (2;10) (patient 16). Unfortunately, this patient’s parents were not available for 
further investigation.
Clinical criteria
All but three patients (n=51) could be scored according to the adapted clinical De Vries 
criteria (Tables 3.1.2 and 3.1.3). 17 Patient 43 died 1 day post-partum, patient 12 died at the 
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age of 2 months, and patient 52 had Sotos syndrome due to an NSD1 mutation interfering 
with the phenotype. The distribution of the scores is shown in Supplementary Figure S3.1.1. 
All patients with a chromosome imbalance in the breakpoint region (n=11) had a score of 
at least 3 with a median score of 5 (range 3-9). The highest score was found in the patient 
with imbalances both at a breakpoint and elsewhere (score 9 in patient 51). Patients with a 
chromosome imbalance restricted to elsewhere in the genome (n=6) tended to have a lower 
score (median 4.5, range 1-6). One of the imbalances in this group was considered not 
clinically relevant (see Discussion and Table 3.1.4B). Correction for this patient 32 led to a 
median score of 5 (range 1-6). 
The median score in the total group with a possibly clinically relevant CNV (n=16) was 5 
(range 1-9), while the median score in the group without a significant CNV (n=35) was 3 
(range 0-7). The difference between these two groups is significant (P=0.002, Mann–Whitney 
U-test).
DISCUSSION
In this study, 54 patients with an apparently balanced, de novo chromosome rearrangement 
were examined by high-resolution genome-wide array analysis. The mean number of CNVs, 
including well-known recurrent copy number polymorphisms, that was detected was 5.6 per 
patient (range 2-12). In general, the number of CNVs detected per patient depends on the 
platform and detection thresholds used, but the number found in our study does not differ 
substantially from patients without apparently balanced rearrangements. 18,29
Out of 46 patients with a two-breakpoint chromosome rearrangement, 11 (25%) appeared to 
have an abnormal genome profile encompassing six losses, each at one of the breakpoints in 
five patients, and five losses and three gains elsewhere in the genome in six patients.
From analysis of their parents, two of the latter category could be specified as rare, inherited 
CNVs. Six out of eight patients with a CCR were found to have one or more clinically 
significant losses at one of the breakpoints. In addition, one of these six patients had a 
paternally inherited imbalance elsewhere in the genome. Although the overall percentage 
of patients with a cryptic or submicroscopic, clinically significant imbalance in this cohort is 
31%, there is a remarkable difference between patients with a two-breakpoint chromosome 
rearrangement (24%) and those with a more complex rearrangement (75%).
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The number of imbalances seen in our patient cohort is similar to the studies of Sismani 
et al. 11 and Baptista et al., 12 but lower than the studies of others (Table 3.1.1). 9,10,13-15 This 
might be due to differences in patient selection (reflected in the high number of aberrations 
found elsewhere in the genome in the studies of Gribble, Higgins and Gijsbers) and to the 
higher number of complex rearrangements studied by De Gregori. Compiling the data of 
the previous and present studies, we conclude that in almost half of the patients with a de 
novo chromosome rearrangement, a genomic imbalance can be detected by genome-wide 
array analysis. We confirmed that, in complex rearrangements, the chance of finding copy 
number alterations at the breakpoints is very high: 75 and 72%, in our study and the combined 
studies, respectively.
Imbalances are not always located at breakpoints 
In most patients (20%) with clinically relevant copy number alterations, the imbalance is 
detected in or near the breakpoints of the chromosomes involved (Table 3.1.4A). However, 
in 13% an imbalance is found elsewhere in the genome (Table 3.1.4B). As shown here and in 
previous studies, this was especially true for two-breakpoint de novo aberrations. In 19% of all 
patients with a two-breakpoint rearrangement, imbalances are found elsewhere. Especially in 
these cases, the clinical significance of the detected CNVs should be determined by parental 
analysis, among other investigations. The observed percentage of 19% is in agreement with 
the general figure of 17% of imbalances that is found in the DD/MCA population. 7,8 These 
results underline the importance of a genome-wide approach in patients with an apparently 
balanced, de novo chromosome rearrangement. If imbalances are found independent of the 
rearrangement breakpoints, this may have implications for the recurrence risk and warrants 
studies in the parents to exclude cryptic balanced translocations and insertions.
Furthermore, it is crucial to critically examine an apparently balanced rearrangement after 
initial detection, because they are often more complex than they appear at first.
Losses are more frequent than gains at breakpoints
The clinically significant imbalances at the breakpoint regions found in this study were all 
deletions. Breakpoint deletions are more frequent in patients with a CCR than in patients with 
a two-breakpoint rearrangement. In the present study, we detected deletions in six out of eight 
CCR patients (75%). This is comparable to the results of De Gregori et al. 9 and Schluth-Bolard 
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et al., 14 who detected deletions in 69 and 80% of patients with a de novo CCR, respectively. 
Thus, deletions may be the main cause of phenotypic abnormalities in patients with a CCR.
The preponderance of deletions is similar to the results of others (Table 3.1.1). 9,10,12-14  Recently, 
Howarth et al. 30 showed that in breast cancer cell lines reciprocal translocations arising 
during mitosis may result in both deletions (up to 31 Mb) and duplications (up to 200 kb) 
at the breakpoint regions. They demonstrated that the underlying mechanism most likely is 
stalled replication bubbles during the interchromosomal exchange. De novo constitutional 
translocations have their origin during meiosis. Nonetheless, the same mechanism may cause 
imbalances during meiotic interchromosomal exchanges.
That we and others did not find breakpoint duplications in DD/MCA patients might 
be explained by their size (often under the detection threshold) and the fact that small 
duplications rarely result in a phenotype.
Clinical significance of the detected imbalances
The size of the deletions and gains in our patients ranged from 100 kb to 15.3 Mb and from 
240 to 650 kb, respectively. In patient 6 with deletions at both breakpoints, the abnormal 
phenotype was considered to be a consequence of the 9.2-Mb deletion at chromosome 6, 
because the small deletion at chromosome 1 did not contain any known genes. All other 
breakpoint deletions were considered pathogenic based on the criteria mentioned in Methods.
In four of the seven patients with an imbalance elsewhere in the genome, the imbalance was 
found to be inherited from a clinically unaffected parent. The deletion 16p13.11 (patient 30) 
and deletion 1q21.1 (patient 51) are known microdeletion syndromes with variable phenotypes. 
31-33 Patient 51 also carries two significant losses at a breakpoint region, but we cannot exclude 
that the 1q21.1 deletion also contributes to the phenotype. The maternally inherited gain in 
1q23.3 (patient 32) was considered unlikely to be clinically relevant because a larger gain has 
been detected in two control individuals from one study in the Database of Genomic Variants. 29 
The paternally inherited loss in patient 29 is in a gene-less region of 12p11.22 and therefore 
likely to be benign. Of the two de novo losses in the same patient (29), the 4.9-Mb loss in 
2q33.3q34 is most likely to be clinically relevant. The 9q21.12q21.1 loss has not been detected 
before; and thus, its clinical significance remains uncertain, although a contribution to the 
clinical phenotype of patient 29 cannot be excluded.
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The 650-kb gain in 1p34 in patient 10 is not a known polymorphism according to the Database 
of Genomic Variants, and is only partially overlapping gains that have been found in normal 
individuals (Nijmegen and Groningen in-house control data). Patient 18 had a similarly 
sized duplication, of which 450 kb overlapped with the gain of patient 10. The distal 200 
kb, non-overlapping region, contains several genes, including POMGNT1. The phenotype 
of patient 18 is similar to previously published patients with larger overlapping duplications 
that included this gene. 25
The 270-kb loss in 5p13.1 (patient 16) is not a known polymorphism but only contains the 
LIFR gene involved in autosomal recessive Stuve-Wiedemann syndrome, although the patient’s 
clinical features do not resemble this syndrome. Unfortunately, the parents were unavailable 
for further studies and the clinical significance of the deletion remains unclear, as no similar 
microdeletion has been found in controls or other patients so far.
Thus, in at least four of the seven patients with imbalances elsewhere, the detected imbalance 
was considered to contribute to the abnormal phenotype.
Clinical features pointing to an imbalance
All 16 patients with a potentially clinically relevant CNV showed DD, ranging from mild 
psychomotor or speech delay (in five patients) to severe DD (in seven patients). As discussed 
above, the gain in patient 32 with severe DD was, in retrospect, considered very unlikely to 
be causative for the phenotype. If we had only analyzed patients with an adapted De Vries 
score >3, we would not have missed any clinically relevant chromosome imbalances at the 
breakpoint regions (Supplementary Figure S3.1.1). This is in line with the results of the 
original study using De Vries criteria: all patients with a subtelomeric aberration had a De 
Vries score of at least 3. 17
Two out of six patients with an aberration elsewhere in the genome had a score <3. This 
concerned the maternally inherited 1q23 gain in patient 32 (score 2) that was considered 
unlikely to be clinically relevant, and one 1p34 gain in patient 10 of uncertain clinical relevance 
(score 1). The median De Vries score of all 14 patients with a certainly clinically relevant 
CNV (Table 3.1.4) was 5 (range 3-9), while in the 35 patients without a relevant CNV the 
median score was 3 (range 0-7). Three patients could not be scored (see Results), and two 
patients had an imbalance of uncertain clinical relevance.
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Other mechanisms causing DD/MCA in balanced rearrangements
A truly balanced, de novo chromosome rearrangement may still contribute to an abnormal 
clinical phenotype due to disruption of a gene or due to a position effect. An example of 
the former was seen in patient 45 who appeared to have a disruption of the TCF4 gene at 
18q21.1, as described in a previous study. 27 Conventional methods for mapping chromosome 
breakpoints, such as FISH, are laborious, and often fail to identify the disrupted gene. 
Combining DNA array hybridization with chromosome sorting improves the efficiency of 
breakpoint mapping, but can only be applied when the physical properties of the derivative 
chromosomes allow them to be flow sorted. Nowadays more efficient and accurate breakpoint 
identification can be performed by next-generation paired-end sequencing. 34
A position effect was most likely responsible for the split-hand-feet syndrome (SHFM) in 
patient 37 with an inversion breakpoint in 7q near the SHFM1 locus and the candidate genes 
DSS1, DLX5 and DLX6. 26 
Conclusion
The combined results of our study and previous reports show that in 79/171 (46%) of DD/
MCA patients with a de novo chromosome rearrangement, a genomic imbalance could be 
detected by genomewide array analysis. In patients with a rearrangement involving more than 
two breakpoints, there is a high chance of detecting an imbalance at one of the breakpoints 
(21/29; 72%). In two-breakpoint rearrangements, an imbalance located at a breakpoint was 
detected in 26/142 (18%) patients. However, a substantial number of imbalances were also 
detected outside the breakpoint regions: in 33/171 (19%) patients, an imbalance was found 
elsewhere in the genome, which is comparable to the general DD/MCA population. In 
conclusion, diagnostic studies should not only focus on the rearrangement breakpoints, but 
a genome-wide approach should be used to investigate patients with apparently balanced, 
de novo chromosome rearrangements.
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Supplementary Figure S3.1.1 Distribution of the adjusted De Vries score (Table 3.1.2) in patients 
without clinically relevant imbalance (          ), patients with a clinically relevant imbalance at the 
breakpoint region (          ), patients with a clinically relevant imbalance elsewhere in the genome 
(       ), and patients with a potentially clinically relevant imbalance elsewhere in the genome 
(           ). 
* Patient 51 who had imbalances at a breakpoint region and elsewhere in the genome.
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ABSTRACT
We evaluated both clinical and laboratory aspects of our new strategy offering quantitative 
fluorescence (QF)-PCR followed by non-targeted whole genome 250K single-nucleotide 
polymorphism array analysis instead of routine karyotyping for prenatal diagnosis of fetuses 
with structural anomalies.
Upon the detection of structural fetal anomalies, parents were offered a choice between QF-
PCR and 250K single-nucleotide polymorphism array analysis (QF/array) or QF-PCR and 
routine karyotyping (QF/karyo).
Two hundred twenty fetal samples were included. In 153/220 cases (70%), QF/array analysis 
was requested. In 35/153 (23%), an abnormal QF-PCR result was found. The remaining 
samples were analyzed by array, which revealed clinically relevant aberrations, including two 
known microdeletions, in 5/118 cases. Inherited copy number variants were detected in 11/118 
fetuses, copy number variants with uncertain clinical relevance in 3/118 and homozygous 
stretches in 2/118. In 67/220 (30%) fetuses, QF/karyo was requested: 23/67 (34%) were 
abnormal with QF-PCR, and in 3/67, an abnormal karyotype was found.
Even though QF/array does not reveal a high percentage of sub-microscopic aberrations in 
fetuses with unselected structural anomalies, it is preferred over QF/karyo, as it provides a 
whole genome scan at high resolution, without additional tests needed and with a low chance 
on findings not related to the ultrasound anomalies.
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INTRODUCTION 
Chromosome abnormalities have been reported in 9% to 27% of pregnancies in which (major) 
ultrasound (US) anomalies have been observed. 1-3 Traditional karyotyping, with a resolution 
of 5 to 10 Mb, is still the gold standard in prenatal cytogenetics. Array analysis, however, 
allows for a much higher resolution genome-wide scan of unbalanced genomic aberrations, 
but its application in prenatal diagnosis is still under debate, in particular because of the 
possible detection of copy number variants (CNVs) for which the clinical consequences are 
uncertain or unknown. Furthermore, there is a possibility of detecting CNVs in genomic 
regions that are related to late-onset diseases, such as deletions in regions including the 
BRCA1 or BRCA2 genes, or detecting a carrier status such as an intragenic deletion in the 
Duchenne muscular dystrophy gene. 4-7
Targeted or low-resolution arrays were used in a number of laboratories. 8-15 These offer the 
advantage of being able to carefully select the genomic regions under study, with the ability 
to focus on regions with known clinical relevance. However, as we 16 and others 17 stated, the 
disadvantage of using a targeted approach is that currently unknown, clinically important 
aberrations might be missed, and targeted array platforms require continuous redesigning 
with the discovery of new disease loci. Furthermore, Coppinger et al. 18 showed that targeted 
with genome-wide backbone coverage array comparative genomic hybridization (aCGH) 
analysis reveals clinically significant submicroscopic abnormalities without an increase in 
unclear results or benign CNVs as compared with targeted aCGH.
The studies published so far on the use of array analysis in prenatal diagnosis all report on 
array analysis after karyotyping. 8-15,19-22 In our department of Human Genetics in Nijmegen, 
the Netherlands, the Affymetrix 250K genomewide single-nucleotide polymorphism (SNP) 
array has replaced routine chromosome studies since January 2009 as the first tier postnatal 
diagnostic test for patients with intellectual disability and/or congenital anomalies. Since 
October 2010, the same strategy is routinely followed in prenatal diagnosis if US structural 
anomalies are detected.
After extensive counseling, parents are offered a choice between routine karyotyping and 
non-targeted whole genome array analysis. If array analysis is preferred, a written informed 
consent needs to be signed by both parents, including the decision whether or not they want 
to receive information on aberrations unrelated to the US anomalies but possibly related to 
(late-onset) diseases.
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The present paper reviews our experiences with this new strategy, including an evaluation 
of parental choices and the results of genetic analysis.
MATERIALS AND METHODS 
Patients and samples 
Since October 2010, pregnant women with US structural fetal anomalies (including nuchal 
translucency >3.5 mm), opting for an invasive procedure, were offered a choice between QF-
PCR and 250K SNP array analysis or quantitative fluorescence (QF)-PCR and karyotyping. If 
the detected anomalies were not structural fetal anomalies (e.g., isolated poly-hydramnios or 
intrauterine growth restriction without other anomalies), if only so-called soft markers were 
seen (e.g., absent nasal bone, single umbilical artery or choroid plexus cysts), or if intrauterine 
fetal death was detected, women were excluded from the “choice” strategy.
Pretest and posttest counseling was carried out by the obstetrician–gynecologist, specifically 
trained for this by a clinical geneticist, through (individual) oral presentations and written 
information considering SNP array analysis.
Pretest counseling included oral and written information on the following:
• the resolution and detection rate (both strategies);
• the chance of detecting aberrations with unknown or uncertain clinical 
relevance (both strategies);
• the (low) possibility to detect an aberration, unlikely causative for the US 
anomalies, but with possibly clinical consequences for either the fetus or the 
parents themselves, including (lateonset) diseases for which screening and/or 
treatment is currently (un)available (array analysis strategy); and
• the necessity of collecting parental blood samples (array analysis strategy).
The clinical geneticist was always involved in posttest counseling if an aberration was detected 
by either strategy.
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Strategies
Regardless of the parental choice, all samples were first analysed by QF-PCR to test for one of 
the common aneuploidies of chromosomes 13, 18, 21, X, or Y. Samples with abnormal QF-
PCR results were subsequently karyotyped to study whether the abnormality could be due 
to a parental rearrangement. After a normal QF-PCR result, either 250K SNP array analysis 
(QF/array strategy) or karyotyping (QF/karyo strategy) was performed, depending on the 
parental choice (Figure 3.2.1A).
Figure 3.2.1 Schematic overview of the new strategy (A) and the results in the QF/array and 
QF/karyo groups (B).
QF-PCR
Normal Abnormal
Karyotyping 250K SNP array Karyotyping
Normal Abnormal AbnormalNormal
A
B
54%
16%
10%
20%
Choice: QF/array
QF-PCR normal (N=118)
Array result:
normal: 99 
(including two with homozygous stretches)
clinically relevant CNVs: 6
inherited CNVs: 12 (11 fetuses)
CNVs with uncertain clinical relevance: 3
(suscepƟbility loci)
Choice: QF/array
QF-PCR abnormal (N=35)
Choice: QF/karyo
QF-PCR abnormal (N=23)
Choice: QF/karyo
QF-PCR normal (N=44)
Karyotype result:
normal:     N=41 
abnormal: N=3
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For array analysis, informed consent from both parents was obtained, in which they signed 
for having received and understood sufficient information on the test and chose whether they 
wanted to be informed about CNVs unrelated to fetal US anomalies, but possibly related to 
(late-onset) diseases, subdivided in currently treatable or untreatable disorders.
Parental DNA was almost always available and simultaneously collected with the fetal 
sample.
DNA isolation for array analysis
In case of chorionic villi, DNA was isolated from the mesenchymal core cell fraction of 
uncultured chorionic villi. For amniotic fluid, DNA was isolated from uncultured amniotic 
fluid cells in case of sampling at or after 20 weeks of gestation. Amniotic fluids sampled 
before 20 weeks of gestation were first cultured before DNA isolation was carried out to 
obtain sufficient DNA. DNA was isolated using the QIAamp MinElute Virus Spin Kit for 
DNA from uncultured amniotic fluid samples (following the “Purification of viral nucleic 
acids from plasma or serum” protocol) and the QIAamp DNA Mini Kit for cells from cultured 
amniotic fluid samples and chorionic villi (following the “DNA purification from blood or 
body fluids” spin protocol) (QIAgen, Westburg bv, the Netherlands). DNA concentrations 
used as input for array analysis were between 17 and 50 ng/L.
DNA from uncultured blood cells from parental blood was isolated following standard 
procedures (Chemagic Magnetic Separation Module 1 from Chemagen, Waltham, USA).
QF-PCR
Fetal DNA was extracted using a Chelex-based procedure (Instagene Matrix, Bio-Rad 
Laboratories, CA). QF-PCR analysis was performed using the AneufastTM kit (version 1 or 
2, Genomed Ltd, Kent, UK). For both the DNA extraction and QF-PCR analysis, instructions 
of the AneufastTM kit manufacturer were followed.
Karyotyping
Routine cytogenetic analysis was carried out according to standard procedures.
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Affymetrix NspI SNP array hybridization and analysis
All array analyses were carried out using the Affymetrix GeneChip 250K (NspI) SNP array 
platform (Affymetrix, Inc., Santa Clara, CA, USA). Hybridizations, analysis, and data 
interpretation were performed according to the manufacturer’s protocols and as described 
previously. 16,23 On the basis of the data published by Hehir-Kwa et al., 24 we set our 250K 
SNP array detection criteria for constitutional genome diagnostic applications at ≥150 kb 
for losses and ≥200 kb for gains (p-value >0.9 at a power of 95%). For carrier testing, these 
settings were the same for the region that was found aberrant in the index patient but was 
arbitrarily set at a threefold lower resolution for the remainder of the genome. Parents are 
considered healthy individuals unless otherwise indicated, and because their array data can 
be used as a control data set, we opted for this approach. The breakpoint positions of each 
aberrant region were converted to UCSC hg19 (UCSC Genome Browser, release February 
2009) using hgLiftOver (http://genome.ucsc.edu/cgi-bin/hgLiftOver). 
In addition to copy number analysis, SNP array data analysis also provided genotyping data 
and therefore, the possibility to detect homozygous stretches. This not only enabled the 
detection of uniparental disomy but might also reveal a possible candidate recessive disease 
gene in a homozygous stretch. 23
Array analysis was not carried out in duplicate. To avoid sample mix-up as much as possible, 
all Qiagen-isolated DNA samples were additionally tested by QF-PCR prior to array analysis, 
to compare profiles and thus ensure that samples from the same pregnant woman were used 
for initial QF-PCR testing and subsequent array analysis. Furthermore, samples were loaded 
on the array platform with alternating sexes (known from the results of the QF-PCR), and 
in case parental samples were analyzed, patient–parent trio genotype analysis was routinely 
performed to rule out sample mix-up.
For efficiency reasons, array experiments were run twice a week. If array analysis was started 
after 20 weeks of gestation, fetal and parental samples were analyzed simultaneously to avoid 
a delay in reporting time. Because more time was available if array analysis was started before 
20 weeks of pregnancy, parental DNA was only analyzed in case this was necessary for the 
interpretation of abnormal array results from fetal DNA.
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RESULTS
Between October 2010 and September 2011, a total of 220 samples (amniotic fluid or 
chorionic villi) from fetuses with structural US anomalies were sent to our laboratory for 
genetic analysis: In 70%, QF/array was chosen and in 30%, QF/karyo.
In the QF/array group, 23% of the samples showed an aberration with QF-PCR (16% of the 
total group); in the QF/karyo group, this was 34% (10% of total). Subsequent karyotyping 
showed all QF-PCR aberrations to be de novo aberrations, mostly so-called “free”, non-
inherited forms of trisomies 13, 18, or 21, monosomy X or triploidy, except for one with a 
46, XY,der(14;21)(q10;q10)dn,+21 karyotype.
Figure 3.2.1B gives a schematic overview of these results, and in Table 3.2.1, an overview 
of the clinical features of the fetuses in both groups with normal QF-PCR results is given.
QF/karyo strategy
Thirty percent of pregnant women (n=67) chose the QF/karyo strategy (Figure 3.2.1B). Of 
these, 66% (n=44) were normal with QF-PCR. In 3/44, subsequent karyotyping revealed 
Table 3.2.1 Overview of the clinical features of the fetuses in the QF/karyo and QF/array groups 
with normal QF-PCR results
Ultrasound anomaly QF/karyo group QF/array group
Multiple 7 [1] 42 [2+1 a]
Single
Nuchal translucency / hygroma colli 20 28 [1]
Congenital heart anomaly 7 10 [1 a]
Brain anomaly 2 [1] 7 [1]
Cleft lip and palate - 2
Hydrops / hydrothorax 2 5
Diaphragmatic hernia 1 4
Spina bifida 2 1
Others 3 19
TOTAL 44 [2] 118 [4+2 a]
Between brackets: the number of fetuses in the specific group with an abnormal, clinically relevant karyotype 
or array profile.
a Not detectable with karyotyping.
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an aberration. Details of the clinical features of these three foetuses and the aberrations are 
summarized in Table 3.2.2. Two of the three aberrations, 46, XX,r(15)(p?11.1q26.?2) and 46, 
XY,r(22)(p?11q?13), could be classified as “clinically relevant, explaining the US anomalies”. 
Of the third aberration, 47, XY,+mar dn[3]/46,XY[26] in the long-term culture of chorionic 
villi only, this could not be established, as the marker was not further characterized and a 
cultural artifact could not be ruled out. However, considering the US anomaly of this fetus 
(anencephaly), the aberration is most likely not related to the US anomaly.
QF/array strategy
Seventy percent of the couples (n=153) chose the QF/array strategy. Of these, 77% (n=118) 
were normal with QF-PCR and analyzed by array (Figure 3.2.1B). All array experiments 
resulted in data that met our quality criteria, and the mean reporting time of the results of 
QF-PCR and subsequent array analysis was 12.1 days (range 8-17 days) after sampling (if 
uncultured samples could be used and parental analysis was either carried out simultaneously 
or not needed).
In 62 cases (52%), parental array analysis was performed, either simultaneously with (n=60) 
or after fetal array analysis (n=2).
In 99/118 cases, a normal array result was obtained. In 6/118, a clinically relevant CNV was 
detected that could explain the US anomalies; in 11/118, one or two inherited, most likely 
benign CNVs were detected (in total 12 in 11 fetuses); and in 3/118, an inherited CNV was 
detected not explaining the US anomalies but involving a susceptibility locus for intellectual 
disability and autism (CNVs with uncertain clinical relevance).
One of these fetuses also had an inherited, not clinically relevant CNV. In two cases without 
CNVs, one or more homozygous stretches (>10 Mb) were detected. The parents of one of 
these two fetuses were known to be consanguineous and pretest counseled that there would 
be a higher percentage of common genetic material in the fetus.
There were no findings of CNVs related to (late-onset) diseases, without explaining the fetal 
US anomalies. Details of the US anomalies and the detected aberrations are summarized in 
Table 3.2.2. Of the six clinically relevant aberrations explaining the US anomalies, two were not 
cytogenetically visible: a 4.5-Mb interstitial loss in 4q21.1q21.21 (arr 4q21.1q21.21(77,514, 977-
82,004,241)x1 dn) and a 2.3-Mb loss in 22q11.21 (arr 22q11.21(18,895,227-21,277,471)x1 dn).
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Through the informed consent form, 46% of parents chose to receive information on CNVs 
unrelated to the fetal US anomalies, regardless whether or not a possibly associated (late-onset) 
disease was currently treatable. Thirty-three percent of couples chose not to be informed on 
such CNVs at all, and 21% chose to receive information only on CNVs related to diseases for 
which screening and/or treatment is currently available. In most cases, both parents chose 
the same options: only in two cases, parental choices differed.
DISCUSSION
In our previous study, 16 we concluded that, despite potential results with unknown or 
uncertain clinical relevance, 250K SNP array analysis is ready for implementation in daily 
practice of prenatal diagnosis for pregnancies highly suspected for chromosomal aberrations. 
We now, indeed, offer non-targeted whole genome 250K SNP array analysis as replacement 
for karyotyping in the prenatal diagnostic setting of fetuses with structural US anomalies, 
a strategy that has been debated during the 15th meeting of the International Society for 
Prenatal Diagnosis in Amsterdam in July 2010. 25 In the present study, we have evaluated 
both laboratory and counselling aspects of this new strategy.
Seventy percent of the parents chose the QF/array strategy, a percentage biased by the fact 
that the obstetrician–gynecologists were not immediately familiar and confident with the 
new strategy. If this study had been based on the last 100 included pregnancies only, the 
percentage requesting QF/array would have been 82%. Assuming a nondirective counseling, 
these figures illustrate the parents’ preferences for high-resolution analysis of the fetal material, 
even though more results with unknown or uncertain clinical relevance are expected, as 
compared with the lower resolution QF/karyo strategy. In the QF/karyo group, about one 
third of the foetuses showed an aberrant QF-PCR profile. A number of these foetuses were, 
on the basis of US findings, highly suspicious for an aberration detectable by QF-PCR, and 
therefore, the parents were not extensively counseled on the QF/array strategy before the 
results of the QF-PCR were known. In case of a normal result, parents could still opt for 
array analysis. This explains the higher percentage of abnormal QF-PCR results in the QF/
karyo group compared with the QF/array group (34% vs. 23%). Considering the high overall 
percentage of aberrations detected with QF-PCR, the low costs, and the short turn-around 
time of this test, especially when performed each day in our laboratory, we prefer to perform 
QF-PCR first on all samples. With array run twice a week, this approach does not cause a 
delay in reporting time.
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In the total group of 220 fetuses, 66 aberrations, causative for the US anomalies, were detected 
(30%): 58 by QF-PCR, two by karyotyping, and six by array analysis. Thus, in the group of 
162 fetuses with normal QF-PCR results, 5% showed a clinically relevant aberration. Of the 
six of those detected by array analysis, two were only visible by array (1% of the 162 fetuses 
with normal QF-PCR results). The de novo 4.5-Mb loss in a fetus with multiple anomalies 
partially overlapped with a previously described microdeletion syndrome, caused by deletions 
in 4q21. 26 Except for the congenital heart anomaly, the phenotype of this fetus was comparable 
with the clinical features described by the group of Bonnet et al., and therefore, this 4q21 
microdeletion was considered clinically relevant, explaining the US findings. The second 
submicroscopic aberration in the QF/array group was a de novo 2.3-Mb loss in 22q11.21, the 
known, recurrent 22q11 microdeletion, involved in the DiGeorge/VCF syndrome. 27 It was 
detected in a fetus with a heart anomaly suspected for this deletion and considered clinically 
relevant and causative for the US anomalies.
The other clinically relevant aberrations detected in the QF/array group are listed in Table 
3.2.2 and all concerned large CNVs, both losses and gains that would also have been detected 
by routine karyotyping.
The 2% submicroscopic aberrations detected in the QF/array group (2/118) is in concordance 
with the percentages detected in the studies of Shaffer et al., 10 Kleeman et al., 15 and van den 
Veyver et al., 11 but it is much lower than the percentage we previously reported ourselves 
(16%). 16 In our previous study, only DNA samples of karyotypically normal fetuses, still 
highly suspected for a chromosomal aberration, were included. The inclusion criteria in the 
present strategy were less stringent and regardless of the karyotype. Therefore, one might opt 
for a list with US anomalies particularly suspect for a (sub)microscopic aberration. From the 
data obtained so far, however, such a list cannot be defined. Alternatively, as submicroscopic 
aberrations are often associated with intellectual disability, which cannot be diagnosed 
prenatally, one might also opt for even less stringent criteria for offering high-resolution 
array analysis.
Non-targeted whole genome SNP array analysis can not reveal only CNVs explaining the 
fetal US anomalies but also other types of CNVs, including inherited (benign) CNVs, CNVs 
of unknown or uncertain clinical significance (including CNVs located in regions containing 
so-called susceptibility loci), and CNVs related to (late-onset) diseases like hereditary breast 
cancer or Duchenne muscular dystrophy. In the present study, we detected inherited (benign) 
CNVs in 11 fetuses (8%), CNVs with uncertain clinical relevance (in regions with susceptibility 
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loci) in three fetuses (2%), and no CNVs related to (late-onset) diseases. In the QF/karyo 
group, however, we also detected one aberration with unknown clinical relevance (47, XY,+mar 
dn[3]/46, XY[26]; 1%), thereby underscoring the fact that the issue of obtaining results with 
unknown or uncertain clinical relevance is not new and only restricted to new technologies 
but is related to (genetic) testing in general. Even though more results causing counseling 
difficulties and stress for the pregnant couple are expected with the non-targeted whole 
genome approach as compared with karyotyping, our results do not confirm this expectation, 
and we did not find results that are impossible to interpret, as expected by de Jong et al. 7 Of 
the three pregnancies with CNVs with uncertain clinical relevance (susceptibility loci), two 
were terminated because of the US anomalies and the third pregnancy was continued. The 
carrier father of the fetus with the 16p13.11 gain had learning difficulties and epilepsy, features 
which are known to be possibly related to the 16p13.11 gain. 28 The carrier parent of the arr 
1q21.1(146,101,297-146,953,752)x3 gain was not clinically evaluated. The carrier parent of 
the arr 1q21.1 (145,479,219-147,814,694)x3 gain was phenotypically normal, although her 
brother (not array analyzed yet) showed autistic features.
Rare inherited CNVs cannot always be classified as benign, but they are, depending on the size, 
gene content, and type of CNV (gain/loss), less likely to directly lead to a clinical phenotype. 
Small CNVs (<0.1 Mb) and gains are less likely to be pathogenic than large CNVs (>1 Mb) 
and losses, respectively. 29,30 
Moreover, inherited CNVs are usually not related to physical anomalies, yet rather to 
susceptibility for mental disorders, such as autism spectrum disorder. The inherited CNVs, 
we categorized as “most likely benign”, were indeed all but one <1 Mb in size.
Copy number variants with unknown or uncertain clinical relevance and those involved in 
(late-onset) diseases raise ethical questions, particularly in prenatal diagnosis. We evaluated 
postnatal array data from more than 7500 samples from patients and parents and estimated 
the frequency of a CNV unrelated to the referral reason but possibly related to a (late-onset) 
disease to be <0.1% (unpublished results). In spite of this low frequency, in our prenatal 
strategy, we started counseling parents about the possibility to detect such a CNV and asked 
them whether they want to be informed on such a finding. The parental choices were diverse: 
Almost half of all parents wanted to be informed on CNVs related to both treatable and 
untreatable traits, 33% did not want to be informed at all on unrelated CNV findings, and 21% 
only wanted to be informed about CNVs related to diseases that can currently be screened 
or treated for. In routine practice, we did not find any such CNV in the group included in 
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this study. This is in line with the findings of Srebniak et al., 22 who, in their study on array 
analysis in prenatal diagnosis, also did not find any fetal CNV with a possible adverse effect 
later on in life. In their pretest counseling policy, they included information about results 
not explaining the US anomalies but with a possible adverse health effect later on in life and 
made a distinction between infancy/childhood and adulthood. They also included a choice 
option to be informed about new information from future studies. We do agree with the group 
of Srebniak that adequate and sufficient information should be offered during counseling, 
but we believe that there should be an appropriate balance to prevent unnecessary anxiety 
in the future parents. Therefore, we decided to limit the number of choice options and not 
to mention in detail the possibility of uncovering nonpaternity, consanguinity, or incest (as 
reported by Schaaf et al. 31). Even though up till now no cases of nonpaternity nor incest have 
been detected in our prenatal setting, one might opt for the development of international 
practice guidelines concerning issues of consent, result disclosure, and reporting of array 
results in both prenatal and postnatal settings.
To summarize, we have evaluated several aspects of our new strategy in routine prenatal 
diagnosis of replacing karyotyping by non-targeted, whole genome 250K SNP array analysis 
in fetuses with structural US anomalies. In our experience, most future parents prefer the 
high resolution QF/array strategy, even though this can lead to unsolicited findings. In the 
QF/array group, only two (2%) clinically relevant submicroscopic aberrations were detected. 
Despite this low frequency, which can be explained by the broad inclusion criteria, we do 
promote the use of non-targeted whole genome array analysis in this group of fetuses, as it 
provides a more accurate and reliable whole genome scan within the same time frame as 
karyotyping, and all clinically relevant aberrations detected in the QF/karyo group would 
have been detected with the QF/array strategy as well, but not vice versa. Furthermore, in 
our experience, the disadvantages of high-resolution array analysis, that is, detecting CNVs 
with unknown or uncertain clinical relevance or CNVs causative for (late-onset) diseases 
unrelated to the US anomalies, do not outweigh the advantages of the high resolution of 
array analysis. Concluding from our findings, during pretest counseling, the focus should 
not be on the finding of CNVs possibly related to (late-onset) diseases. However, as in 8% of 
the fetal samples, an inherited, most likely benign, CNV was detected, and in another 2%, 
a CNV with uncertain clinical relevance was found, parents should be well informed about 
such findings, and parental blood samples should always be available.
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ABSTRACT
Partial deletions of the long arm of chromosome 18 lead to variable phenotypes. Common 
clinical features include a characteristic face, short stature, congenital aural atresia, 
abnormalities of the feet and mental retardation. The presence or absence of these clinical 
features may depend on the size and position of the deleted region. In reverse, it is also known 
that patients whose breakpoints are localized within the same chromosome band may exhibit 
distinct phenotypes. New molecular techniques such as array CGH allow for a more precise 
determination of breakpoints in cytogenetic syndromes, thus leading to better-defined 
genotype-phenotype correlations. In order to update the phenotypic map for chromosome 
18q deletions, we applied a tiling resolution chromosome 18 array to determine the exact 
breakpoints in 29 patients with such deletions. Subsequently, we linked the genotype to the 
patient’s phenotype and integrated our results with those previously published.
Using this approach, we were able to refine the critical regions for microcephaly (18q21.33), 
short stature (18q12.1-q12.3, 18q21.1-q21.33 and 18q22.3-q23), white matter disorders 
and delayed myelination (18q22.3-q23), growth hormone insufficiency (18q22.3-q23) and 
congenital aural atresia (18q22.3).
Additionally, the overall level of mental retardation appeared to be mild in patients with 
deletions distal to 18q21.33 and severe in patients with deletions proximal to 18q21.31. The 
critical region for the ‘typical’ 18q- phenotype is a region of 4.3 Mb located within 18q22.3-q23. 
Molecular characterization of more patients will ultimately lead to a further delineation of 
the critical regions and thus to the identification of candidate genes for these specific traits.
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INTRODUCTION 
Chromosome 18 abnormalities including deletion 18q, deletion 18p and ring (18) are among the 
most frequently occurring autosomal anomalies, together occurring in approximately 1/40,000 
live births. 1 Of these abnormalities, deletions of the long arm of chromosome 18 are the most 
common, including the typical (distal) 18q- syndrome and proximal interstitial 18q deletions.
 The typical 18q- syndrome, also named De Grouchy syndrome, is caused by distal chromosome 
18q deletions and was first described in 1964. 2 Numerous reports have been published since. 1,3-7
The most common manifestations of patients with 18q- syndrome are short stature, 
microcephaly, midface hypoplasia, hypertelorism, congenital aural atresia, foot deformities, 
mental retardation and hypotonia. 1,3,7
Compared to distal deletions, proximal interstitial 18q deletions involving bands q12 to 
q21 have been encountered less frequently. 8-11 Clinical features described in patients with 
proximal interstitial 18q deletions are prominent forehead, midface hypoplasia, strabismus, 
seizures and behavioural problems.
The combined literature suggests that a wide phenotypic spectrum exists among patients 
with 18q deletions, and that distinct genotype-phenotype correlations await to be defined.
Array-based comparative genomic hybridization (array CGH) has been proven to be effective 
in determining molecular profiles with a resolution 5-10 times higher than conventional 
karyotyping methods 12-14 and has shown to be useful in defining critical regions for phenotypic 
traits, including congenital aural atresia in De Grouchy syndrome. 15
In this study, we analysed clinical and molecular data of 29 patients with cytogenetically 
visible 18q deletions in order to establish a genotype-phenotype map for 18q. We employed 
tiling resolution array CGH to determine the exact size and position of the chromosome 
aberrations. By comparing the extent of the deletions with the respective phenotypes, 
significant genotype-phenotype correlations were established.
PATIENTS AND METHODS 
Patients 
A series of 29 patients was selected for this study. All patients were examined by a clinical 
geneticist. G-banded karyotyping (650 band level) was performed and all patients were 
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diagnosed either with a cytogenetically visible deletion or with clinical features suggesting 
chromosome 18 abnormalities. Genomic DNA was isolated from peripheral blood lymphocytes 
of all patients, using a QIAamp kit according to the instructions of the manufacturer (QIAgen, 
Venlo). For the genomic array experiments, reference DNA was isolated from cytogenetically 
normal and healthy individuals using the same QIAamp kit (QIAgen, Venlo).
Patients 6, 8-15, 18-20, 22-24 and 26-27 were previously described and patient 28 was 
previously described. 15,16 
Array CGH
The array contained 1424 chromosome 11 BAC clones and 815 chromosome 18 BAC clones, 
all part of the 32K fingerprint validated BAC clone set. 17 This resulted in a more than two 
times coverage of chromosome 18 with an average of 1 clone per 93 kb. All clones were 
spotted in sixfold onto UltraGAPS slides (Corning) using an Omnigrid 100 arrayer (Genomic 
Solutions, Ann Arbor). Array CGH was performed essentially as described before, with 
minor modifications. 14,18 In brief, the chromosome 18 array CGH profiles were established 
through co-hybridization of 500 ng Cy3-dUTP and Cy5-dUTP (Amersham Biosciences, 
Buckinghamshire) labeled test and reference DNA, using a GeneTac Hybridization station 
(Genomic Solutions, Ann Arbor). After scanning, test-over-reference ratios (T/R values) were 
determined for each clone and log2-transformed. Log2 T/R values were normalized per array 
subgrid on the basis of the average logarithmic fluorescent intensities of the chromosome 
11 BAC clones by Lowess curve fitting with a smoothing factor of 0.1 to predict the log2-
transformed test-over-reference (T/R) value. 19 Log2 T/R ratios for chromosome 18 BAC clones 
were calculated on the basis of the smoothing curve through the ratios of the chromosome 11 
BAC clones. After data normalization, an automated statistical procedure based on a Hidden 
Markov Model (HMM) algorithm was used for detection of genomic copy number changes 
and precise localization of start- and end-points of each copy number variation.
Array validation
To test the specificity and sensitivity of the tiling resolution chromosome 11/18 BAC array, 
we performed a series of validation experiments. To test the specificity of the array, two 
normal-versus-normal control hybridizations (including a dye-swap) using normal healthy 
blood donors were conducted. All clones showed log2 intensity ratios in between the a 
priori set thresholds for copy-number gain (>0.3) or loss (<-0.3). Additionally, the HMM 
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algorithm did not detect any abnormalities and marked all clones as normal, indicating that 
the array is specific. Next, we tested the sensitivity of the array by hybridizing DNA from 
two patients with known (sub) microscopic chromosome 18 abnormalities to the array. After 
optimization of the normalization procedure using the chromosome 11 BAC clones also 
present on the array, the two chromosome 18 abnormalities as detected in previous studies 
and by conventional karyotyping, were readily identified by the HMM algorithm using the 
tiling chromosome 18 array.
In conclusion, the sensitivity of the array for detection of (sub) microscopic deletions and 
duplications was validated and the specificity of the array was assured by performing a 
stringent normalization procedure.
FISH validation experiments
DNA from chromosome 18 BAC clones selected for FISH validation was amplified with 
the TempliPhi Large Construct DNA Amplification Kit (Amersham Biosciences) according 
to the instructions of the manufacturer. FISH validation experiments were performed on 
metaphase spreads prepared from patient-derived cell lines. Probe labeling, slide preparation 
and hybridization were carried out essentially as described before. 20
RESULTS
Cytogenetic karyotypes
Upon routine karyotyping, 28 of the 29 patients showed 18q deletions. Six patients had a 
proximal interstitial deletion and 22 patients had a terminal deletion. Patient number 6 
presented with a complex aberration affecting chromosomes 7q, 18p and 18q. In patients 
number 8 and 10, the distal deletion was present in a mosaic fashion (33% and 75%, 
respectively). Patients 16 and 18 had a ring chromosome 18 with deletions of only q-arm 
segments. Patient number 28 was previously diagnosed with Rasmussen syndrome, which is 
characterized by bilateral atresia of the external auditory canals, vertical talus and increased 
interocular distance. 16,21 She had a normal GTG-banded karyotype, but a submicroscopic 18q 
deletion was suspected due to the fact that she displayed several features of 18q- syndrome, 
i.e. congenital aural atresia, typical shape of the ears with prominent crus of the helix, 
hypertelorism and clubfeet. Patient number 29 had, in addition to the 18q deletion, an 18p 
duplication due to an unbalanced pericentric inversion. 
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Table 4.1.1 Overview of the cytogenetic results of the 29 patients
Patient 
number
Conventional karyotypes Molecular karyotypes Megabase 
positions
Refi nement
1 46,XY,del(18)(q11.1q21.1) 46,XY,del(18)(q11.2q21.1) 18.9 - 42.9 +
2 46,XY,del(18)(q21.2q22.1) 46,XY,del(18)(q12.1q21.1) 25.2 - 42.9 +
3 46,XX,del(18)(q21.1q21.3) 46,XX,del(18)(q21.1q21.33) 46.8 - 59.5 +
4 46,XY,del(18)(q21.3) 46,XY,del(18)(q21.1q22.2) 47.2 - 65.7 +
5 46,XY,del(18)(q21.1q21.3) 46,XY,del(18)(q21.1q22.1) 47.9 - 61.3 +
6a 46,XY,der(7)t(7;18)(q36.1;q23)(18) 
(pter->q23::p11.2pter),del(18)
(q22.3q23)
46,XY,der(7)t(7;18)
(q36.1;q23)(18)                                          
(pter->q23::q11.1pter),del(18)
(q22.3q23)
67.7 - 74.9 +
7 46,XY,del(18)(q21.2) 46,XY,del(18)(q21.2) 49.0 - 76.0 -
8 46,XY[67%]/46,XY,del(18)(q21.31)
[33%]
46,XY[67%]/46,XY,del(18)
(q21.2)[33%]
51.2 - 76.0 +
9 46,XY,del(18)(q21.2) 46,XY,del(18)(q21.31) 53.3 - 76.0 +
10 46,XY[25%]/46,XY,del(18)(21.3)
[75%]
46,XY[25%]/46,XY,del(18)
(21.31)[75%]
53.3 - 76.0 +
11 46,XX,del(18)(q21.31) 46,XX,del(18)(q21.31) 54.1 - 76.0 -
12 46,XX,del(18)(q21.31) 46,XX,del(18)(q21.31) 54.4 - 76.0 -
13 46,XY,del(18)(q21.31) 46,XY,del(18)(q21.31) 54.9 - 76.0 -
14 46,XY,del(18)(q21.32) 46,XY,del(18)(q21.32) 55.1 - 76.0 -
15 46,XX,del(18)(q21.3) 46,XX,del(18)(q21.32) 57.4 - 76.0 +
16 46,XY,r(18)(p?q21.31) 46,XY,r(18)(q21.33) 57.1 - 76.0 +
17 46,XY,del(18)(q21.3) 46,XY,del(18)(q21.33) 58.1 - 76.0 +
18 46,XX,r(18)(pterq23) 46,XX,r(18)(q21.32) 58.5 - 76.0 +
19 46,XY,del(18)(q21.3) 46,XY,del(18)(q21.33) 59.1 - 76.0 +
20 46,XY,del(18)(q22) 46,XY,del(18)(q22.1) 61.4 - 76.0 +
21 46,XX,del(18)(q22) 46,XX,del(18)(q22.1) 61.8 - 76.0 +
22 46,XX,del(18)(q21.33) 46,XX,del(18)(q22.1) 63.0 - 76.0 +
23 46,XX,del(18)(q22.3) 46,XX,del(18)(q22.1) 63.1 - 76.0 +
24 46,XX,del(18)(q22.1) 46,XX,del(18)(q22.1) 64.0 - 76.0 -
25 46,XX,del(18)(q22) 46,XX,del(18)(q22.2) 65.1 - 76.0 +
26a 46,X,del(X)(q21.2),der(18)t(X;18)
(q21.2;q22)
46,X,del(X)(q21.2),der(18)
t(X;18)(q21.2;q22.3)
67.7 - 76.0 +
27 46,XY,del(18)(q22.2) 46,XY,del(18)(q22.3) 68.8 - 76.0 +
28 46,XX 46,XX,del(18)(q22.3) 69.1 - 76.0 +
29 46,XX,der(18)(pter->q23:                               
:p11.2->pter).ish del(18)(q23)
46,XX,der(18)(pter-
>q23::q11.1->pter),                      
del(18)(q22.3)
69.9 - 76.0 +
a Breakpoints in present study in concordance with detailed FISH validation of previous study Veltman et al. 
(2003).
Genotype-phenotype mapping of chromosome 18q
109
4.1
Karyotypes from all patients were re-evaluated and the cytogenetic diagnoses were confirmed 
(Table 4.1.1).
Molecular karyotypes
A total of 29 patients was molecularly characterized by array CGH using the tiling resolution 
array. Of these, 18 patients were described in a previous study defining a critical region for 
CAA. 15
In all 29 patients a deletion of chromosome 18q was detected. The array CGH approach 
resulted in a more precise delineation of the deleted region in 23 cases and the cytogenetic 
diagnoses could be refined (Table 4.1.1).
The six interstitial deletions ranged in size from 7.2 Mb to 24.0 Mb, with proximal breakpoints 
ranging from 18q11.2 (18.9 Mb) to 18q22.3 (67.7 Mb) and distal breakpoints ranging from 
18q21.1 (42.9 Mb) to 18q23 (74.9 Mb), respectively. All six deletions were unique since none 
of the patients shared a common breakpoint (Figure 4.1.1a). A representative chromosome 
18 profile of an interstitial deletion is shown in Figure 4.1.1b.
Figure 4.1.1a Overview of the array CGH results of the 29 patients. At the left the ideogram of 
chromosome 18 and the corresponding megabase positions (Mb) are shown. The chromosome 
material present in each patient is indicated by a grey line.
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Figure 4.1.1b Chromosome 18 plot of Patient 3, as obtained by array CGH. BAC clones on the 
microarray are indicated by dots, representing the log2-transformed and normalized test over 
reference intensity ratios [log2(T/R)], ordered on Mb position from pter to qter. The 12.7 Mb deletion 
of 18q21.1q21.33 detected by HMM analysis is indicated by a double-sided arrow.
Figure 4.1.1c Chromosome 18 plot of Patient 29, as obtained by array CGH, showing a duplication 
of 18p11.1pter and a 6.1 Mb terminal deletion of 18q23qter.
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The size of the 23 terminal deletions varied considerably, with the largest deletion spanning 
27.0 Mb in size, whereas the smallest deletion encompassed 6.1 Mb of genomic sequence, 
thus the proximal breakpoints ranged from 18q21.2 to 18q22.3 (Figure 4.1.1a). This latter 
submicroscopic 6.1 Mb deletion was identified in patient number 29 who also showed a 
microscopically visible duplication on the short arm of chromosome 18 (Figure 4.1.1c). All 
23 patients exhibited genuine terminal deletions since no distal interstitial deletions were 
detected by array CGH. An overview of all deletions detected in 18q including the location 
and size is shown in Figure 4.1.1a.
Genotype-phenotype correlations
After high-resolution chromosome 18 profiles were obtained from all the patients included 
in this study, we made an attempt to correlate the clinical findings of the patients (Table 4.1.2) 
with the location and size of the deletions identified by array CGH (Table 4.1.1).
Microcephaly
Microcephaly is defined as a reduction in head circumference greater than 2.5 SD below 
the mean value for age and sex. Head circumference was measured at different ages in all 
patients. Microcephaly was consistently detected in four patients with an interstitial deletion 
and in eight patients with a terminal deletion (patient numbers 3-6 and 11-18). The smallest 
overlapping region in this group of patients is a region of approximately 1 Mb, between 58.5 
and 59.5 Mb, located in band 18q21.33.
Short stature
The definition of short stature is a height of more than 2 SD below the mean value at a certain 
age, corrected for sex and race. This clinical feature is commonly described in patients with 18q 
deletions. 1,22 In all patients, height was determined multiple times. Only four of our 29 patients 
had a height measure of 0 SD or higher for their age. A total of 22 of 29 patients had a height 
below average and of these, 15 were officially reported with short stature (< -2 SD). These 
15 patients showed three regions of deletion overlap, including the regions  18q12.1-q12.3 
(25.2-42.9 Mb), 18q21.32-q21.33 (58.5-61.3 Mb) and 18q22.3-q23 (67.7-74.9 Mb).
In two patients with short stature, IGF1 was determined and provocative tests using arginine 
hydrochloride or clonidine were performed in order to measure growth hormone release. A 
growth hormone deficiency was detected in one patient (number 18). 
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Congenital Aural Atresia
Congenital aural atresia (CAA) may vary from a mild abnormality with narrowing of the 
external auditory canal and hypoplasia of the tympanic membrane and middle ear cavity to 
entire absence of the middle ear in combination with anotia, bony atresia and hypoplasia of 
inner ear structures. 23 CAA was seen by an otholaryngologist in all but one patient (patient 
number 7) with terminal deletions. In two patients (number 16 and 21), it is unknown. 
Patients with CAA shared a common deleted region of ~5 Mb located in 18q22.3-qter 
(69.9-74.9 Mb).
Cleft palate with or without cleft lip
Cleft palate with or without cleft lip (CP/CL) is sometimes described in patients with 18q 
deletions. 1,24,25 In our series, four patients had a cleft palate and two patients had both a cleft 
palate and cleft lip. Of the six patients with CP/CL, two patients had a proximal interstitial 
deletion (patients number 2 and 6) and four patients had terminal deletions (patients number 
14, 18, 19 and 26). These data indicate a proximal critical region located in 18q12.1-q12.3 
(25.2-42.9 Mb) and a distal critical region located in 18q22.3-23 (67.7-74.9 Mb).
Mid- and forefoot deformities
Abnormalities of the lower extremities are often encountered in patients with chromosome 
18q aberrations. 1,3,7,26 A total of 13 patients in our study cohort had mid- and forefoot 
deformities, like clubfoot, vertical talus, pes planus or pes cavus. Patients number 1-5 with 
a proximal interstitial 18q deletion did not show any foot deformities. A common deleted 
region for abnormalities of the lower extremities was located in 18q22.3-q23 (69.1-74.9 Mb).
White matter alterations and delayed myelination 
White matter alterations and delayed myelination have been described in a number of 
patients with terminal 18q deletions. 27-30 In our cohort, four patients with a terminal deletion 
underwent a brain MRI. Each MRI study consisted of at least axial T1- and T2-, and sagittal 
T1-weighted images and was evaluated by a neuroradiologist. In two patients a delay in 
myelination was seen, including patient 29 with the smallest deletion (69.9-76.0 Mb), a region 
which includes the recently suggested critical region for myelination in 18q23. 26,27
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Mental retardation
Mental retardation can be classified based on severity, represented by a Full Scale Intelligence 
Quotient: mild (IQ=50-70); moderate (IQ=35-50); severe (IQ=20-35) and profound (IQ=0-
20). 31 All patients of our study cohort were tested for mental retardation at various ages. Most 
commonly used tests were the Bayley Scales of Infant Behavior-II, the Wechsler Intelligence 
Scale for Children-Revised (WISC-R) and the Wechsler Adult Intelligence Scale III.     
Most 18q deletion patients in our cohort were mentally retarded, although the level of mental 
retardation (MR) ranged from very mild to severe. Patients 1-7 all had severe MR, patients 
8-19 had various levels of MR and patient 20 to 29 all showed mild or no mental retardation. 
Therefore, a critical region for mental development could be located proximal from 18q21.33 
(25.2-61.4 Mb). Deletions located distal to 18q21.33 did not consistently cause MR and when 
present, the retardation was usually very mild.
Other, less known features
Seventeen patients were assessed for immunoglobulin A (IgA) deficiency. In two patients, 
number 7 and 17, a deficiency was detected, suggesting that a gene(s) for IgA production 
could be located distal to band 18q21.32 (58.1-76.0 Mb). However, a high number of patients 
with overlapping deletions displayed normal IgA levels.  
Other common features in our group of patients were obesity, hyperlaxity, strabismus, 
eczema and behavioral problems. However, no clear genotype-phenotype correlations could 
be established for these traits. An overview for all phenotypic traits for which a genotypic 
correlation was established is shown in Figure 4.1.2.
DISCUSSION
Patients with deletions of the long arm of chromosome 18 display a wide variety of phenotypic 
traits. In order to correlate these phenotypic traits with the chromosome 18q abnormalities, 
we assessed molecular karyotyping results obtained by array CGH and clinical features in 
a cohort of 29 patients with an 18q deletion. This is the first study in which the tiling path 
array CGH technique has been used to exactly determine the size and position of the 18q 
deletion in such a large number of patients.
In all 29 patient samples different breakpoints were detected, thereby confirming previously 
published data that there is no breakage hotspot involved in 18q deletions. 7
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In 1993, Kline et al. studied seven patients with an 18q deletion. 6 These authors defined a 
critical region for microcephaly to be located between 18q21.2 and 18q21.3. Our data are 
in conformity with these results and further refine the critical region to a 1 Mb segment in 
band 18q21.33 (58.5-59.5 Mb). 
Within this region, seven known genes are located including BCL2, FVT1, VPS4B and 
four members of the serpin B family (UCSC Genome Browser, release March 2006, http://
genome.ucsc.edu/cgi-bin/hgGateway). Whether any of these genes may cause microcephaly 
is currently unknown. The deleted region in patient 6 does not overlap with the 1 Mb 
region, however, the microcephaly in this patient can be explained by the complexity of his 
chromosome aberration.
Short stature was seen in 19 out of 29 patients (66%) in our cohort. This is in accordance with 
the frequency of 64% reported in a systematic review on growth abnormalities in 18q deletion 
Figure 4.1.2 A new phenotypic map of chromosome 18q indicating the critical regions for various 
clinical features. CAA, congenital aural atresia; CP/CL, cleft palate/cleft lip; MR, mental retardation.
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patients. 22 Our data confirm and further delineate the previously suggested terminal 18q22.3-
qter region by Strathdee and colleagues 7 to 67.7-74.9 Mb. Furthermore, we identified two 
interstitially located regions for short stature: 18q12.1-q12.3 (25.2-42.9 Mb) and 18q21.32-q21.33 
(58.5-61.3 Mb). Recently, a study on 14 patients with an 18q deletion was published 26 including 
a patient with a deletion 18q21q22.3 (46.7-69.8 Mb) and a stature of -4 SD below the mean. 
Two of our suggested critical regions for short stature are located within this deletion, thereby 
supporting the notion that these regions are involved in the development of body height.
A suggested factor involved in growth failure in patients with a terminal 18q deletion is growth 
hormone deficiency. 32-34 Several years ago, the group of Cody proposed a ~2 Mb critical 
region for growth hormone insufficiency located on 18q23 (72-74 Mb). 35 Among the genes 
located in this region are Myelin Basic Protein (MBP) and a galanin receptor (GALR1). The 
latter is involved in growth hormone response and is therefore a good candidate gene for 
growth hormone insufficiency. In our group only two patients underwent growth hormone 
provocative testing and one of them (patient 18) showed growth hormone insufficiency. Her 
deletion includes the proposed 2 Mb critical region. 
Interestingly, the growth hormone deficiency critical region appears to exactly overlap with a 
region previously suggested for delayed cerebral myelination. 27,28 As MBP plays a considerable 
role in the formation and maintenance of CNS myelin 36, this gene has been put forward as 
the primary candidate gene in delayed myelination in 18q- patients. 27,30,37
Recently, a study on the beneficial effects of growth hormone therapy on the cognitive function 
of children with terminal 18q deletions was published 38, recommending that all children with 
an 18q deletion should be carefully examined for short stature and growth hormone levels 
in order to search for the causative mechanism and to provide optimal care. In contrast to 
short stature in terminal deletions, no possible explanation for short stature in patients with 
proximal interstitial 18q deletions has been postulated yet, although disorders within the 
growth hormone pathway could play a role here as well. 
In our previous study on a part of this cohort, we found that the critical region for congenital 
aural atresia (CAA) was located on 18q22.3-q23 (70-76 Mb). 15 Our current results on 11 
additional patients are consistent with these findings and in addition the terminal side of 
the region was restricted to 74.9 Mb. Recently, this CAA critical region was delineated to a 
2.3 Mb region on 18q22.3 (70.6-73.2 Mb) by Dostal and colleagues. 39 This region contains 
nine known genes and the authors postulated ZNF407 to be the most interesting candidate 
gene because of its high conservation and expression in bone tissue.
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A less frequently described feature in 18q- patients is cleft palate with or without cleft lip (CP/
CL). 24,40 In our cohort, patient 2 defines the proximal critical region for CP/CL: 18q12.1-q12.3 
(25.2-42.9 Mb) and patient 6 the distally located critical region: 18q22.3-q23 (67.7-74.9 Mb). 
An isolated cleft lip was not seen and, interestingly, has never been described in patients with 
an 18q deletion.
The level of mental development varies among patients with 18q deletions, ranging from 
severe mental retardation to normal development. 1,7,41 In our cohort of patients, the level 
of mental retardation was severe in all patients with an interstitial deletion, thus including 
patient 6 with a terminally located interstitial deletion. However, the severe MR in this 
patient can be explained by the complexity of the aberration, involving a large duplication 
of 18p and a deletion of 7q as well. Patients 20-29, who carried a terminal deletion, were 
all mildly mentally retarded or had a normal cognitive development. We therefore propose 
a critical region for mental development to be located proximal from 18q21.33 (25.2-61.4 
Mb). The region 18q21.33-qter (61.4-76.0 Mb) is associated with mild MR or even normal 
mental development. 
Taken together, the combination of our data and the data from the literature allows for an 
update of the genotype-phenotype map for 18q (Figure 4.1.2). This map shows that proximal 
and terminal deletions of chromosome 18q relate to clearly distinct clinical phenotypes.
The key features of De Grouchy syndrome include short stature, delayed myelination, 
congenital aural atresia, foot deformities and a characteristic facial appearance including 
midface hypoplasia, hypertelorism, low set malformed ears and a carp shaped mouth. 
Based on data of previous studies and the present study, all these features can be mapped to 
chromosome bands 18q22.3 and 18q23, locating the critical region of the typical De Grouchy 
syndrome to 70.6-74.9 Mb. However, there are different critical sub-regions defined for the 
various clinical features and the entire region contains over 8 known and 3 putative genes. 
Further studies are needed to determine whether the terminal 18q deletion syndrome is a 
single gene disorder or should be considered as a true contiguous gene deletion syndrome.
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ABSTRACT
The 18q deletion syndrome can be caused by several terminal and interstitial deletions of 
which terminal deletions of the distal part of 18q are the most frequent and known as the De 
Grouchy syndrome. The neuropsychiatric phenotype is not well documented and includes 
disorganised and disinhibited behaviours as well as language difficulties. Non development of 
language seems to be specific for cases with a more proximally located interstitial deletion. In 
the present paper a 18-year-old severely mentally retarded male with an interstitial deletion of 
18q is described (46.XY,del(18)(q12.1q21.1)dn) who was referred for behavioural problems 
and neuropsychiatric evaluation. No categorical psychiatric diagnosis could be established. 
Given this and other reports, it is advocated to describe the psychopathological phenotype of 
18q deletions in a dimensional way that will result in a clinical picture characterised mainly 
by symptoms from the motor and motivation domains. Treatment should include primarily 
behavioural measures, combined if necessary with symptomatic psycho-pharmacotherapy.
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INTRODUCTION 
Since the first description of a deletion of the long arm of chromosome 18 by De Grouchy and 
co-workers in 1964, patients with deletions of 18q have been reported relatively frequent. 1 
Its prevalence is estimated to be 1/40,000. Several types of deletions have been described and 
it has been demonstrated that each individual may have a unique deletion. 2 The majority of 
the patients has a deletion of the distal part of 18q including region q22q23 and they present 
with a great variety of somatic anomalies of which hearing loss 3,4, endocrine abnormalities 
5,6, immunological dysfunctions 7-9, epilepsy 10 and dysmyelinisation 11 are the most frequent 
findings. In addition, facial dysmorphisms, hypotonia, short stature and a variable degree of 
mental retardation are found. 12 The neuropsychiatric phenotype is not well documented and 
includes impulsivity, temper tantrums, lack of social reciprocity sometimes called autism, 
obsessive compulsive behaviour, language difficulties and incidentally psychotic symptoms. 
For post pubescent patients impulsivity, aggressiveness and temper outbursts are the most 
commonly reported behaviour problems (review reference 12). Interstitial deletions are less 
frequent and affect either more proximal parts 13,14 or imply a fragment of the distal region of 
the long arm of the chromosome. These conditions are generally accompanied by a moderate 
to severe mental retardation and the distally located interstitial deletions may be expected to 
manifest a subset of the characteristics of the 18q- syndrome. 15,16
In the present study, we describe a young adult male with an interstitial deletion of 
chromosome 18 (q12.1q21.1) who was referred because of behavioural problems for which 
neuropsychiatric evaluation was requested.
CASE REPORT 
The patient is an 18 years old severely mentally retarded male who is the second child from 
non-consanguineous parents. He was born premature at 34 weeks gestation by caesarean 
section and had a birth weight of 1965 grams. Because of bradycardia artificial ventilation 
was necessary directly postnatal. In addition, subluxation of the right hip was present and he 
suffered from feeding problems due to a cleft palate that was surgically corrected at the age 
of two. During his first year, the patient suffered from recurrent upper airway infections and 
fever-induced seizures. His developmental milestones were markedly delayed and he did not 
develop active language skills. From the age of 10, the patient showed progressive hyperactive 
and chaotic behaviour with choreoathetotic movements, distractibility and stereotypic 
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behavioural sequences. EEG registration did not show epileptic features. He was treated for 
behavioural control with carbamazepine for some months without any result. Subsequently, 
a diagnosis of attention deficit hyperactivity disorder was considered and treatment with 
methylphenidate was started. Despite chronic treatment with this psychostimulant, no 
behavioural improvement was achieved. In addition, an autistic disorder was supposed. 
Both psychiatric diagnoses were proposed elsewhere by a general practitioner. At age 15 
chromosome analysis was performed and demonstrated an interstitial deletion of the long 
arm of chromosome 18: 46,XY,del(18)(q12.1q21.1)dn (Figure 4.2.1). The breakpoints were 
confirmed by array CGH analysis (Figure 4.2.2).
Physical examination revealed a height of 161 cm (-2.5 SDs), a bodyweight of 54 kg (+1.0 
SDs corrected for height) and a head circumference of 58 cm (+0.5 SDs). Biochemical tests, 
including endocrine parameters (GH, T4, T3 and TSH) showed no abnormalities. His 
phenotype was characterized by a flat midface, epicanthal folds, dysmorphic and low set 
ears (Figure 4.2.3), scoliosis (most likely the result of hip subluxation) and cryptorchidism. 
At examination, the patient presented with hyperactive, poorly goal-oriented, over reactive 
and chaotic behaviour, badly coordinated movements, severe distractibility and several forms 
of stereotyped behaviour. He did not show expressive language and his receptive language 
was poor. The patient actively sought physical contact showing a capacity for emotional 
interactions without, however, any insight, self-appraisal or signs of differentiated mental 
processes. There were no abnormalities in the regulation of mood and anxiety and no 
Figure 4.2.1 (A) Both chromosomes 18 of the patient are pictured, with the right chromosome 
showing the interstitial deletion (18)(q12.1q22.1). (B) The ideogram of chromosome 18.
Chromosome 18
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Figure 4.2.2 The array was composed of 815 cloned chromosome 18 genomic DNA targets, 
ordered from pter to qter on the basis of mapping positions obtained from the May 2004 freeze 
of the UCSC genome browser (http://genome.ucsc.edu/). The circles represent the mean log2 
test-over-reference (T/R) intensity ratios for this patient, showing a deletion of 17.61 Mb genomic 
sequence. Note that the vertical lines represent the boundaries of the chromosome 18 banding 
pattern. The vertical lines at Log2 T/R ratios of 0.3 and -0.3 indicate the thresholds for copy number 
gain and copy number loss, respectively.
Figure 4.2.3 The patient at the age of 16 years.
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signs of bizarre, incomprehensible behaviour suggestive for psychotic experiences. Clinical 
manifestations of epilepsy were absent. Screening of cognitive functions and assessment of 
IQ were not possible.
Although his behaviour over time appeared to be highly determined by external contingencies, 
a treatment with valproic acid was started. After one year of treatment with this anticonvulsant 
(dose: 700 mg daily; plasma concentration: 60 to 80 mg/l), no improvement was observed. 
Subsequently a behavioural treatment was applied and the patient was treated symptomatically 
with twice-daily 1 mg risperidone (plasmaconcentrations risperidone and hydoxyrisperidone: 
10 and 9 μgr/l), which resulted in a substantial diminuation of his hyperactive behaviour.
DISCUSSION
In this case report the neuropsychiatric profile of a severe mentally retarded young male with 
a de novo interstitial deletion of the long arm of chromosome 18 is described. His behavioural 
phenotype is characterized by a non-specific profile of behaviours, the absence of expressive 
language and poorly developed receptive verbal comprehension as well as by a desire for 
physical contact in the absence of insight, self-appraisal and differentiated mental processes. 
So far, only four patients with a comparable interstitial deletion have been reported. 7,15,17
Other publications deal either with more proximal interstitial deletions 13,14,17,18 or with 
terminal deletions due to different unbalanced translocations. 7,19,20 Most reports, however, 
describe patients with a terminal deletion. Terminal and distal deletions including the 
18q22q23 region result in the De Grouchy phenotype including mild to moderate mental 
retardation, short stature, hypertelorism, narrow or atretic external ear canals, typical shape 
of the ear with prominent crus helix, small hands with proximally implanted thumbs, club 
feet and eczema. The described patient has a deletion 18q12.1q21.1, not including the region 
responsible for the typical De Grouchy phenotype. Although he has features that are also 
found in De Grouchy syndrome like short stature and cleft palate, he lacks the characteristic 
ears and hands and has a more severe mental retardation than usually seen in De Grouchy 
syndrome.
With respect to the limited number of cases with a proximal interstitial deletion, the clinical 
pattern comprises mild dysmorphic features, mental retardation, lack of major malformations, 
epilepsy and ‘behavioural abnormalities’ such as impulsivity, irritability, hyperactivity and 
increased distractibility. 17,18 
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In patients with terminal deletions a possible relationship has been demonstrated between 
the extent of the deletion and the number/size of somatic anomalies. 2,21 
No relationship could be established between the deletion size and measures of cognition and 
behaviour. 12 Although not mentioned in all reports, a more proximally located interstitial 
deletion may be associated with non-development of expressive language.
According to the literature, the neuropsychiatric profile of 18q- syndrome is characterized by 
disinhibited and maladaptive behaviours. In some cases, autistic-like features are described 
that, however, may be related to the level of cognitive functioning. 12,22 Despite the suggested 
genetic linkage between bipolar affective disorder and the q21-23 region of chromosome 18 23,
no cases with fluctuating affective symptoms have been reported. In the described patient, 
the behavioural abnormalities were previously attributed to an autistic or an attention deficit 
hyperactivity disorder. His symptom profile, however, does not meet the diagnostic criteria 
for either of these categories.
With respect to the assessment of neuropsychiatric symptoms in mentally retarded patients it 
has to be emphasized that the current practice to establish categorical psychiatric diagnoses 
is not appropriate and even unsuitable since they do not account for the highly variable 
developmental history, the level of cognitive and emotional functioning and the great variation 
in the phenotypical expression of mental and behavioural symptoms. It is therefore advocated 
to delineate related symptom clusters because they reflect the real world and may point to 
treatment options and prognosis. 24-26 Although the literature on 18q deletions does not allow 
constructing a concise psychopathological phenotype, it is of importance that no symptoms 
from the affective, anxiety and psychotic domains are described in the various case reports. 
Like in this case, the clinical picture is mainly characterised by symptoms from the motor 
(impulsivity, distractibility and disinhibition) and motivation (dysexecutive signs) domains. 
These clinical characteristics exclude a treatment with antidepressants or mood stabilisers 
and indicate the utility of behavioural measures that can be combined with a symptomatic 
treatment to reduce disinhibited behaviours.
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ABSTRACT
Individuals with the 18q deletion syndrome are presented with various clinical characteristics, 
including cardiac anomalies in 24 to 36% of the reported cases. Nonetheless, genotype-
phenotype correlations for cardiac anomalies in the 18q deletion syndrome have rarely 
been reported. We report on two girls with a terminal 18q deletion, one in whom an Ebstein 
anomaly and Wolf-Parkinson-White syndrome were detected and the other with multiple 
valve stenosis and a ventricular septal defect. The genotype and cardiac abnormalities of these 
girls and 17 other individuals with a de novo 18qter deletion reported in the literature are 
reviewed. All 19 individuals shared a small overlapping deletion region between 18q22.3q23. 
The most common cardiac defects detected were pulmonary valve anomalies and atrial septal 
defects. Ebstein anomaly, a rare cardiac malformation, was diagnosed in two individuals. 
Additional molecularly based genotype-phenotype studies are needed in order to pinpoint 
candidate genes within this region that contribute to normal cardiac development. A careful 
cardiac evaluation consisting of physical examination, ECG and ultrasound examination 
should be performed in all individuals diagnosed with the 18q deletion syndrome.
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INTRODUCTION 
Within the group of individuals with a rare chromosome abnormality, deletions of the long 
arm of chromosome 18 occur relatively frequently with an incidence of 1 in 40,000 live 
births. 1 In 1964, De Grouchy for the first time described an individual with an 18q deletion, 
stating that she displayed a wide range of features including short stature, characteristic facial 
features, malformation of the ears suggestive of congenital aural atresia, edema of the foot and 
severe intellectual disability. 2 Since then, more than 100 individuals have been described. 1,3
The majority of these individuals carry a microscopically visible terminal 18q deletion. 
Individuals with a distal 18q deletion display phenotypic variation, the most common features 
being short stature, intellectual disability, characteristic facial dysmorphisms, cleft lip/palate, 
delayed myelination, foot deformities and congenital aural atresia. 1,3 
The reported incidence of cardiac abnormalities in individuals with 18qter deletions is 
between 24 and 36%. 1,4 Cody et al. reported a cardiac anomaly in 24% out of 42 individuals 
with breakpoints between 18q21 and 18q23. The cardiac anomalies reported in that study 
were atrial septal defect, ventricular septal defect, pulmonary stenosis and total anomalous 
pulmonary venous return. No single cardiac defect was predominant. 1 
In this article we describe two new patients with a de novo, terminal 18q deletion and a 
cardiac defect. One patient (individual 1) has severe stenosis of the pulmonary valve, aortic 
valve, and tricuspidalis, as well as a ventricular septal defect. The other patient, individual 
11, has an Ebstein anomaly, which is a condition where the tricuspid valves are displaced 
into the right ventricle and because of tricuspid valve displacement, the right ventricle may 
show arterializations and a significant loss of function. The severity of Ebstein anomaly 
varies widely and it has only once been reported before to be associated with the 18q deletion 
syndrome. 5 She was also diagnosed with Wolf- Parkinson-White (WPW) syndrome, which 
has not previously been associated with an 18q deletion. 
Furthermore, we reviewed the literature for 18q deletion patients with cardiac anomalies and 
we reevaluated previously described individuals known in our centre. In total 19 persons with 
a distal 18q deletion and a heart defect were included in this review: two girls described in 
this clinical report and 17 individuals previously reported in the literature, including three 
individuals from our centre.
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CLINICAL REPORT 
The first patient (individual 1 in Table 4.3.1) was born after an unremarkable pregnancy by 
caesarean section due to fetal distress at 41+5 weeks of gestation with a birth weight of 2,460 
grams (SDS < -2.5). This girl was the first child of healthy, non-consanguineous parents of 
Caucasian origin. Family history revealed no abnormalities. 
Due to respiratory failure the child was intubated and ventilated. Although she was ventilated 
with 100% of oxygen the transcutaneous arterial oxygen saturation never reached more than 
70%. 
Clinical examination showed dysmorphic ears and severe hypotonia. A loud heart murmur 
was heard. Cardiac ultrasound showed severe biventricular hypertrophic cardiomyopathy, 
severe pulmonary valve stenosis with a gradient of 90 mm Hg, severe aortic valve stenosis 
with a transaortic gradient of 78 mm Hg, tricuspidalis stenosis and ventricular septal defect. 
A terminal 18q21.2 deletion was detected by routine karyotyping. As the parental karyotypes 
were both normal, the 18q21.2qter deletion had occurred de novo in this girl. At the age of 
11 days she died due to respiratory failure and inoperability of the cardiac anomaly.
The second patient (individual 11 in Table 4.3.1) was born after an unremarkable pregnancy 
and normal vaginal delivery at 39 weeks of gestation with a birth weight of 3,200 grams (SDS 
-0.5). She was the fourth child of healthy, non-consanguineous parents of Caucasian origin. 
The mother was a 40-year-old woman at the time of delivery. Family history revealed no 
abnormalities. 
Clinical examination showed hypotonia, bilateral club feet and dysmorphic ears. No heart 
murmur was heard. Drinking difficulties occurred probably due to the hypotonia and a poor 
sucking reflex. A terminal 18q21.33 deletion was detected by routine karyotyping. As the 
parental karyotypes were both normal, the 18q21.33-qter deletion had occurred de novo in 
this girl. 
At the age of 18 months her psychomotor development was delayed. She was functioning at the 
level of a nine-month-old infant. A brain MRI showed a delay in myelination. Furthermore, 
bilateral congenital aural atresia and as a consequence a hearing loss of 70 dB was detected, 
for which she received a Bone-Anchored Hearing Aid (BAHA). At the age of 5.5 years a well 
speaking girl with a normal height of 112.3 cm (SDS -0.5) and a weight of 19.9 kg (SDS 0) 
was seen. No cardiac murmur was noticed.
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At a regular outpatient clinic control at the age of 7.5 years, she complained of tiredness and 
tachycardia. Clinical evaluation showed, apart from the previously described features of the 
18q deletion syndrome, a tachycard (130 beats per minute) (bpm) girl with a high pitched 
systolic heart murmur at the left sternal border. There were no signs of cardiac failure. 
An ECG showed a regular sinus tachycardia (130 bpm) with a short PQ-time, delta waves 
and widened QRS complexes consistent with Wolf-Parkinson-White syndrome. Cardiac 
ultrasound showed an Ebstein anomaly with tricuspid valve insufficiency, right atrium 
enlargement and a high pressure in the right ventricle (42 mm Hg). The 24-hours ECG 
presented a regular sinus tachycardia, but without any supraventricular tachycardia or atrial 
flutter, so both cardiac rhythm disorders and decompensation caused by Ebstein anomaly 
were excluded. Additional laboratory testing showed hyperthyroidism due to Graves’ disease. 
After medical treatment of the hyperthyroidism with methimazole (antithyroid drug) and 
propanolol (beta-blocker), the tachycardia disappeared, as did the cardiac murmur. As a 
consequence propanolol medication was stopped.
MATERIALS AND METHODS 
In this study a total of 19 individuals with a de novo, terminal 18q deletion and a cardiac 
anomaly were included to examine the genotype-phenotype correlation, being the two 
individuals described above and 17 individuals previously reported in the literature, including 
three individuals from our centre.
In addition to the aforementioned individuals (individuals 1 and 11), three additional 
individuals (individuals 2, 10 and 12 of the current study) were formerly seen in our 
department and have previously been published in a series of 29 individuals with the 18q 
deletion syndrome. 3 
In all five G-banded karyotyping (650 band level) was performed on metaphase spreads from 
cultured, peripheral blood lymphocytes. Furthermore, additional molecular characterization 
was performed by tiling resolution chromosome 18 BAC array (individuals 2, 10 and 12) or by 
high-resolution SNP genotyping with the Affymetrix 250K single nucleotide polymorphism 
(SNP) array (individuals 1 and 11).
The array analysis was completed on genomic DNA isolated from blood following standard 
procedures. The SNP array experiments were performed according to the manufacturer’s 
protocols (Affymetrix, Inc., Santa Clara, CA, USA) and data analysis and interpretation was 
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done as previously described. 6 The positions of the BAC and SNP array targets were converted 
to the hg19 (GRCh37) assembly of the human genome.
To the best of our knowledge, 14 other individuals with a pure terminal 18q deletion and 
a cardiac malformation have been published in the literature. Of these, one individual was 
investigated by array-CGH and confirmation by FISH was performed (individual 17). 
Five individuals underwent conventional karyotyping only and in seven cases additional 
molecular studies including FISH and microsatellite marker analysis were performed. In one 
case (individual 3) additional FISH was performed, although the 18qter probe used was not 
informative for the determination of the breakpoint.
To assess an unbiased comparison of the cardiac defects, we only included individuals with a 
pure deletion of chromosome 18q. Individuals with complex chromosomal rearrangements 
or additional imbalances were excluded.
RESULTS
Table 4.3.1 provides an overview of all 19 individuals, including their (molecular) karyotype 
and cardiac anomaly. A graphic overview of the 18q deletion sizes is given in Figure 4.3.1A. 
The girls presented in the clinical reports of this article are listed as individual 1 and 11. Out 
of the 29 individuals in the study of Feenstra et al., 19 could be classified as a pure distal, 
non-mosaic 18q deletion and in three out of these 19 individuals (16%) a cardiac anomaly 
was diagnosed, presented as individual numbers 2, 10 and 12, respectively, in Table 4.3.1.
The breakpoints in 18q in the 19 individuals with a de novo, terminal 18q deletion currently 
described, are all located in the bands between 18q21.2 and 18q23 (Figure 4.3.1A). Only two 
individuals (18 and 19) were reported with breakpoints located in band 18q23. The remaining 
17 individuals carried an extended deletion with the breakpoint located in the various sub 
bands of 18q21 and 18q22. 
Pulmonary valve anomaly is the most common heart defect, occurring in nine out of 19 
individuals (47%). Five individuals (26%) are diagnosed with an atrial septal defect, either 
isolated or as part of a complex cardiac defect. In three individuals (16%) a ventricular septal 
defect was seen. Furthermore, in three individuals (16%) an aortic valve stenosis was detected. 
The types of cardiac abnormalities varies widely, as the first individual in this report had 
a hypertrophic cardiomyopathy, while others had insufficient, absent or stenotic valves, an 
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anomalous pulmonary venous return and the other girl in this clinical report was diagnosed 
with an Ebstein anomaly and WPW-syndrome. 3-5,7-13 
DISCUSSION
Cardiac malformations are reported to be diagnosed in 24-36% of the terminal 18q deletion 
syndrome individuals. 1,4,12 No single cardiac defect is predominantly described, although in the 
series of Cody et al. pulmonary stenosis and atrial septal defects dominated to some extent. 1 
In the present series, nine out of the 19 individuals with heart anomalies were diagnosed with 
pulmonary valve anomalies (47%), which therefore is the most common heart anomaly in 
individuals with 18q deletion syndrome. An atrial septal defect was detected in five individuals 
(26%). So our findings are roughly consistent with the results of Cody and colleagues.
To access an unbiased comparison of congenital heart diseases, we only included individuals 
with a pure terminal deletion of chromosome 18 described in the literature plus the additional 
five individuals from our centre. Individuals with a complex chromosome 18 rearrangement 
as well as isopseudodicentric chromosome 18 and mosaic ring chromosome 18 aberrations 
were excluded from our study and review. The reason for exclusion was that cardiac anomalies 
detected in these individuals might not only be due to the absence of the distal part of 18q, 
but this could also be caused or aggravated by the other chromosomal aberration involved. 
Additional studies are needed to uncover the clinical effects of these complex chromosome 
aberrations.
All 19 individuals carry a terminal 18q deletion, leading to a critical overlapping region 
for cardiac anomalies in general in the most distal part of chromosome 18, i.e. 18q22.3q23 
(Figure 4.3.1B). 
Besides the conventional karyotyping and FISH-analysis, we have used tiling resolution 
chromosome 18 BAC-array or genome wide 250K SNP-array analysis, both with an average 
resolution of approximately 200 kb, for a more accurate determination of the breakpoints. 
All other individuals were mostly investigated before the implementation of the microarray 
technique and therefore were examined by conventional chromosomal analysis with 
or without additional FISH and microsatellite marker analysis. Ideally, additional array 
analysis should be performed in these individuals for an accurate determination of the 
breakpoints, as correlations between the exact extent of the deletion and cardiac defect 
could lead to the identification of key genes in cardiac development. The various congenital 
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heart defects, including rare cardiac abnormalities as anomalous pulmonary venous return, 
absent pulmonary valve and Ebstein anomaly, suggest a correlation between the terminal 
18q deletion syndrome and congenital heart defects. Among the genes located within the 
commonly deleted 18q22.3q23 region is a highly interesting candidate gene named Nuclear 
Factor for Activated T-Cells (NFATC1; NM_172387). NFATC1 belongs to the Rel/NF-kb 
family of transcription factors, which have been implicated in different aspects of embryonic 
development, transcriptional regulation, cell growth, and apoptosis. In mice, nfatc1 is 
expressed in endocardium and is essential for proper valve development. 14,15 It has been 
shown that a tandem repeat in the intronic region of NFATC1 is associated with ventricular 
septal defects. 16 Recently, two heterozygous mutations have been described in a patient with 
tricuspid atresia. 17
Another interesting gene within the commonly deleted 18q region is KCNG2, a gene encoding 
a member of the potassium channel, voltage-gated, subfamily G, which may contribute to 
cardiac action potential repolarization. 18
In two of the 19 patients described in this article, an Ebstein anomaly was detected, a very 
rare congenital heart defect. 5 It accounts for less than 1% of all congenital heart diseases and 
occurs in 1/ 200,000 live births.
About 20 percent of individuals with an Ebstein anomaly have Wolf-Parkinson-White 
(WPW) syndrome as well. WPW syndrome is characterized by abnormal electrical pathways 
in the heart, due to an accessory electrical connection between the atrium and ventricle, 
leading to a disruption of the heart’s normal rhythm. Sometimes it leads to delta waves on 
an electrocardiography, which was also seen in our patient, individual 11. 19
Since Ebstein anomaly accounts for less than 1% of all congenital heart defects, there might 
be a significant association between Ebstein anomaly and the 18q deletion syndrome. The 
finding of Ebstein anomaly in a boy with a terminal 18q21.3 5 and a girl with a terminal 
18q21.33 deletion respectively, suggests the presence of a specific causally related gene located 
within the distal 18q region. A molecular determination of the 18q21.3 breakpoint in the 
individual described by Digilio and colleagues could be beneficial in order to compare the 
exact genotypes of the two individuals with Ebstein anomaly.
Ebstein anomaly has been described in syndromic and non-syndromic individuals. Syndromes 
associated with Ebstein anomaly are Noonan syndrome, CHARGE syndrome, VACTERL, 
Kabuki syndrome, Cornelia de Lange syndrome, Ellis-van Creveld syndrome and two 
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individuals with Holt-Oram syndrome. 5,20,21 Several chromosome aberrations have been 
described to be associated with Ebstein anomaly, of which 1p36 deletions and 8p23 deletions 
are most frequently reported. 5,22-26 Others include trisomy 21 27-29, duplication of the distal 
long arm of chromosome 15 30,31, deletion and duplication 11q 32, deletion 10p 33, duplication 
9p 34 and a microdeletion in 5q35.1q35.2. 35
This 5q35.1q35.2 microdeletion encompasses the cardiac transcription factor gene NKX2-
5 and mutations in this gene have been detected in patients with non-syndromic Ebstein 
anomaly. 36,37 Interestingly, inactivation of Nkx2-5 in mouse models has shown that this leads 
to prevention of the nuclear localization of NFATc1 in the endothelial endocardial cells, 
consequently inactivating its transcriptional functions. 38 The location of NFATC1 in the 
critical deleted 18q22.3q23 region together with the interaction of this gene with NKX2-5 
provides evidence that NFATC1 plays a role in human cardiac development and strongly 
supports that haploinsufficiency of NFATC1 can lead to Ebstein anomaly.
Another gene related to non-syndromic Ebstein anomaly is MYH7. Heterozygous mutations 
in MYH7 cause Ebstein anomaly associated with left ventricular noncompaction cardio-
myopathy. 39,40 Patients with non-syndromic Ebstein anomaly have also been screened for 
mutations in GATA4, which maps to chromosome 8p23, but no mutations were found. 5,41
In conclusion, individuals with a terminal 18q deletion syndrome are at high risk of having 
a congenital cardiac anomaly. Pulmonary valve anomalies and atrial septal defects are 
most commonly detected. Therefore, we highly recommend performing a careful cardiac 
examination consisting of physical examination, ECG and ultrasound examination in all 
individuals diagnosed with the 18q deletion syndrome. The finding of Ebstein anomaly in two 
18q deletion individuals suggests the presence of one or more genes within this chromosome 
region involved in the etiology of this rare cardiac defect. Our study supports the findings 
that NFATC1 plays an important role in human cardiac development and we suggest that 
disruption of this gene can lead to Ebstein anomaly. Further studies are needed to unravel 
the exact genotype-phenotype correlation.
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ABSTRACT
We have characterized a de novo balanced translocation t(18;20)(q21.1;q11.2) in a female 
patient with mild to moderate mental retardation (MR) and minor facial anomalies. 
Breakpoint-mapping by fluorescence in situ hybridization indicated that on chromosome 
18, the basic helix-loop-helix transcription factor TCF4 gene is disrupted by the breakpoint. 
TCF4 plays a role in cell fate determination and differentiation. Only recently, mutations 
in this gene have been shown to result in Pitt-Hopkins syndrome (PHS), defined by severe 
MR, epilepsy, mild growth retardation, microcephaly, daily bouts of hyperventilation starting 
in infancy, and distinctive facial features with deep-set eyes, broad nasal bridge, and wide 
mouth with widely spaced teeth. 
Breakpoint mapping on the derivative chromosome 20 indicated that here the rearrangement 
disrupted the chromodomain helicase DNA binding protein 6 (CHD6) gene. To date, there 
is no indication that CHD6 is involved in disease. 
Our study indicates that TCF4 gene mutations are not always associated with classical PHS 
but can give rise to a much milder clinical phenotype. Thus, the possibility exists that more 
patients with a less severe encephalopathy carry a mutation in this gene.
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INTRODUCTION 
Mental retardation (MR) is one of the most common disorders, affecting approximately 2% 
of the general population. The underlying genetic defects are so far largely unknown, and 
finding the disease genes has important implications for health care and for research into the 
function of the human brain. During the past few years, we and other groups have shown that 
one very powerful approach for identifying novel MR genes is the mapping of breakpoints 
in patients with balanced chromosome rearrangements.
In the ideal situation, the causation between disrupted gene and disease is validated by the 
presence of additional unrelated patients with a breakpoint in the same gene, as we could 
recently show for CDKL5 1, SHROOM4 (KIAA1202) 2 and AUTS2 3, and/or by the presence 
of mutations in unrelated patients with MR, for example CDKL5 4, ZNF41 5, EHMT1 6. 
Likewise, there are numerous examples documenting that the application of array techniques 
has enabled the identification of disease-causing DNA copy number changes in patients with 
MR, including both nonsyndromic 7 and various syndromic forms, for example, CHARGE 
syndrome 8, the 15q24 9 and 17q21.31 deletion syndromes 10-12, and 16p13.1 duplications and 
deletions 13. Using this technique, mutations in the basic helix-loop-helix transcription factor 
4 (TCF4) gene, which maps to the long arm of chromosome 18, was recently found to cause 
a syndromic form of severe MR that was first described in 1978 by Pitt and Hopkins (OMIM 
610954). 14-17 In this study, we found TCF4 truncated by a de novo balanced translocation 
present in a female patient with mild to moderate MR and minor facial anomalies, but not 
the features of the classical Pitt-Hopkins phenotype.
MATERIALS AND METHODS 
Cytogenetic analysis and breakpoint mapping by FISH 
Samples from the patient and her parents were obtained after informed consent. Chromosome 
analysis was performed according to standard high resolution methods. Breakpoint analysis 
was performed by fluorescence in situ hybridization (FISH) experiments on metaphase spreads 
from the patient lymphoblastoid cell line with YAC, BAC or PAC clones selected from the 
breakpoint regions. Clones were prepared by standard techniques, labeled with appropriately 
coupled dUTPs by nick translation or directly labeled by DOP-PCR, and used as probes in 
FISH as described previously. 18
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RT-PCR experiments
Total RNAs were isolated from the patient and control lymphoblastoid cell lines using Trizol 
(Invitrogen, Karlsruhe, Germany) according to the manufacturer’s recommendations. Five 
micrograms of RNA were used for reverse transcription with Superscript III (Invitrogen), 
essentially according to the manufacturer’s protocol, but in the presence of RNAguard 
(Amersham Pharmacia, Freiburg, Germany), using random hexamers for priming. Sequences 
for primers used for PCR and sequencing of TCF4–CDH6 fusion transcripts from der(18) 
are as follows: CHD6 ex1f 5’-CAA TGG GTC TGT GTT TTG GA-3’, TCF4 ex4r 5’-CCC 
AGG ACC CTG AGC TAC TT-3’, TCF4 ex6r 5’-CTG GTG GCA ACC CTG TAA GT-3’.
Array CGH
Total genomic DNA from the translocation patient was analyzed by array CGH as previously 
described, 19 using a sub-megabase resolution whole genome tiling path array, consisting 
of the Human ‘‘32k’’ BAC Re-array set, a series of 32,450 overlapping BAC clones obtained 
from the BAC/PAC Resources Center at Children’s Hospital Oakland Research Institute, the 
1 Mb Sanger set, and a set of 390 sub-telomeric clones (assembled by members of COSTB19: 
Molecular cytogenetics of solid tumors). Copy number gains and losses were determined by 
a conservative log2 ratio threshold of 0.3 and -0.3, respectively. Profile deviations consisting 
of three or more neighboring BAC clones were considered genomic aberrations, unless they 
coincided with a DNA copy number variant as listed in the Database of GenomicVariants 
(http://projects.tcag.ca/variation/ version December 13, 2005) and/or which was frequently 
observed in a reference set of more than 800 samples analyzed on the same array platform.
RESULTS
Patient description
The patient is the 15-year-old daughter of healthy, unrelated parents. She has an older healthy 
brother. She was born after an uneventful pregnancy at 41 weeks of gestation and had a birth 
weight of 3,100 g (-1 SD). During her first year of life she had hypotonia and recurrent infections 
of the middle ear cavities. At the age of 20 months she was referred to a pediatric neurologist 
because of developmental delay. Physical examination showed a normal height (85 cm), head 
circumference (48 cm), and weight (11.5 kg), and minor facial dysmorphisms including a broad, 
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square face, hypertelorism, flat nasal bridge, normally formed but prominent ears and a short 
neck (Figure 5.1.1). There was a bilateral single palmar crease and her left leg was longer than 
the right. She had normal neuromuscular tone and normal reflexes.
She could crawl at the age of 16 months and stand at the age of 17 months. She could not 
speak at the age of 20 months. A cerebral CT scan of the brain showed no abnormalities. A 
Brainstem Auditory Evoked Potentials (BAEP) examination showed a decrease of sensitivity 
of both ears at 3 KHz, probably due to cochlear dysfunction.
Follow-up examination at the age of 9 years and 9 months revealed a normal height (140.5 
cm), weight (33.6 kg) and head circumference (53.4 cm). The left leg was 4 cm longer than 
the right. She had mild to moderate MR and attended a school for children with severe 
learning impairment.
She is now 15 years old. Her height, weight and head circumference are all around the mean 
for sex and age. The epiphysis of the left knee has been removed because of the significant 
difference in length of the limbs. She walks easily without stereotypic or abnormal movements. 
She has had a normal pubertal development. She can speak in sentences, is able to read and 
write simple text and understands simple tasks. Her behavior is characterized by shyness and 
lack of initiative. She and her parents reported that she never experienced problems with 
breathing, such as hyperventilation, and she does not have epilepsy.
Figure 5.1.1 Patient at age 7 years (left) and at 14 years (right). Note the broad, square face, 
hypertelorism, fl at nasal bridge and short neck.
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Cytogenetic & molecular analysis
Routine karyotype analysis indicated a de novo balanced translocation between the long 
arms of chromosomes 18 and 20 (t(18;20)(q21.1;q11.2)) (schematically shown in Figure 
5.1.2A). Array CGH of total genomic patient DNA did not show any genomic imbalances 
that might be disease relevant (see Figure 5.1.3). Therefore, we fine-mapped the breakpoints 
on both derivative chromosomes by FISH using genomic clones from the regions of interest. 
On chromosome 20, neighboring PAC clones RP4-540H1 (GenBank accession number 
AL121674) and RP4-661I20 (GenBank accession number AL031669, complete sequence) 
mapped, respectively proximal and distal to the breakpoint (Figure 5.1.2B). The 5’ end of 
the CHD6 gene spans most of this region. Therefore, it was likely that CHD6 was disrupted 
by the breakpoint (Figure 5.1.2D).
On chromosome 18, BAC clone RP11-409K17 (GenBank accession numbers AC090684, 
AQ547670, AQ547672) showed hybridization signals on the derivative chromosome 18 
but not on derivative chromosome 20 (data not shown), whereas sequence-overlapping 
clone RP11-619L19 (GenBank accession number AC018994) showed signals on both the 
derivative 18 and derivative 20 chromosomes (Figure 5.1.2B), demonstrating that it spanned 
the breakpoint.
FISH with BAC clone RP11-824D7 (GenBank accession number AC090346) revealed that 
it also spans the breakpoint (data not shown), placing the breakpoint within the overlapping 
region of approximately 70 kb (Figure 5.1.2C). Interestingly, clone RP11-619L19 lies 
completely within the TCF4 gene (also known as SL3-3 enhancer factor SEF2 or E2-2, or 
immunoglobulin transcription factor ITF2), indicating that this gene is clearly affected by 
the patient’s chromosome rearrangement. Given that both truncated genes are transcribed in 
the same orientation, it was possible that the chromosome rearrangement resulted in fusion 
genes. To investigate this possibility further we have combined TCF4 and CHD6 specific 
primers for RT-PCR amplification studies on patient cell line RNA. Sequence analysis of 
specific products generated with primers located in CHD6 exon 1 and TCF4 exon 4 (GenBank 
accession number NM_001083962), respectively exon 6, indicated that fusion transcripts 
are produced, with CHD6 exon 1 spliced to exon 4 (Figure 5.1.4). Therefore, the breakpoint 
in TCF4 lies most likely in intron 3 and in CHD6 it maps within intron 1, upstream of the 
translational start codon in exon 2.
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Figure 5.1.2 (A) Ideogram depicting the patient’s balanced translocation t(18;20)(q21.1;q11.2). 
(B) Fluorescence in situ hybridization of overlapping clone RP11-619L19 to patient metaphase 
chromosomes, with signals on chromosome 18 and split signals on both derivative chromosomes 
18 and 20 (left panel). Fluorescence in situ hybridization of sequence-overlapping clones with 
signals on chromosome 20 and derivative chromosome 20 (middle panel), and on chromosome 
20 and derivative chromosome 18 (right panel). (C) Chromosome 18 breakpoint region showing 
locations of the proximal clone (grey bar) and overlapping clones (black bars) with respect to the 5’ 
ends of TCF4 splice variants (arrows) and the deletions reported in patients with the classical Pitt-
Hopkins syndrome (open bars). (D) Chromosome 20 breakpoint region showing locations of the 
proximal and distal clones with respect to the CHD6 gene. In both C and D, the estimated breakpoint 
locations are depicted.
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DISCUSSION
We have characterized a de novo balanced translocation in a patient with MR and mild facial 
dysmorphisms and identified disrupted genes at each breakpoint. CHD6 was disrupted by 
the chromosome 20 breakpoint upstream of the translational start codon. There is so far no 
indication that this gene plays a role in disease.
Figure 5.1.4 Sequence of specifi c RT-PCR product obtained from patient cell line RNA with primer 
set CHD6ex1f 5’-CAA TGG GTC TGT GTT TTG GA-3’, TCF4 ex6r 5’-CTG GTG GCA ACC CTG TAA GT-
3’. Sequence analysis indicated that in the translocation patient CHD6 exon 1 (shaded in grey) is 
perfectly spliced to TCF4 exon 4.
Figure 5.1.3 Array CGH on patient DNA using a 32k whole human genome tiling path bacterial 
artifi cial chromosome (BAC) array as previously described. 19
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Disruption of the TCF4 gene provides the most likely cause of the clinical phenotype 
present in the patient. The TCF4 gene product belongs to the basic helix-loop-helix class 
of DNA binding proteins and was first found to be a transcriptional activator that binds to 
glucocorticoid response elements of retrovirus enhancers. 20 Of note, three recent studies 
have highlighted a role for TCF4 in the autosomal dominant Pitt-Hopkins syndrome (PHS), 
which is defined by severe motor retardation and MR, epilepsy, microcephaly, daily bouts of 
diurnal hyperventilation, short stature, and a distinctive facial appearance. The TCF4 mutation 
spectrum includes microdeletions (0.5-1.8 Mb in size) identified by array-comparative 
genomic hybridization and molecular karyotyping, and missense, stop or splicing mutations. 
Therefore, the authors suggested that haploinsufficiency of TCF4 causes PHS. 15-17
The clinical features present in the translocation patient with disrupted TCF4 gene only 
partially overlap with the more complex picture seen in the published PHS patients, including 
MR and facial anomalies. Overall, the translocation patient we report is much less severely 
affected. Her MR is mild to moderate, whereas in patients with PHS, the MR is severe, and 
they cannot speak and have difficulties walking. It is also relevant that so far (at the age of 
15 years) the translocation patient showed no epilepsy or breathing abnormalities, which 
are clinical features frequently present in PHS patients (see Table 5.1.1). In addition, growth 
parameters are normal in the translocation patient, whereas PHS patients have short stature.
There are several potential explanations for the difference in clinical severity. In the 
translocation patient the chromosome breakpoint disrupts TCF4 upstream to exon 4. 
Therefore, not all splice variants are affected by the rearrangement. In addition, fusion 
transcripts between TCF4 and CHD6 are produced in the patient cell line. These might be 
translated into truncated TCF4 protein, which could be partially functional, thereby resulting 
in a less severe handicap.
These hypotheses are further supported by the observations that PHS patients with missense 
mutations and microdeletions are similarly severely affected and that in mice, embryonic 
development is sensitive to basic-helix-loop-helix transcription factor copy number, including 
Tcf4. Recently, it has been shown that Tcf4-/- deficient mice have disrupted pontine nucleus 
development. 21
Still another possibility is that mutations in TCF4 result in a broader clinical spectrum than 
known to date, ranging from the mild to moderate MR and minor facial anomalies (as seen 
in our translocation patient) to the severe MR encephalopathy.
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There are many specific genotype–phenotype correlations in other MR-associated disorders. 
Several XLMR genes, for example, have now been shown to cause both syndromic and 
non-syndromic forms of MR (depending on the nature of the mutation), and it is also well 
established that identical mutations can lead to diverse phenotypes. Our findings suggest 
that the selection criteria for including patients into future TCF4 mutation screening should 
perhaps also include milder clinical phenotypes than the typical clinical picture present in PHS 
patients. In this context, it is worth noting that the contribution of the second translocation 
breakpoint, which lies within the CHD6 gene region, is unclear. It might have an impact 
on the cochlear dysfunction present in the translocation patient but not observed in other 
PHS patients. CHD6 belongs to the family of CHD proteins and might play a role in RNA 
polymerase II-mediated transcriptional processes.
Taken together, the TCF4 disruption described here in a girl with MR, in conjunction with 
published results of TCF4 mutations in patients with PHS, 15-17 provide clear evidence for 
TCF4 playing an important role in the brain. Our observations suggest that not all mutations 
in this gene cause a severe phenotype that is characteristic for PHS.
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ABSTRACT
Congenital aural atresia (CAA) can occur as an isolated congenital malformation or in the 
context of a number of monogenic and chromosomal syndromes. CAA is frequently seen 
in individuals with an 18q deletion, which is characterized by intellectual disability, reduced 
white-matter myelination, foot deformities, and distinctive facial features. Previous work has 
indicated that a critical region for CAA is located in 18q22.3. 
We studied four individuals (from two families) with CAA and other features suggestive of 
an 18q deletion, and we detected overlapping microdeletions in 18q22.3 in both families. The 
minimal region of deletion overlap (72.9-73.4 Mb) contained only one known gene, TSHZ1, 
which was recently shown to be important for murine middle-ear development. 
Sequence analysis of the coding exons in TSHZ1 in a cohort of 11 individuals with 
isolated, nonsyndromic bilateral CAA revealed two mutations, c.723G>A (p.Trp241X) and 
c.946_947delinsA (p.Pro316ThrfsX16), and both mutations predicted a loss of function. 
Together, these results demonstrate that hemizygosity of TSHZ1 leads to congenital aural 
atresia as a result of haploinsufficiency.
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INTRODUCTION 
Congenital aural atresia (CAA) is a rare malformation of the ear that occurs in approximately 1 in 
10,000 live births. 1 It presents unilaterally more often than bilaterally. Its characteristics can vary 
from a narrow external auditory canal and hypoplasia of the tympanic membrane and middle 
ear cleft to a complete absence of middle-ear structures and anotia (bony atresia of the external 
auditory canal and hypoplasia of inner ear structures). In the past, different classifications of 
CAA have been introduced on the basis of clinical findings. In 1955, Altmann was the first to 
describe a CAA classification, 1 which has been modified over the years by others. 2-4 
CAA type I is classified by a bony or fibrous atresia of the lateral part of the external auditory 
canal and an almost normal medial part and middle ear. CAA type II is the most frequent 
type and is characterized by partial or total aplasia of the external auditory canal. In type IIA, 
the external auditory canal is either affected by a complete bony atresia of its medial part or 
partially aplastic, ending blindly in a fistula that leads to a rudimentary tympanic membrane. 
CAA type IIB is characterized by a bony stenosis of the total length of the external auditory 
canal. Finally, CAA type III is characterized by bony atresia of the external auditory canal 
and a very small or absent middle-ear cavity. 2
CAA might be present as an isolated malformation but is also seen as a feature of complex 
syndromes such as Crouzon syndrome [MIM 123500], Treacher Collins syndrome [MIM 
154500], Townes Brocks syndrome [MIM 107480], and branchiootorenal syndrome [MIM 
113650], as well as aneuploidy syndromes including Turner syndrome (45,X) and trisomies 
13, 18, and 21. 5-10 Although not fully penetrant, CAA type IIA in the absence of microtia or 
anotia is most frequently seen in individuals with a deletion of the long arm of chromosome 
18 (MIM 601808). 11 In 1964, De Grouchy described individuals with an 18q deletion, stating 
that they displayed CAA and a wide range of associated features including short stature, 
characteristic facial features, intellectual disability, and foot deformities. 11,12
The majority of individuals with an 18q deletion carry a microscopically visible terminal 
deletion of the long arm of chromosome 18. 13 Yet, in a small subset of individuals, routine 
cytogenetic studies reveal a normal G banded karyotype.
Several genotype-phenotype studies have been performed in persons with 18q deletions of 
various sizes so that critical regions corresponding to the different clinical symptoms of the 
18q deletion syndrome could be defined. 14-16 These efforts have resulted in overlapping critical 
regions for white-matter disorders and delayed myelination, growth hormone insufficiency, 
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foot deformities, and CAA, all nested within the region from 18q22.3 to 18q23. 14-16 Given that 
multiple genes reside in the region of deletion overlap, it was concluded that further studies 
would be needed to determine whether the typical 18q deletion syndrome represents a single 
gene disorder or whether it should be considered a contiguous deletion syndrome. 14 Fine 
mapping of microscopically visible deletions via molecular techniques, such as a chromosome 
18q BAC array, mapped CAA to a 2.3 Mb region in 18q22.3q23 (between markers D18S489 
and D18S554). However, it remained unclear whether CAA could be separated from the 
other common features of the 18q deletion syndrome. 17,18
Here, we report that isolated CAA and the CAA phenotype in the 18q deletion syndrome are 
both caused by haploinsufficiency that results from a heterozygous deletion or loss-of-function 
mutation of TSHZ1, whose ortholog is essential for murine middle-ear development. 19
PATIENTS, METHODS AND RESULTS 
All procedures were performed in accordance with the ethical standards of the Radboud 
University Nijmegen Medical Centre Ethical Committee. After obtaining informed consent, 
we evaluated the presence of microdeletions in four individuals (from two different families) 
who had a phenotype consistent with the 18q deletion syndrome. We used 250K (Nsp1) single-
nucleotide polymorphism (SNP) microarrays (Affymetrix, Inc., Santa Clara, CA, USA). 20 
SNP microarray experiments were performed according to the manufacturer’s instructions. 
Copynumber estimates were determined with the CNAG software package v2.0, and the 
genomic locations of the SNP positions were mapped according to the Genome Reference 
Consortium Human Genome Build 37 (GRCh37).
Individual 1 is the second son from nonconsanguineous parents. He was born at term after 
an uncomplicated pregnancy and had a normal birth weight. Psychomotor development was 
delayed: He started walking at 21 months, and at the age of 4 years, a 10-15 month delay in 
speech and language development was detected. A pure-tone audiogram was performed when 
the child was cooperative at 4 years of age and showed mild left- and right-sided conductive 
low-frequency hearing loss of 17 and 22 dB, respectively (Table 5.2.1). At eight years of age, 
he developed epileptic seizures, and EEG abnormalities occurred after sleep deprivation. 
He was also noted to have mild intellectual disability (an IQ of 60) and behavioral problems 
involving autistic features. He was a cooperative, healthy boy with a normal height and head 
circumference. His dysmorphic features included hypertelorism, an upturned nasal tip, and 
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a thin upper lip (Figure 5.2.1A). CT scans showed bilateral, narrow external auditory canals. 
This finding was confirmed by otoscopy, from which only a small part of the tympanic 
membrane could be visualized (Figure 5.2.3A).
SNP-array analysis of DNA isolated from blood revealed a 4.3 Mb interstitial deletion in 
18q22.3q23, extending between the genomic coordinates 69.2 and 73.4 Mb (arr snp 18q22.3q23 
[SNP_A-2065000 > SNP_A-184607]x1; Figure 5.2.2A). SNP-array analysis of the phenotypically 
normal mother revealed no abnormalities. The father was not available for testing.
Individual 2 is a 30-year-old woman, born at 39 weeks gestation after an uneventful pregnancy 
to unrelated, healthy parents. Directly after birth, bilateral forefoot deformities were noted and 
classified as congenital vertical talus (Figure 5.2.1B), for which she received surgical treatment.
She could walk from the age of 2 years. At the age of 15 months, she presented with a bilateral 
conductive 60 dB hearing loss, which was caused by bilateral atresia of the external auditory 
canals, consistent with CAA type IIA (Table 5.2.1). She received hearing aids and consequently 
developed speech, although a delay remained. At ten years of age, the aural atresia of her right 
Table 5.2.1 Overview of clinical features in eight individuals with an 18q22.3q23 microdeletion 
or TSHZ1 mutation
Individual Age (yr) Intellectual 
disability
Hearing lossa L/R Type CAA Other
1 (family 1) 8 mild 17 dB/22 dB narrow external 
auditory canals
epilepsy, autism
2 (family 2) 30 borderline 60 dB/60 dB IIA, bilateral bilateral vertical 
talus, strabism
3 (family 2) 5 normal 65 dB/65 dB IIA, bilateral bilateral vertical 
talus
4 (family 2) 1 mild motor delay 70 dB/45 dB IIA, bilateral bilateral vertical 
talus
5 (family 3) 10 normal 42 dB/42 dB IIA, bilateral no
6 (family 4) 41 normal 40 dB/40 dB IIA, bilateral no
7 (family 4) 12 normal 50 dB/55 dB IIA, bilateral no
8 (family 4) 12 normal 48 dB/45 dB IIA, bilateral no
Mb, megabase; L, left; R, right; CAA, congenital aural atresia; Type IIA, complete bony atresia of the medial part of 
the external auditory canal, or the canal is partially aplastic and ends blindly in a fistula that leads to a rudimentary 
tympanic membrane.
a Measurement of air conduction before surgical intervention or use of bone-anchored hearing aid.
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ear was successfully operated on, and at the age of 26, she received a boneanchored hearing 
aid (BAHA) on the left side. Physical examination at the age of 30 years showed a healthy 
woman with normal height, weight, and head circumference.
Dysmorphic features included hypertelorism, midfacial hypoplasia, and a broad mouth with 
prominent lips. There was a normal implantation of the ears, which showed a prominent 
superior crus of the antihelix and underdevelopment of the descending part of the helix 
(Figure 5.2.1B).
Figure 5.2.2 Detailed genomic view of 18q22.3q23; organization of TSHZ1 and mutations de-
tected. (A) A schematic representation shows the transcripts mapped to the 18q22.3q23 region. 
Deletions detected by SNP-array analysis in individual 1 and family 2 are shown by red solid lines, 
and details on the fi rst and last deleted SNPs are annotated in gray. The shortest region of deletion 
overlap contains a known gene, TSHZ1, and an open reading frame, c18orf62, of unknown function.
(B) A schematic representation of the TSHZ1 protein shows its domain structure. Targeted Sanger 
sequencing of TSHZ1 in families 3 and 4 revealed mutations in both families; the mutations are 
shown as partial electropherograms for both families, respectively. Of note, the protein sequence 
denoted below the electropherograms only shows the mutated sequence.
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SNP-array analysis revealed a 2.5 Mb interstitial deletion between the genomic coordinates 
72.9 and 75.4 Mb (arr snp 18q22.3q23 [SNP_A-1893660 > SNP_A-1815424]x1; Figure 5.2.2A).
Individual 3 is the first son of individual 2 and her healthy husband. He was born after 
an uneventful pregnancy at term and had normal birth parameters. Like his mother, he 
had congenital bilateral vertical talus and bilateral CAA type IIA (Table 5.2.1). Computed 
tomography (CT) scans showed significant narrowing of the external auditory canals, 
opacification of the mastoid and middle ear probably related to otitis media, and normal 
anatomical aspects of the inner ear.
During the first years of life, his hearing was assisted by a bone-conductive hearing aid on a 
softband. The latter was replaced by a percutaneous titanium screw at the age of 4 3/4 years. 
Examination at 5 1/2 years of age showed a healthy, cooperative boy with normal height, 
weight, and head circumference. Dysmorphisms included hypertelorism, mild down-slanting 
palpebral fissures, a broad mouth, and characteristic low-set ears with a prominent superior 
crus of the antihelix and hypoplasia of the descending helix (Figure 5.2.1C). SNP-array 
analysis revealed the same 2.5 Mb interstitial deletion (arr snp 18q22.3q23 [SNP_A-1893660 
> SNP_A-1815424]x1) as observed in his affected mother (data not shown).
Individual 4 is the second child of individual 2. A prenatal ultrasound at 20 weeks gestation 
showed congenital bilateral vertical talus. He was born at term after an otherwise uncom-
plicated pregnancy and had a normal birth weight. Similar to his mother and older brother, 
he had congenital bilateral vertical talus and distinctive dysmorphic features including 
hypertelorism and low-set ears with hypoplasia of the descending helix (Figure 5.2.1D).
Otoscopic examination showed bilateral narrowing of the auditory canals, consistent with 
CAA type IIA.
During the last examination at the age of 1 year, his parents reported a motor delay. SNP-array 
analysis revealed the same 2.5 Mb interstitial deletion (arr snp 18q22.3q23 [SNP_A-1893660 
> SNP_A-1815424]x1) as observed in his affected mother and brother (data not shown), 
indicating full cosegregation of the deletion with the phenotype in this family.
Interestingly, the microdeletions in individuals 1 and 2 (and both her sons) showed a 459 kb 
deletion overlap, which contains one hypothetical protein (C180rf62) and a single known 
gene, Teashirt Zinc Finger Homeobox 1 (TSHZ1; NM_005786.4) (Figure 5.2.2). TSHZ1 
was considered to be a good candidate gene for the observed CAA phenotype on the basis 
of the deletion overlap and the fact that all four individuals presented with the common 
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feature of narrow or atretic external auditory canals. This hypothesis was further supported 
by previously reported Tshz1 loss-of function mutations in mice; these mutations lead to 
specific malformations of the middle ear components 19 and emphasized the importance of 
TSHZ1 in the developing middle ear. 
Therefore, conventional bidirectional Sanger sequencing was performed for this specific 
gene in 11 persons (6 sporadic and 5 familial individuals) with an isolated, bilateral form 
of CAA type IIA and normally shaped pinnae. In total, four individuals and one unaffected 
relative showed heterozygous loss-of-function mutations, including a sporadic affected person 
(individual 5), his unaffected mother, and a family with three affected individuals consisting 
of a mother and her two daughters (individuals 6-8) (Table 5.2.1).
In individual 5 (family 3), we identified a heterozygous c.723G>A mutation, which was 
predicted to introduce the premature stop codon p.(Trp241X) (Figure 5.2.2B). This boy was 
the first child of healthy, nonconsanguineous parents (Figure 5.2.1). He was born at term 
after an uneventful pregnancy, had normal birth parameters, and no congenital anomalies 
were detected. He had normal motor development, but impaired speech and delayed language 
development were noticed between the ages of 3 and 4 years.
Pure-tone audiometry at the age of five demonstrated a 42 dB bilateral conductive hearing 
loss due to CAA type IIA (Figure 5.2.3B). A BAHA Softband and subsequent percutaneous 
titanium BAHAs were applied successfully.
Physical examination at the age of 10 years showed no facial dysmorphisms or other 
features associated with the previously determined critical 18q deletion regions that include 
TSHZ1. Segregation studies revealed that the detected stop mutation was also present in his 
phenotypically normal mother. Examination of her ears demonstrated no abnormalities to 
the external auditory canal or to the tympanic membrane or her hearing.
In family 4 (Figure 5.2.1), we identified a frameshift mutation due to a single base pair insertion 
(c.946_947delinsA), which is predicted to cause the premature stop codon p.Pro316ThrfsX16 
(Figure 5.2.2B). As expected, this mutation showed an autosomal-dominant segregation 
pattern. The affected mother of this family (individual 6) had isolated bilateral conductive 
hearing loss due to CAA type IIA, for which she had bilateral surgical treatment at the age of 3.
Her hearing declined slowly over the following decades, and she recently received a BAHA 
on the left side at 42 years of age.
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Individuals 7 and 8, a monozygotic twin pair, are the daughters of individual 6 and also both 
displayed CAA type IIA (Figures 5.2.3C and 5.2.3D). They had undergone a canalplasty on 
one ear, and on the contralateral ear, they wore a bone-anchored hearing aid. The mother and 
daughters showed no notable dysmorphic facial features or any other abnormalities associated 
with 18q deletion syndrome. It is worth noting that a sequence analysis of the phenotypically 
normal maternal parents did not reveal the presence of this frameshift mutation, indicating 
that the mutation occurred de novo in the index person of this family.
The remaining seven individuals did not show any base pair mutations in the coding sequence 
of TSHZ1. For these individuals, whole-gene deletions were excluded with the Cytogenetics 
Whole-Genome 2.7M Array (Affymetrix) according to the manufacturer’s instructions.
Figure 5.2.3 CT scan images of individuals with an 18q deletion or TSHZ1 mutation. An axial CT 
scan of individual 1 (A) shows a narrow external auditory canal with a normal tympanic membrane 
and a grommet (white arrow) in place of the right ear. (B) shows an axial-plane bilateral CT scan of 
individual 5 with bilateral CAA type IIA (stars). (C) shows a coronal CT reconstruction of individual 
7, demonstrating a CAA type IIA (arrow) and (D) shows a coronal CT reconstruction of individual 8, 
demonstrating a CAA type IIA (arrow).
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To test the (clinical) specificity of TSHZ1 mutations, we subsequently tested a cohort of 
24 individuals with a unilateral form of CAA type I, IIB, or III (Table 5.2.2). In 10 of the 
24 individuals, the CAA phenotype was accompanied by mild to severe developmental 
malformation of the external ear(s), such as microtia or anotia. Sanger sequencing did not 
reveal any causal mutations in this cohort.
DISCUSSION
In previous studies, we proposed, in accordance with reports of other groups, 17 that the 
critical region for isolated CAA was located on chromosome 18q22.3. 14,18 This region was 
reported to contain nine candidate genes, yet none of the reports mentioned TSHZ1 as a 
potential candidate for CAA.
We detected two small overlapping 18q microdeletions in individuals with CAA as a common 
feature, narrowing the critical interval for CAA to 72.9-73.4 Mb and establishing TSHZ1 as 
a strong candidate for the CAA gene. The subsequent detection of both a nonsense and a 
frameshift mutation in TSHZ1 in two families with nonsyndromic CAA clearly shows that 
hemizygosity of TSHZ1 indeed leads to isolated CAA through haploinsufficiency. This 
observation further suggests that other genes in the previously established critical region in 
18q22.3 should be more relevant to the intellectual disability, facial dysmorphisms, and foot 
deformities that are commonly seen in the 18q deletion syndrome.
The members of family 2 (individuals 2, 3, and 4) displayed a collection of features including 
characteristic facial features, bilateral CAA, and vertical talus. The mother and sons described 
here very much resembled the phenotype of three males and three females in a family 
described by Rasmussen in 1979 (MIM 133705). 21 Possibly, hemizygosity of one of the other 
four genes deleted in individuals 2-4, namely ZNF516, ZNF236 (MIM 604760), MBP (MIM 
159430), and GALR1 (MIM 600377), could lead to haploinsufficiency and cause congenital 
foot deformities like vertical talus. Molecular analysis of the family members described by 
Rasmussen could provide more insight into the hypothesis that Rasmussen syndrome is caused 
by a microdeletion, which is identical or at least overlapping with the deletion detected in 
individuals 2-4 in our study.
TSHZ1 consists of two exons, of which only exon 2 is coding and has a genomic size of 79 
kb. TSHZ1 is a member of the teashirt-type zinc-finger protein family and encodes putative 
zinc finger transcription factors that are broadly expressed during mouse embryogenesis. 22
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In vertebrates, three TSHZ1-related genes (TSHZ1, TSHZ2 [MIM 614118], and TSHZ3 [MIM 
614119]) have been isolated on the basis of sequence homology.
Recently, knockout mice have been generated for Tshz1. 19 Tshz1 inactivation in mice leads 
to neonatal lethality and causes multiple developmental abnormalities, including a severe 
middle-ear phenotype that mimics defects observed in individuals with isolated CAA. In 
addition, Tshz1-deficient mice show a defect of the soft palate, a feature which was not 
seen in any of the individuals in the current study. The phenotype of Tshz1-deficient mice 
resembles the phenotype seen in Hoxa3 and Sall3 mouse mutants. 23,24 Interestingly, the gene 
families to which these genes belong – the Hox and Spalt gene families – genetically interact 
with teashirt (tsh) in Drosophila. 25 Possibly, mutations in genes of these families give rise to 
a similar CAA phenotype, either isolated or as part of a more complex syndrome. Possible 
candidate genes might include other members of the teashirt zinc-finger protein family, such 
as TSHZ2 and TSHZ3, and members of the human HOX and SPALT families. A member 
of the HOX family, HOXA2 (MIM 604685), has indeed been described as playing a crucial 
role in auditory-system malformations, more specifically in an autosomal-recessive form of 
bilateral microtia, hearing impairment, and partial cleft palate. 26 Similar to what we now 
observe for TSHZ1, the human phenotype caused by HOXA2 mutations is in concordance 
with that of the Hoxa2 knockout mouse. 27
However, DNA-sequence analysis of HOXA2 in individuals with isolated microtia did not 
reveal mutations. 28 In the same fashion, not all individuals with an isolated form of CAA 
type IIA selected for the present study showed mutations in TSHZ1; this finding is in line 
with the fact that CAA is observed as an endophenotype in multiple syndromes, thereby 
suggesting that several CAA genes still await discovery.
Most individuals with a terminal 18q deletion have been diagnosed with CAA type I or 
II. 29 Also, all persons in this study had normal external-ear morphology, a finding that is 
consistent with the observation that the majority of 18q deletion individuals either have 
normal external ears or show only minor abnormalities such as low-set ears or prominent 
helices.
On the basis of our observation that intragenic mutations in TSHZ1 could only be detected in 
the four individuals with isolated CAA type IIA who, except for their narrow or atretic auditory 
canals, have no other congenital malformations, it might be speculated that hemizygosity of 
TSHZ1 is limited to and specific to this type of CAA.
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The fact that the nonsense mutation in TSHZ1 in individual 5 was inherited from his 
phenotypically normal mother can be explained by reduced penetrance. This observation is 
in accordance with previous reports that describe a CAA incidence of 26% in individuals with 
an 18q deletion of any kind and an incidence of up to 78% in individuals with a deletion of the 
critical CAA region that includes TSHZ1. 12,16,30 Therefore, nonpenetrance is not unexpected 
in a carrier of a mutation in the CAA gene.
In conclusion, we have detected both point mutations and copy-number variants leading to 
haploinsufficiency due to hemizygosity of TSHZ1 as causes of bilateral CAA type II (in the 
absence of microtia or anotia) both in isolated nonsyndromic individuals and in persons with 
the 18q deletion syndrome. Our results provide compelling evidence that the 18q deletion 
syndrome is a true contiguous gene syndrome, in which the CAA endophenotype is explained 
by the deletion of TSHZ1. Detailed genotype-phenotype studies might further delineate the 
other phenotypic components of this syndrome.
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In this thesis, I have explored the implementation of whole genome microarrays in the 
diagnostic setting and the implications this can have for the generation of phenotypic maps 
of human chromosomes. On doing so it soon became apparent that the benefits of high 
resolution genotyping can only be maximally exploited if the process of phenotyping is 
performed in a comparably sophisticated way. Moreover, in order to create reliable phenotypic 
maps a critical mass of individuals with overlapping chromosomal aberrations are needed. 
While most of the chromosomal anomalies are extremely rare, reliable phenotypic maps may 
still become within reach by using public databases and internet resources. At the same time, 
the world-wide web can be used to disseminate the valuable data that will become available 
by the both quantitatively and qualitatively growing efforts of genotyping and phenotyping, 
as we showed by the introduction of ECARUCA (Chapter 2).
Phenotypic maps
The creation of phenotypic maps for rare chromosome aberrations has been actively pursued 
for over 30 years. One of the first examples is a phenotypic map drawn by Niebuhr in 1978. 1
He searched for the common deleted region on the p-arm of chromosome 5 in 35 patients 
with microcephaly, a high-pitched cry and mental retardation and was thereby able to create a 
first map for the Cri du Chat syndrome, concluding that the midportion of the 5p15 segment 
probably must be deleted in order to develop the main clinical features of this syndrome. 1,2
Today, we still use the basic principle of these phenotypic maps in order to determine 
critical regions for clinical signs and dysmorphic features. However, the introduction of new 
molecular cytogenetic techniques enables us to make much more precise representations 
of genotype-phenotype correlations. Instead of depicting a relatively large region of several 
chromosome bands on the p-arm of chromosome 5, Zhang et al. were able to delimit the 
various sub-regions within 5p15.1-p15.33 that are responsible for specific clinical features of 
the Cri du Chat syndrome. 3 In the same way, we and others applied array CGH results in a 
group of patients with an 18q deletion (Chapter 4.1). 4,5 Using this approach, critical regions 
for various clinical features including microcephaly, short stature, white matter disorders and 
delayed myelination of the brain, kidney malformations and CAA were defined or narrowed. 
By getting as much details as possible from the clinical point of view and combining this 
with high resolution genotyping, we will be able to create highly detailed phenotypic maps 
containing critical regions of several Mb. 3,5-7 Depending on the number of genes within these 
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regions, a candidate gene can then be selected and mutation analysis can be performed in 
new patients with a similar phenotype or an isolated malformation. 
This concept has been used throughout genetic history and its effectiveness has been proven 
by several studies. 8 The introduction of molecular cytogenetic techniques has significantly 
increased the number of known microdeletion syndromes and single-gene disorders described. 
9-11 Among the first and most common clinically recognizable syndromes to arise from 
widespread testing by FISH of subtelomere deletions was the 9q34 deletion syndrome, now 
called Kleefstra syndrome. 12,13 Patients show severe intellectual disability, childhood hypotonia 
with speech and gross motor delay and recognizable facial features. Widespread screening lead 
to the identification of smaller deletions from 3 Mb to 700 kb. 14-17 Subsequently, Kleefstra 
and colleagues showed disruption of the EHMT1 gene in a female patient with a balanced 
translocation and the 9q34 phenotype. 18 Based on de novo point mutations in two patients, they 
concluded that the 9q34 deletion syndrome is caused by haplo-insufficiency of EHMT1, a gene 
whose protein product (Eu-HMTase1) is a histone H3 Lys 9 (H3-K9) methyltransferase. 18,19 
The traditional sequence of identification of phenotypically similar patients (the syndrome) 
and the subsequent exploration of its molecular causes, is nowadays often reversed by the 
identification of novel, recurrent imbalances after screening large numbers of mentally 
retarded patients by high-resolution techniques. 20 One of the new syndromes identified in 
this way is the 17q21.31 microdeletion syndrome. 21-23 Only after its molecular identification 
by high-resolution arrays a specific clinical phenotype was recognized by the investigators. 
Recently, it has been shown that this chromosomal syndrome is caused by haploinsufficiency 
of a single gene, KANSL1. 24 
Generating phenotypic maps based on high resolution whole genome techniques can also 
show the way to genes which, when disrupted, lead to an isolated feature of a particular 
microdeletion syndrome. This is shown in Chapter 5.2, where we describe the localization and 
identification of the gene underlying CAA, through the discovery of two small overlapping 
interstitial microdeletions in individuals with CAA and other features suggestive of an 18q 
deletion. The minimal region of deletion overlap (72.9-73.4 Mb) contained only one known 
gene, TSHZ1, which was recently shown to be important for murine middle-ear development. 25
Sequence analysis of the coding exons in TSHZ1 in a cohort of 11 individuals with isolated, 
nonsyndromic bilateral CAA revealed a loss of function mutation in two individuals. From 
these results, we concluded that congenital aural atresia is caused by hemizygosity of TSHZ1 
as a result of haploinsufficiency. 
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The combination of high-resolution molecular cytogenetics with the use of sophisticated 
phenotypic maps will help clinical geneticists to explain what the future might hold to the 
parents of a newborn child with a rare chromosome aberration. Furthermore, with each 
new patient available in a database, the phenotypic map of a specific chromosome disorder 
becomes more precise. The presence or absence of specific symptoms could lead to a change 
in size of critical regions or give insight into the penetrance of the feature involved. 
At present, microarrays (either oligonucleotide arrays, or SNP arrays) provide the best 
method we have in order to refine chromosomal regions and sometimes single genes for 
well-known syndromes. 26-28 When creating phenotypic maps, a pitfall could be that some 
patients with the exact same deletion or mutation display different phenotypes. Variation 
in clinical expressivity between patients is the rule, and not the exception. This is shown 
for example by the variability of congenital aural atresia in patients with either a deletion of 
the 18q critical region or a TSHZ1 loss of function mutation. In accordance with previous 
reports that describe a CAA incidence of 26% to 78% in individuals with an 18q deletion, we 
detected a nonsense mutation of TSHZ1 in a phenotypically normal mother of an affected 
boy (Chapter 5.2). 5,29,30 
It is known that clinical variability can be caused by stochastic factors, epigenetic mechanisms 
and by the fact that several loci or modifier genes as well as environmental factors can play 
a role in the expression of clinical features. 
Moreover, as it is known that syndromes or isolated malformations that display similar 
phenotypes can be caused by different genes, other candidate genes should be identified and 
sequenced in patients without any copy number changes or mutations detected thus far. The 
upcoming field of bioinformatics will play an important role in the analysis of phenotype 
data collected within databases, since it can be used to make predictions about new genes for 
diseases that form part of the same phenotype cluster. This is done by starting from the first 
gene identified and then searching for genes that are functionally related in gene expression 
pattern, coevolution, or gene ontology. 31
It should also be kept in mind that mutations in a new gene are often found in patients with the 
most severe or typical presentation of the syndrome, i.e. mutations in TCF4 in Pitt-Hopkins 
syndrome. 32-34 By investigating more patients, it can become clear that the phenotype is 
broader than at first expected. In the example of Pitt-Hopkins syndrome, we performed a 
study of a girl with mild to moderate mental retardation and minor facial anomalies carrying 
a de novo balanced translocation t(18;20)(q21.1;q11.2). As shown in Chapter 5.1, TCF4 is 
Discussion and future directions
179
6
disrupted by the translocation breakpoint. We concluded that TCF4 gene haploinsufficiency 
can give rise to a much milder clinical phenotype than the previously reported severe mental 
retardation encephalopathy characteristic of Pitt-Hopkins syndrome and that the possibility 
exists that many more patients with a milder phenotype carry a mutation in this gene.
An example of the expanding phenotypic spectrum is that of CHARGE syndrome, caused 
by mutations in CDH7. 35 Since the discovery of the involvement of CDH7 in CHARGE 
syndrome, numerous unique mutations have been identified, including missense, nonsense 
and splicing mutations. 36-38 Until today, most of the clinical variability is not due to type or 
location of the mutation as demonstrated by the differences in clinical presentation in sib 
pairs with identical mutations. 39 Here, too, a milder phenotype linked to a specific missense 
mutation has been shown to exist. 40 
Technique
Now that we have entered the era of cytogenetic molecular techniques and the possibilities 
for detecting ever-smaller deletions and duplications are almost endless, we may ask ourselves 
how these new techniques can be used within the field of clinical genetic diagnosis.
With the introduction of ultra-high density genome-wide oligonucleotide- and SNP based 
microarrays, alterations in the human genome down to 1-10 kb can be detected. This not 
only leads to a significant added value in detecting chromosome aberrations, but also raises a 
number of technical and clinical questions, concerning the clinical indications for performing 
microarray analysis and the genotype-phenotype correlations.  
Best practice guidelines and comprehensive genetic counselling have been advocated for 
accurate correlation and interpretation of the results. 41,42 In order to determine whether a 
detected deletion or duplication is indeed responsible for the clinical features in a particular 
patient, a number of aspects need to be checked. 
First, DNA of the parents of the patient is investigated in order to check for a de novo 
occurrence. If the aberration is inherited from a normal, healthy parent, it might be less 
likely to be causal for ID and/or MCA. In this case, the clinician should carefully (re)examine 
the parent involved in order to look for any subtle dysmorphic signs and/or congenital 
abnormalities. Due to variable expression and incomplete penetrance, the phenotype of the 
parent can differ from that of the child. It is hypothesized that the manifestation of some 
chromosomal imbalances depends on genetic and environmental background, meaning that 
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familial variants may not always be harmless as was previously assumed. 43 Examples of this 
phenomenon are seen in individuals with the same 22q13.3 terminal duplication, the 15q13 
microdeletion syndrome and deletions/duplications of 16p13.1. 44-46  
On the other side, a de novo occurrence is usually taken to be pathogenic. Recent studies have 
demonstrated that up to 12% of the human genome contains copy number variants (CNVs) 
that probably not cause any clinical features. 47 The frequency of de novo large-segment copy 
number polymorphisms has been discussed by Van Ommen in 2005. 48 Based on the data 
for the DMD gene, he estimated that one in every 8 newborns carries a de novo segmental 
deletion and one in every 50 newborns a segmental duplication. Therefore, the finding of a 
de novo alteration in a patient may not be sufficient to draw conclusions about pathogenicity. 
A major focus of future research will be on the clinical significance of CNVs that are detected 
in almost every patient sample investigated by high-resolution arrays. The complexity of 
this area is high and poses a challenge for researchers within the field of medical genetics.
The use of high resolution microarrays and next generation sequencing techniques will 
provide more insight in the underlying mechanisms of chromosomal rearrangements. In 
Chapter 3.1 we demonstrate that 46% of karyotypically balanced translocations are actually 
unbalanced at the submicroscopic level. A recent study using sequencing showed that many 
such unbalanced translocations involve complex rearrangements with multiple small gains, 
losses and inversions. 49 This indicates a catastrophic local event similar to the chromothripsis 
that has been revealed to occur frequently in cancer cells. 50 Chromothripsis has also been 
demonstrated in germline rearrangements by others. 51 For truly balanced translocations at 
the sequence level, there appears to be an increase in microhomology of a few bases at the 
breakpoints. 49 Nonrecurrent CNVs have also been shown to have frequent microhomology 
at the breakpoints. 52 Finally, there is evidence that recurrent translocations also are driven 
by local genomic architecture, notably by larger segmental duplications and LCRs. 53              
Secondly, when an aberration is detected, one needs to know whether this alteration has been 
described in healthy controls, suggesting a non-causative genomic variation. A number of 
Internet databases can be used, such as the Human Genome Variation Database (http://www.
hgvbase.org/) and the Database of Genomic Variants (http://projects.tcag.ca/variation/). 54 
However, the finding of microdeletions in healthy humans does not exclude the possibility of 
pathogenicity. This has been illustrated by Klopocki and colleagues, who detected a common 
200 kb microdeletion of chromosome 1q21.1 in patients with Thrombocytopenia-Absent 
Radius (TAR) syndrome. 55 Although this deletion occurred de novo in 25% of patients, 75% 
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of patients inherited the microdeletion from one of the unaffected parents. Deletions or 
duplications in this region are not described as CNVs in the Database of Genomic Variants, 
nor were they detected in 700 other individuals. This resulted in speculations that some 
microdeletion related phenotypes only develop in the presence of additional modifiers. 
Recently, Albers and colleagues provided the missing link in TAR etiology. 56 They identified 
the deficiency of Y14 protein, encoded by the RBM8A gene located on the other allele, as the 
underlying abnormality in TAR. A similar mechanism as the cause of variable expressivity of 
the 16p12.1 microdeletion has been described by Girirajan and colleagues. 57 These authors 
describe a second-hit model in which the 16p12.1 microdeletion both acts as a risk factor 
to neuropsychiatric phenotypes as a single event and exacerbates neurodevelopmental 
phenotypes in association with large deletions or duplications elsewhere in the genome.
Thirdly, one can explore the medical literature and databases like ECARUCA (www.ecaruca.
net) and Decipher (http://decipher.sanger.ac.uk/) whether other patients with the same 
aberration and a similar phenotype are known. As described in Chapter 2, we launched 
ECARUCA, a web-based genotype-phenotype database for rare chromosomal aberrations, 
which is accessible for everyone working in this field. ECARUCA is interactive, dynamic, 
and has possibilities to store cytogenetic, molecular, and clinical data for the long term. 
Currently, it contains more than 6,200, mainly unique, chromosomal aberrations detected 
by routine cytogenetic analysis, FISH, MLPA, and/or genome-wide array analysis in over 
4,500 patients. ECARUCA aims to be a database that is easily accessible for all account 
holders and it encourages both exchanges of information and technical knowledge. It aims 
to improve patient care and collaboration between genetic centres in the field of clinical 
cytogenetics.
This free online database grew out to become one of the largest genetic registries with curated 
genetic and clinical information in the world.
Currently, ECARUCA is collaborating with Cartagenia BENCH (www.cartagenia.com), 
a software and database platform which aims to automate the entire routine diagnostic 
laboratory flow. It allows the laboratory to build its internal database, while at the same time 
external registries are embedded. It has a strong clinical focus and will facilitate ECARUCA 
by simplifying the submission of genetic and clinical data from a local database by just a 
single “mouse click”.
Ultimately, database collections such as ECARUCA could serve as an intermediate biobank for 
DNA samples of patients with rare chromosome disorders and, even more relevant, samples 
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of undiagnosed patients. DNA samples should be collected and stored in the genetic centre of 
the patient and in case of relevant studies, DNA can be sent to the research group involved. 
At the present time, arrays are still relatively expensive and require substantial laboratory 
expertise. Nonetheless, the costs per experiment have lowered significantly over a short 
period and the cost of performing whole-genome arrays is currently less than that of standard 
G-banded karyotyping using microscopic methods. The rapid progress in the development 
of cheaper commercial whole-genome arrays, coupled with the realisation that most 
chromosome abnormalities are unique, leaves no doubt that whole genome approaches are 
the method of first choice in postnatal cytogenetics of patients with intellectual disability 
and/or congenital malformations. 
Although we might sometimes forget, financial feasibility and expertise are not as easily 
available in all laboratories around the world, especially in less-developed countries. Therefore 
I would like to argue for laboratories performing whole-genome microarrays as a service 
to those with limited access, thereby guaranteeing a constant quality and correctness of 
interpretation of the test results. Clinical genetic centres that lack the ability to investigate 
patients with these revolutionary techniques should be able to submit samples to the 
specialized laboratory in order to have equal access.
From karyotyping to microarray in prenatal diagnosis
Now that high resolution whole genome approaches are the method of first choice in postnatal 
cytogenetics, one could discuss on the application of these techniques in prenatal diagnosis. 
Most prenatal cytogenetic laboratories perform conventional karyotyping, thereby detecting 
abnormalities in 9% to 27% of pregnancies in which ultrasound abnormalities have been 
observed. 58-60 For most of these anomalies the phenotype is known.
The rate at which array CGH can detect clinically significant submicroscopic aberrations 
in fetuses with ultrasound anomalies ranges from 2% to 16% in retrospective studies. 61-63 
However, although array analysis allows for a much higher resolution genome-wide scan of 
unbalanced genomic aberrations, its prospective application in prenatal diagnosis is under 
debate, in particular because of concerns about uninterpretable CNVs and the associated 
parental anxiety. 
In Chapter 3.2, we presented the outcome of a prospective study evaluating several aspects 
of a new strategy in routine prenatal diagnosis; replacing karyotyping by non-targeted, 
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whole genome 250K SNP array analysis in fetuses with structural US anomalies. In our 
experience, most future parents prefer the high resolution application, even though this 
can lead to unsolicited findings. Despite the low frequency (2%) of clinically relevant 
submicroscopic aberrations detected, we do promote the use of non-targeted whole genome 
array analysis in this group of fetuses, as it provides a more accurate and reliable whole 
genome scan within the same time frame as karyotyping. Recently, Lee and colleagues tested 
the clinical utility of whole genome microarray in a large cohort of 3171 fetuses. 64 In line 
with our opinion, they concluded that prenatal array CGH is a valuable tool for screening 
for chromosomal microdeletions and -duplications, particularly in fetuses with normal 
karyotypes and structural ultrasound anomalies and should be included as a routine prenatal 
screening tool. 
Clinical guidelines can be of help in the future integration of new molecular techniques in 
the daily workflow of prenatal diagnosis. 65
Furthermore, Lee et al. recommend array CGH analysis in all fetuses with a de novo chromo-
some anomaly, including apparently balanced translocations. 64 The frequency of congenital 
abnormalities in fetuses and newborns with de novo, reciprocal translocations or inversions 
has been estimated at 6.1 and 9.4%, respectively. 66 The combined results of previous reports 
and our study presented in Chapter 3.1 has shown that in 46% of patients with a de novo 
apparently balanced chromosome rearrangement and developmental delay and/or congenital 
anomalies, a small genomic imbalance could be detected. The chance of finding an imbalance 
is highest in patients with a complex chromosome rearrangement and/or a De Vries score 
of at least 3. 67 The use of a similar clinical checklist might be of use in the prenatal setting 
as well, thereby improving the diagnostic pick up rate of genomic imbalances among fetuses 
with ultrasound anomalies. 
Phenotyping
In contrast to the enormous improvement of techniques to investigate a person’s genotype, 
the development of instruments to determine a phenotype remains behind. Or better said; 
the use of new techniques in this field did not find its way to implementation yet. How can 
this be explained?
At present, the common manner for the establishment of a phenotype is a description of 
physical features, subdivided in dysmorphic traits, malformations and disorders of organs and 
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organ functions. Describing dysmorphic features is largely subjective and much depends on 
individual recognition: the more often you see a feature, the more easily you will recognize 
it. Standardized definitions and terms to describe the physical variations used in human 
phenotypic analyses were developed during a project called the Elements of Morphology. 
Almost 400 phenotypic variations of the head and face; periorbital region; ear, nose, and 
philtrum; mouth and lips; and hands and feet have been defined and terminology for the 
trunk, genital region skin and remainder of the limb will follow. 68-74  
As an objective support, a computer program for dysmorphology using 3D images has been 
developed (http://www.3dmd.com/) and can currently be used for, amongst others, Williams 
syndrome and Wolf-Hirschhorn syndrome. 75,76 One can imagine that this technique can be 
helpful to clinicians in making a diagnosis in other chromosome disorders and syndromes 
in which patients display a common pattern of facial features.
This technique has potential utility for Fabry disease, a lysosomal storage disorder. Although 
facial dysmorphisms are not considered a prominent sign in this disorder, computerized 3D 
images revealed significant differences in face shape. 77 However, since the discrimination 
between patients and healthy controls is too low, this new technique will probably not play 
a key role in the diagnostic recognition of Fabry disease.
For syndromes in which patients display more prominent features, such as Cornelia de 
Lange, Noonan syndrome or specific chromosome aberrations, the discrimination level of 3D 
images is higher. Yet, in such genetic disorders a clinician will have a higher chance of making 
the correct diagnosis from the facial features as well and the added value of computerized 
phenotyping is not yet significant. Perhaps the 3D images can play a role in clinical training 
in order to precisely point out the prominent and subtle features in different syndromes to 
clinical geneticists in training. 76 Furthermore, these computerized techniques can contribute 
to genotype-phenotype mapping once a cytogenetic aberration or gene mutation has been 
established, as shown by a milder facial WHS-phenotype in individuals with a small terminal 
deletion. 75
Nowadays the behavioural phenotype is more and more appreciated as an important aspect 
of the phenotype in patients with syndromes and rare chromosome aberrations. So far, 
behavioural aspects of the phenotype are often poorly investigated and documented in rare 
chromosome aberrations. However, behavioural studies are gaining popularity among clinical 
scientists, mainly because of the hypothesis that behaviour is to a large degree based in genetics. 
Different groups are investigating neurobehavioural phenotypes in various (chromosomal) 
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syndromes, like Smith-Magenis and Fragile X syndrome. 78,79 In patients with chromosome 
disorders, specific forms of behaviour can be explicitly present, like sleeping disorders and 
self-destructive behaviour in Smith-Magenis syndrome, laughing paroxysms in Angelman 
syndrome and hypersensitivity to sound and high sociability in Williams-Beuren syndrome. 80-82
Most patients carrying a chromosome abnormality have a developmental delay and many 
have autistic features, aggressiveness or self-injurious behaviour. 
More subtle aspects of behaviour like shyness or fondness of specific materials, may also 
contribute to syndrome recognition. The complex field of studying behavioural genetics will 
be a challenge for the coming years. The development of complex neuroimaging techniques 
for the in-vivo scanning of activity in the human brain, like functional Magnetic Resonance 
Imaging (fMRI) and Magnetoencephalography (MEG), allows researchers to analyse 
brain function in detail. 83 This technique can offer new possibilities to gain insight in the 
aetiology of the specific behavioural profile of syndromes, as has been shown in patients with 
Williams syndrome. 84-86 These latter studies revealed evidence of a different neurofunctional 
processing of music and noise stimuli in patients with Williams syndrome compared to healthy 
individuals. Furthermore, a widely distributed network in (sub)cortical structures is activated 
during music processing in WS patients, whereas this is not seen in healthy individuals. In 
studies using mouse knockout models, similarities have been revealed between neural systems 
in patients with Williams syndrome and neuropathological, -physiological and behavioural 
abnormalities in mice. 87 
The understanding of the aetiology and characteristics of behavioural disorders is not only 
interesting from a biological point of view, but may be similarly important for parents and 
other caretakers.
In Chapter 4.2 we describe the neuropsychiatric features of a patient with a proximally located 
interstitial 18q deletion. The limited literature on proximal interstitial 18q deletions does not 
allow constructing a concise psychopathological phenotype. However, extensive investigation 
of this patient showed that the clinical picture is mainly characterised by symptoms from 
the motor (impulsivity, distractibility and disinhibition) and motivation (dysexecutive 
signs) domains. These clinical characteristics exclude a treatment with antidepressants or 
mood stabilisers and indicate the utility of behavioural measures that can be combined with 
symptomatic psycho-pharmacotherapy.
The knowledge that a specific behaviour is part of the phenotype that is caused by the 
chromosome disorder, could make it easier to understand and cope with these matters. 
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Moreover, insight in the aetiology of behaviour could ultimately lead to the design of rational 
and effective interventions to handle this complex aspect of chromosomal aberration 
syndromes.
With the advent of technologies that allow fast whole genome sequencing, computerized 
phenotyping and Internet-based databases, one may assume that all these developments are 
going to have a significant impact on the care for the individual patient. 
However, making the diagnosis can be one of the most challenging tasks for medical doctors, 
and this is especially the case for rare diseases. In a survey of eight relatively common rare 
diseases such as Marfan syndrome, it was found that 25% of patients waited from 5 to 30 
years for a diagnosis and that the initial diagnosis was wrong in 40% of the cases. 88 Although 
exact statistics are not available, it is safe to believe that the situation is even worse for most 
of the other, rarer diseases. 
In the group of individuals with intellectual disability and/or congenital anomalies the 
introduction of high resolution whole genome analysis lead to an increase of diagnoses in 
10-15%. 89-92 The recent introduction of next generation sequencing techniques is leading to 
the identification of new Mendelian disease genes in many well known syndromes as well 
as in idiopathic intellectual disability. 93-102
Nevertheless, in a significant percentage of patients the cause of the handicap remains 
unidentified. 
Major clinical problems result from delayed or inaccurate diagnosis including delayed 
treatment, unnecessary diagnostic procedures, and a psychological burden on patients and 
families because of persistent uncertainty about the cause and prognosis of their clinical 
problems. Studies have shown that certainty about a diagnosis in children with developmental 
delay leads to psychological benefit for their mothers. 103 Therefore, the increase in the 
percentage of the causative factor in patients with previously unexplained intellectual disability 
is of great value.
Furthermore, increasing awareness among medical doctors and parents on the possible 
occurrence of specific organ malformations due to a rare chromosome aberration is of great 
importance for careful screening and improved healthcare (Chapter 4.3). 
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Patient empowerment and patient organisation networks
ECARUCA is primarily a database providing information on rare unbalanced chromosome 
aberrations to professionals. Why did we specifically choose to provide all information 
to care-providers of patients with chromosomal imbalances and their family members? 
Because an increase in knowledge on these rare aberrations will lead to a higher quality of 
personal counselling by the clinical geneticist. Most parents crave for digital documentation 
and we do feel that there also should be information available on the Internet that is written 
for non-professionals. Therefore we support the initiative of Unique, a rare chromosome 
disorder support group, http://www.rarechromo.org, which provides leaflets on over 100 
rare chromosome aberrations. These information leaflets are written by professionals and 
are family-friendly, medically-verified and disorder-specific.
Another organisation that provides freely available information on rare diseases is Orphanet, 
http://orpha.net. This organisation provides services for patients, professionals, support 
groups, industry and also for the general public and the information is provided in six 
different languages. Presently, the information on a lot of rare chromosome disorders is 
under construction.  
The Dutch organisation for rare chromosome aberrations is Zeldzaam, http://www.zeldzame-
syndromen.nl/. Their website includes brochures on a small number of chromosome disorders 
which have been published in the newsletter of the patient organisation.
The virtual umbrella organisation of European support groups for people with rare chromosome 
disorders is named Eurochromnet and can be found at http://www.eurochromnet.org. 
A more general umbrella organisation concerning rare diseases is The European Organisation 
for Rare Diseases, Eurordis (http://www.eurordis.org/), a patient-driven alliance of patient 
organisations and individuals active in the field of rare diseases. Eurordis’ mission is to build 
a strong pan-European community of patient organisations and people living with rare 
diseases, to be their voice at the European level, and - directly or indirectly - to fight against 
the impact of rare diseases on their lives. 
The European Union Science and Society Work Programme for 2006 was focused on the 
idea that both policy makers and citizens should be equipped to make informed choices 
from the ever-growing range of options thrown up by scientific and technological progress. 
This is very true for European rare disease patients and patient organisations, who often 
wish to take part in research activities on their disease, but don’t know where to start or 
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simply do not master the language used in research. A project called CAPOIRA, funded by 
the European Commission and leaded by The European Organisation for Rare Diseases, 
Eurordis (http://www.eurordis.org/), was set up to respond to these needs. The main idea is 
to foster the participation of patient organisations in research activities by increasing their 
knowledge, skills and capabilities.
A close collaboration between European patient support groups and professional organisations 
can be a firm ground to perform scientific research on one hand and returning information 
on relevant results to patients on the other hand.
In the Netherlands follow-up of patients with rare chromosome disorders takes place in two 
centres in a multi-disciplinary setting, in Groningen and Nijmegen. Through the exchange of 
information between parents and medical doctors that occurs within these out-patient clinics, 
a constant increase in genotype-phenotype knowledge and patient empowerment takes place. 
Concluding remarks
In summary, it is clear that careful phenotyping using standardized approaches, the storage of 
such information in public accessible databases and bioinformatic skills will be of paramount 
importance if we are to translate the enormous potential for genotyping of individuals that 
is before us, into meaningful knowledge for doctors, patients and families. 
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SUMMARY
An ever increasing number of chromosomal syndromes has been identified, since the first 
microscopic visualization of human chromosomes. Chromosomal rearrangements are an 
important cause of distinctive and recognizable clinical phenotypes, with considerable clinical 
variation between patients. Relatively common cytogenetic syndromes like Cri du Chat and 
Wolf-Hirschhorn syndrome were studied extensively, and by the late 1970’s first attempts 
were made to construct phenotypic maps of the critical regions for these chromosomal 
syndromes. An historical overview of the deconstruction of a number of chromosomal 
aberrations and the establishment of the critical regions of specific features in a phenotypic 
map is described in Chapter 1.
A considerable improvement in diagnostic techniques in recent years has led to the identifi-
cation of many new submicroscopic chromosome aberrations. At the same time, the use of 
new molecular techniques enabled detailed breakpoint mapping in known, microscopically 
visible chromosomal syndromes. For some conditions, the phenotype appears to be primarily 
caused by disruption of a single gene, whereas other cytogenetic syndromes are a contiguous 
gene deletion syndrome.
Abnormal phenotypes have played significant roles in the discovery of critical chromosome 
regions and gene function, and the organized collection of phenotype data has had trouble 
keeping up with the developments in genetic technology. Standardized phenotype nomencla-
ture is crucial for a ‘Human Phenome Project’, in which comprehensive databases are created 
for such systematically collected clinical information. Some advances were made in the field 
of computational recognition of a facial phenotype by using 3D imaging techniques, but this 
technology is not yet in standard use and requires further improvement.
Due to the considerable improvement in diagnostic techniques, more and smaller chro-
mosomal aberrations are detected. Accurate clinical knowledge about rare chromosome 
disorders is frequently lacking, mostly due to a significant decline in published case reports. 
At the same time, there is an increasing demand from parents and physicians for reliable 
prognostic information. In Chapter 2, we describe a genotype-phenotype database for 
rare, unbalanced chromosomal aberrations named ECARUCA. This web-based database 
is accessible for everyone working in this field, and aims to increase the level of knowledge 
among physicians, patients, and their families.
The ECARUCA database contains cytogenetic and clinical data of patients with rare chromo-
some abnormalities, including microscopically visible aberrations, as well as microdeletions 
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and -duplications. The ECARUCA database provides health care workers with accurate 
information on clinical aspects of rare chromosome disorders. ECARUCA is dynamic and 
professionals submit new cases regularly. Frequent submission of new data ensures the up-
to-date quality of the collection. From a scientific perspective, detailed correlations between 
chromosome aberrations and their phenotypes may aid in deconstructing chromosomal 
syndromes and localising genes responsible for specific features.
In Chapter 3.1, we studied submicroscopic imbalances in individuals with congenital 
abnormalities or developmental delay and an apparently balanced, de novo translocation or 
inversion. 
We added the results of genome-wide array analysis in 54 patients to data on 117 patients 
from the literature. A chromosome imbalance was detected in 37% of all patients with 
two-breakpoint rearrangements. In 49% of these patients, the imbalances were located in 
one or both breakpoint regions. Imbalances were more frequently (90%) found in complex 
rearrangements, with the majority (81%) having deletions in the breakpoint regions. We 
applied a predictive clinical scoring system, the adjusted De Vries criteria, that indicates the 
complexity of the phenotype. The median De Vries score was significantly higher in those 
patients with an imbalance compared to patients with a normal array result. 
This study provided accurate percentages of cryptic imbalances that can be detected by 
genome-wide array analysis in simple and complex de novo microscopically balanced 
chromosome rearrangements and confirmed that these imbalances are more likely to occur 
in patients with a complex phenotype.
In Chapter 3.2, the use of non-targeted whole genome array analysis in a prenatal diagnostic 
setting is described. Upon the detection of structural fetal anomalies, parents were counseled 
and were offered a choice between quantitative fluorescence (QF)-PCR followed by a 250K 
single-nucleotide polymorphism (SNP)array analysis (QF/array) or QF-PCR followed by 
a routine karyotyping (QF/karyo). The majority of parents (70%) choose for the QF/array 
analysis. First, a QF-PCR was performed, which detected an abnormal result in 23% of the 
fetuses. The remaining samples were analyzed by array, which revealed clinically relevant 
aberrations, including two known microdeletions, in 4.2% of the cases. Inherited copy 
number variants (CNV) were detected in 9.3% of the fetuses and CNVs with uncertain 
clinical relevance in 2.5%. 
In 30% of the cases, QF/karyo was requested. Of these, 34% of the samples were abnormal 
with QF-PCR, and in 6.8% of the remaining cases an abnormal karyotype was found. Two 
of these were classified as causally related to the ultrasound abnormalities. 
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This study showed that QF/array does not reveal a high percentage of (sub)microscopic 
aberrations in fetuses with unselected structural anomalies. However, microarray analysis 
is preferred over QF/karyo, as it provides a whole genome scan at high resolution, without 
additional tests needed. The chance of detecting a chromosome aberration not related to the 
ultrasound anomalies appears to be low.
In Chapter 4.1, the phenotype associated with chromosome 18q deletions is discussed. 
DNA samples of 29 individuals with an 18q deletion were investigated by a tiling resolution 
chromosome 18 array to determine the exact breakpoints. Subsequently, we linked the 
genotype to the patient’s phenotype and integrated our results with those previously published.
Using this approach, we were able to refine the critical regions for microcephaly (18q21.33), 
short stature (18q12.1-q12.3, 18q21.1-q21.33 and 18q22.3-q23), white matter disorders 
and delayed myelination (18q22.3-q23), growth hormone insufficiency (18q22.3-q23) and 
congenital aural atresia (18q22.3).
The overall level of intellectual disability appeared to be mild in patients with deletions distal 
to 18q21.33 and severe in patients with deletions proximal to 18q21.31. The critical region 
for the ‘typical’ 18q- phenotype was determined to be a region of 4.3 Mb located within 
18q22.3-q23.
This study allowed us to update the phenotypic map for chromosome 18q deletions. 
In Chapter 4.2, we report on the neuropsychiatric phenotype in a patient with an 18q12.1q22.1 
deletion. 
His behavioural phenotype was characterized by a non-specific profile of behaviours, the 
absence of expressive language and poorly developed receptive verbal comprehension as well 
as by a desire for physical contact in the absence of insight, self-appraisal and differentiated 
mental processes. Only a small number of individuals with a proximally located 18q deletion 
have been described and the neuropsychiatric phenotype is not well documented. It includes 
disorganized and disinhibited behaviours as well as language difficulties. Non development 
of language seems to be specific for individuals with a more proximally located interstitial 
18q deletion. 
Although the literature on 18q deletions did not allow constructing a precise psychopatholo gical 
phenotype, it is of importance that symptoms from the affective, anxiety and psychotic domains 
were not described in previous case reports. The clinical picture is mainly characterised by 
symptoms from the motor (impulsivity, distractibility and disinhibition) and motivation 
(dysexecutive signs) domains. These clinical characteristics exclude a treatment with 
antidepressants or mood stabilisers and instead indicate the utility of behavioural measures. 
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In Chapter 4.3, the occurrence of various forms of cardiac anomalies in 19 individuals with 
a de novo 18qter deletion was studied. The heart problems in these individuals varied from 
relatively common pulmonary valve anomalies to very rare cardiac malformations like 
Ebstein anomaly in two individuals. All 19 individuals shared a small overlapping deletion 
region between 18q22.3qter. 
The finding of Ebstein anomaly in two 18q deletion individuals suggested the presence of one 
or more genes within this chromosome region involved in the etiology of this rare cardiac 
defect. Among the genes located within the critical region was a highly interesting candidate 
gene named Nuclear Factor for Activated T-Cells (NFATC1), a member of the Rel/NF-kb 
family of transcription factors, which have been implicated in different aspects of embryonic 
development and transcriptional regulation. Our study supported the findings that NFATC1 
plays an important role in human cardiac development and we suggested that disruption of 
this gene can lead to Ebstein anomaly. Additional molecularly based genotype-phenotype 
studies are needed to unravel the exact genotype-phenotype correlation.
This study points out the importance of a careful cardiac evaluation consisting of physical 
examination, ECG and ultrasound examination in all individuals diagnosed with the 18q 
deletion syndrome. 
In Chapter 5.1, we describe a girl with a de novo balanced translocation t(18;20)(q21.1;q11.2). 
She had mild to moderate intellectual disability and minor facial anomalies. 
Breakpoint-mapping by fluorescence in situ hybridization indicated that the basic helix-loop-
helix transcription factor TCF4 gene was disrupted by the breakpoint on chromosome 18. 
TCF4 plays a role in cell fate determination and differentiation and mutations in this gene 
have been shown to result in Pitt-Hopkins syndrome (PHS), characterized by severe ID, 
epilepsy, mild growth retardation, microcephaly and daily bouts of hyperventilation starting 
in infancy. Furthermore, patients show distinctive facial features including deep-set eyes, 
broad nasal bridge, and wide mouth with widely spaced teeth. 
Breakpoint mapping on the derivative chromosome 20 indicated that here the rearrangement 
disrupted the chromodomain helicase DNA binding protein 6 (CHD6) gene. To date, there 
is no indication that CHD6 is involved in disease. 
Our study indicated that TCF4 gene mutations are not always associated with classical PHS 
but can give rise to a much milder clinical phenotype. 
In Chapter 5.2, the discovery of the genetic cause of congenital aural atresia (CAA) type 2A 
is described. 
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CAA can occur as an isolated congenital malformation or in the context of a number of 
monogenic and chromosomal syndromes. CAA is frequently seen in individuals with an 18q 
deletion. Four individuals with CAA and other features suggestive of an 18q deletion were 
studied and overlapping microdeletions in 18q22.3 were detected. The minimal region of 
overlap between these deletions contained only one known gene, TSHZ1, which has been 
shown to be important for murine middle-ear development. 
Sequence analysis of the coding exons in TSHZ1 in a cohort of 11 individuals with isolated, 
nonsyndromic bilateral CAA subsequently revealed loss of function mutations in four 
individuals. 
In Chapter 6, the importance of developing standardized, reliable phenotyping in relation 
to the advances made in molecular cytogenetic techniques, and sharing of this information 
in public databases, is discussed. With submission of the genotype and the phenotypic 
information of each new patient in a database, the phenotypic map of a specific chromosome 
disorder becomes more precise and may further add to disease gene discovery. However, in 
contrast to the enormous improvement of techniques to investigate a person’s genotype, the 
development of instruments to determine a phenotype lags behind. Yet, the precise delineation 
of a rare chromosome aberration is not what patients or their parents are looking for. What 
they in fact want to know, is what the future consequences are likely to be. Combining 
high-resolution genotyping and sophisticated phenotypic maps in interactive, open-access 
databases is crucial if we are to translate the enormous potential for genotyping of individuals 
that is before us, into meaningful knowledge for doctors, patients and families. 
201
*
Samenvatting
SAMENVATTING
Vanaf het moment dat het mogelijk werd de menselijke chromosomen door een microscoop 
te bestuderen zijn een toenemend aantal chromosomale syndromen geïdentificeerd. Veran-
deringen in zowel aantal als vorm van de chromosomen zijn een belangrijke oorzaak van 
verschillende herkenbare chromosomale syndromen, waarbij vrijwel altijd sprake is van een 
aanzienlijke variatie tussen patiënten. Relatief vaak voorkomende cytogenetische afwijkingen 
zoals het Cri du Chat en het Wolf-Hirschhorn syndroom, zijn intensief bestudeerd en aan 
het einde van de jaren ’70 van de vorige eeuw zijn de eerste pogingen gedaan om fenotype 
overzichtskaarten te maken. Hierbij wordt bepaald welke chromosomale regio’s (het geno-
type) een rol spelen bij het ontstaan van de specifieke klinische kenmerken (het fenotype). 
Dergelijke chromosomale gebieden die gerelateerd zijn aan een specifiek klinisch kenmerk 
worden kritische regio’s genoemd. Een historisch overzicht van een aantal chromosoomaf-
wijkingen en de bijbehorende fenotype overzichtskaarten wordt beschreven in Hoofdstuk 1. 
Recente verbeteringen in diagnostische technieken, waarbij kleinere afwijkingen opgespoord 
kunnen worden, hebben ertoe geleid dat veel nieuwe submicroscopische chromosoomaf-
wijkingen zijn geïdentificeerd. Het gebruik van deze nieuwe moleculaire technieken heeft 
het tegelijkertijd mogelijk gemaakt om de breukpunten van reeds bekende, microscopisch 
zichtbare chromosoomafwijkingen nauwkeuriger in kaart te brengen. Bij een aantal syndro-
men blijkt het fenotype bepaald te worden door de afwezigheid van één enkel gen, terwijl 
andere beelden juist het gevolg zijn van het tegelijkertijd afwezig zijn van een aantal genen 
in de kritische regio van het chromosoom. 
Het zorgvuldig bestuderen van afwijkende fenotypes heeft een belangrijke rol gespeeld bij het in 
kaart brengen van de kritische regio’s voor de fenotypes, evenals bij het bepalen van de functie 
van genen. De vooruitgang in het gestructureerd verzamelen van fenotypische informatie 
verloopt langzamer dan de ontwikkeling van genetische technieken. Om een zogenaamd 
“Humaan Fenotype Project” te laten slagen, een project waarbij databases worden ontwikkeld 
voor de systematische opslag van klinische gegevens, is het invoeren van fenotype nomenclatuur 
cruciaal. Er zijn stappen gemaakt op het gebied van biometrische gezichtsherkenning van een 
aantal syndromen, waarbij gebruik wordt gemaakt van 3D beeldvormende technieken. Echter, 
deze technologie maakt op dit moment nog geen onderdeel uit van het standaard klinisch 
genetisch onderzoek en dient verder geoptimaliseerd te worden. 
Door de significante verbeteringen op het gebied van genetische diagnostiek, worden steeds 
meer en kleinere chromosoomveranderingen gevonden. De kennis over de klinische gevolgen 
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van zeldzame chromosoomafwijkingen is meestal beperkt, onder andere ten gevolge van een 
sterke daling in de publicaties van individuele case reports. Tegelijkertijd hebben ouders en 
dokters behoefte aan betrouwbare informatie. In Hoofdstuk 2 beschrijven we ECARUCA, 
een genotype-fenotype database voor zeldzame, ongebalanceerde chromosoomafwijkingen. 
Deze via internet toegankelijke database kan gebruikt worden door iedereen die werkzaam 
is op het gebied van zeldzame chromosoomafwijkingen en heeft als doel om de kennis bij 
artsen, patiënten en families te vergroten.
De ECARUCA database bevat cytogenetische en klinische informatie over personen met een 
zeldzame chromosoomafwijking, zowel microscopisch zichtbare afwijkingen als microdeleties 
en -duplicaties. ECARUCA voorziet artsen van betrouwbare informatie aangaande klinische 
afwijkingen die voor kunnen komen bij zeldzame chromosoomafwijkingen. Gebruikers 
voeren tevens informatie over de bij hen bekende patiënten in, wat ECARUCA interactief, 
dynamisch en up-to-date maakt. Vanuit wetenschappelijk oogpunt is het delen van genotype-
fenotype informatie eveneens waardevol, omdat dit leidt tot het verkleinen van kritische 
regio’s en kan helpen bij het opsporen van nieuwe kandidaatgenen. 
In Hoofdstuk 3.1 wordt het onderzoek beschreven bij personen met een ontwikkelings-
achterstand of aangeboren afwijkingen, bij wie een microscopisch bepaalde, ogenschijnlijk 
gebalanceerde, de novo chromosoomverandering, zoals een translocatie of een inversie, was 
vastgesteld. Bij 54 personen werd microarray onderzoek verricht om een submicroscopische 
deletie of duplicatie op te sporen en de data van 117 personen beschreven in de medische lite-
ratuur werd hieraan toegevoegd. Bij 37% van alle personen met een chromosoomverandering 
waarbij sprake was van twee breukpunten, werd een microdeletie of -duplicatie gevonden. In 
49% van deze gevallen bevond de deletie of duplicatie zich rondom een of beide breukpunten. 
Bij personen met een complexe chromosoomverandering (≥3 breukpunten) werd in 90% 
van de gevallen een ongebalanceerde afwijking gevonden, waarbij meestal sprake was van 
een deletie (81%). Om de complexiteit van het fenotype aan te geven, hebben we gebruik 
gemaakt van een aangepaste versie van de De Vries criteria, een systeem om klinische ken-
merken te scoren. De gemiddelde De Vries score was significant hoger bij personen met een 
ongebalanceerde chromosoomafwijking in vergelijking met de personen waarbij de uitslag 
van het microarray onderzoek normaal was.
Dit onderzoek geeft een accuraat overzicht van de kans op een submicroscopische afwijking 
bij personen met een de novo, ogenschijnlijk gebalanceerde chromosoomverandering en 
bevestigt dat microdeleties en -duplicaties vaker voorkomen bij personen met een complex 
fenotype.
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In Hoofdstuk 3.2 wordt het gebruik van genoombreed microarray-onderzoek in de prena-
tale diagnostiek beschreven. Wanneer tijdens een zwangerschap structurele echoscopische 
afwijkingen werden vastgesteld, werden de zwangere en haar partner gecounseld over de 
mogelijkheden van genetisch onderzoek. Paren konden kiezen voor quantitatieve fluores-
centie (QF)-PCR, gevolgd door een 250K microarray onderzoek (QF/array), of voor QF-PCR 
gevolgd door karyotypering (QF/karyo). De meerderheid van de ouders (70%) koos voor de 
optie QF/array onderzoek. Als eerste werd een QF-PCR onderzoek verricht, waarbij in 23% 
van de foetussen een afwijking werd gevonden. Bij de resterende monsters werd vervolgens 
een microarray-onderzoek verricht, waarbij in 4.2% van de gevallen een klinisch relevante 
afwijking werd gevonden. In 33% van het totaal aantal array-afwijkingen was sprake van 
een microdeletie, welke niet met karyotypering zou zijn gevonden. Parentaal overgeërfde 
CNVs werden bij 9.3% van de foetussen gevonden en bij 2.5% was sprake van een CNV met 
onbekende klinische relevantie.  
In 30% van de gevallen werd de optie QF/karyo gekozen. Bij 34% van de ontvangen monsters 
was sprake van een afwijkende QF-PCR uitslag en in 6.8% van de overige gevallen werd een 
afwijkend karyogram gezien. 
Dit onderzoek toonde aan dat het gebruik van QF/array onderzoek niet leidt tot een hoger 
percentage vastgestelde (sub)microscopische afwijkingen bij foetussen met algemene structu-
rele echoscopische afwijkingen. Toch wordt de voorkeur gegeven aan de microarray-analyse, 
omdat het gebruik van deze genoombrede, hoog-resolutie techniek de voorheen gebruikte 
aanvullende onderzoeken na microscopische karyotypering overbodig maakt. De kans dat 
met microarray-analyse een (klinisch relevante) chromosoomafwijking wordt gevonden die 
geen relatie heeft met de echoscopische afwijkingen lijkt in deze studie laag te zijn.    
In Hoofdstuk 4.1 wordt het fenotype van personen met een 18q deletie beschreven. Om de 
exacte breukpunten te bepalen, werden DNA-monsters van 29 personen met een 18q dele-
tie onderzocht met behulp van een hoog-resolutie chromosoom 18 array. Vervolgens werd 
het genotype van iedere persoon gekoppeld aan het fenotype en tot slot gecombineerd met 
gegevens uit de medische literatuur. 
Op deze manier was het mogelijk om de kritische regio’s voor diverse klinische kenmerken 
in kaart te brengen; microcefalie (18q21.33), kleine lengte (18q12.1-q12.3, 18q21.1-q21.33 
en 18q22.3-q23), witte stof-afwijkingen en vertraagde myelinisatie (18q22.3-q23), groeihor-
moondeficiëntie (18q22.3-q23) en congenitale gehoorgangatresie (18q22.3). Bij personen 
met een distaal gelokaliseerde deletie (vanaf breukpunt 18q21.33) was over het algemeen 
sprake van een milde verstandelijke beperking, terwijl deze ernstig was bij personen met een 
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deletie proximaal van 18q21.31. De kritische regio voor het 18q deletie syndroom fenotype, 
bestaande uit de combinatie van gehoorgangatresie, voetafwijkingen, een aantal uiterlijke 
gezichtskenmerken en een milde ontwikkelingsachterstand, werd gelokaliseerd in een gebied 
van 4.3 Mb in 18q22.3q23. 
Door dit onderzoek kon een update van de fenotype overzichtskaart van chromosoom 18q 
worden gemaakt.    
In Hoofdstuk 4.2 beschrijven we het neuropsychiatrische fenotype van een persoon met een 
18q12.1q22.1 deletie. Zijn gedrag werd gekenmerkt door een niet-specifiek profiel, de afwe-
zigheid van spraak,  onderontwikkeling van verbaal begrip en een sterke behoefte aan fysiek 
contact. Er was geen of onvoldoende sprake van zelfinzicht en -kennis, alsmede van gedif-
ferentieerde mentale processen. Er zijn slechts een klein aantal personen met een proximaal 
gelokaliseerde 18q deletie beschreven in de medische literatuur en over het neuropsychiatri-
sche fenotype is weinig bekend. Kenmerken die er deel van uitmaken zijn ongestructureerd 
en ongeremd gedrag, evenals taalproblemen. Het niet ontwikkelen van gesproken taal lijkt 
specifiek te zijn voor personen met een proximaal gelokaliseerde interstitiële 18q deletie.  
Het was niet mogelijk om een gedetailleerde overzichtskaart te construeren voor het 
psychopathologische fenotype, maar er worden geen personen beschreven met afwijkingen 
van de affectieve, angst-, of psychotische domeinen. Het klinisch beeld wordt met name 
gekenmerkt door symptomen van het motore domein (impulsiviteit, afleidbaarheid en 
ongeremdheid) en het motivatiedomein (onder andere verminderde cognitieve functies). 
Bij deze personen is een behandeling met antidepressiva of stemmingstabilisatoren 
gecontraïndiceerd en kan de behandeling beter op het gedrag worden gericht.
In Hoofdstuk 4.3 worden verschillende congenitale hartafwijkingen bij 19 personen met 
een de novo 18q deletie beschreven. De hartafwijkingen varieerden van relatief frequente 
afwijkingen van de pulmonalisklep tot zeer zeldzame aanlegstoornissen, zoals een Ebstein 
anomalie, welke bij twee personen aanwezig was. Bij alle 19 personen was sprake van een 
terminale 18q deletie en de kritische regio werd gelokaliseerd in 18q22.3qter.
De aanwezigheid van een Ebstein anomalie bij twee personen met een 18q deletie zou 
erop kunnen wijzen dat zich een of meerdere genen in deze chromosomale regio bevinden 
welke een rol spelen bij het ontstaan van deze zeldzame hartafwijking. In deze regio ligt een 
interessant kandidaatgen, NFATC1, lid van de Rel/NF-kb-familie van transcriptiefactoren, 
welke een rol spelen bij diverse aspecten van embryonale ontwikkeling en transcriptieregulatie. 
Dit onderzoek ondersteunt eerdere publicaties dat NFATC1 een belangrijke rol speelt bij de 
ontwikkeling van het humane hart en onze hypothese is dat disruptie van dit gen tot een 
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Ebstein anomalie kan leiden. Aanvullende genotype-fenotype-onderzoeken zullen nodig zijn 
om de exacte correlatie tussen NFATC1 en Ebstein anomalie te achterhalen. 
Dit onderzoek toonde aan dat een zorgvuldig cardiologisch onderzoek, bestaande uit een 
lichamelijk en echoscopisch onderzoek en een ECG, geïndiceerd is bij alle personen met het 
(terminale) 18q deletie syndroom.  
In Hoofdstuk 5.1 beschrijven we een meisje met een de novo gebalanceerde translocatie 
t(18;20)(q21.1;q11.2). Ze had een milde tot matige verstandelijke beperking en enkele faciale 
dysmorfieën. 
Het in kaart brengen van de breukpunten met behulp van FISH toonde aan dat het breukpunt 
op chromosoom 18 gelokaliseerd was in TCF4. TCF4 speelt een rol bij celdifferentiatie en 
mutaties in dit gen zijn aangetoond bij personen met het Pitt-Hopkins syndroom (PHS), wat 
gekenmerkt wordt door een ernstige verstandelijke beperking, epilepsie, milde groeiachter-
stand, microcefalie en aanvallen van hyperventilatie vanaf de babyleeftijd. Verder hebben 
personen met PHS een aantal opvallende uiterlijke kenmerken, zoals diepliggende ogen, een 
brede neusbrug en een brede mond met vergroting van de ruimte tussen de tanden. 
Het in kaart brengen van het breukpunt op het derivaatchromosoom 20 toonde aan dat dit 
leidde tot disruptie van CHD6. Er is tot op heden niet bekend of CHD6 een rol speelt bij het 
ontstaan van een ziektebeeld.
Dit onderzoek toonde aan dat mutaties in TCF4 niet altijd geassocieerd zijn met het klassieke 
PHS, maar ook kunnen leiden tot een milder fenotype. 
In Hoofdstuk 5.2 wordt de ontdekking van de genetische oorzaak van congenitale gehoorgang-
atresie (CAA) type 2A beschreven. CAA is beschreven als geïsoleerde congenitale afwijking, 
maar het kan ook onderdeel uitmaken van een aantal monogenetische en chromosomale 
syndromen. CAA wordt vaker gezien bij personen met een 18q deletie.  Vier personen met 
CAA en een aantal andere kenmerken die passen bij een 18q deletie werden onderzocht en 
hierbij werden overlappende microdeleties in 18q22.3 aangetoond. De kritische regio bevatte 
slechts één gen, TSHZ1, waarvan bekend is dat deze een belangrijke rol speelt bij de ontwik-
keling van het middenoor bij muizen. Vervolgens vond sequentieanalyse van TSHZ1 plaats 
in een cohort van 11 personen met geïsoleerde, non-syndromale, bilaterale CAA en hierbij 
werden mutaties in vier personen aangetoond.  
In Hoofdstuk 6 wordt de waarde van gestandaardiseerde, betrouwbare fenotypering in 
combinatie met gedetailleerde genotypering door moleculaire cytogenetische technieken 
besproken, alsmede het belang van het invoeren en opslaan van deze gecombineerde data in 
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openbare databases. Door het invoeren van genotypische en fenotypische informatie van iedere 
nieuwe patiënt wordt de fenotype overzichtskaart van de betreffende chromosoomafwijking 
nauwkeuriger en draagt daarmee bij aan het in kaart brengen van verantwoordelijke 
ziektegenen. In tegenstelling tot de enorme ontwikkelingen op het gebied van genotypering 
blijft de ontwikkeling van instrumenten om het fenotype te beschrijven achter. De exacte 
bepaling van de grootte van de chromosoomafwijking is echter niet het enige waar patiënten 
of hun ouders naar op zoek zijn. De belangrijkste vragen die zij hebben zijn wat deze 
afwijking voor mogelijke gevolgen kan hebben, nu en in de toekomst. Het combineren van 
het gedetailleerde genotype en verfijnde fenotype overzichtskaarten in interactieve, publieke, 
beveiligde databases is cruciaal om de enorme hoeveelheid beschikbare data te vertalen naar 
zinvolle en begrijpelijke informatie voor artsen, patiënten en families.
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